

WEBVTT

NOTE duration:"01:12:55.4880000"

NOTE language:en-us

NOTE Confidence: 0.8253415

00:00:00.000 --> 00:00:03.232 OK, good afternoon everyone it's 12:00

NOTE Confidence: 0.8253415

00:00:03.232 --> 00:00:06.914 PM on this beautiful Friday and today

NOTE Confidence: 0.8253415

00:00:06.914 --> 00:00:10.735 is the next session and our yield.

NOTE Confidence: 0.8253415

00:00:10.740 --> 00:00:12.740 Hematology hash highlights from

NOTE Confidence: 0.8253415

00:00:12.740 --> 00:00:15.240 the 2020 American Society of

NOTE Confidence: 0.8253415

00:00:15.240 --> 00:00:17.160 Hematology Meeting highlights.

NOTE Confidence: 0.8253415

00:00:17.160 --> 00:00:21.072 So as you can see on the agenda

NOTE Confidence: 0.8253415

00:00:21.072 --> 00:00:24.119 in the last few weeks,

NOTE Confidence: 0.8253415

00:00:24.120 --> 00:00:26.260 we covered multiple myeloma,

NOTE Confidence: 0.8253415

00:00:26.260 --> 00:00:28.494 lymphoid malignancies, myeloid malignancies,

NOTE Confidence: 0.8253415

00:00:28.494 --> 00:00:31.404 and pediatric leukemia and hematology.

NOTE Confidence: 0.8253415

00:00:31.410 --> 00:00:35.022 And today we will be discussing

NOTE Confidence: 0.8253415

00:00:35.022 --> 00:00:36.828 classical or B9,

NOTE Confidence: 0.8253415

00:00:36.830 --> 00:00:39.840 but not so benign hematology.

NOTE Confidence: 0.83330727

00:00:54.230 --> 00:00:56.450 So as usual, many abstracts are

NOTE Confidence: 0.83330727

00:00:56.450 --> 00:00:58.410 presented in about classical hematology

NOTE Confidence: 0.83330727

00:00:58.410 --> 00:01:00.465 in the ash mythology meeting.

NOTE Confidence: 0.83330727

00:01:00.470 --> 00:01:02.906 However, due to time limitations the focus

NOTE Confidence: 0.83330727

00:01:02.906 --> 00:01:05.930 will be on the most prominent abstracts,

NOTE Confidence: 0.83330727

00:01:05.930 --> 00:01:08.390 and the ones that have the

NOTE Confidence: 0.83330727

00:01:08.390 --> 00:01:10.030 highest clinical relevance to

NOTE Confidence: 0.83330727

00:01:10.108 --> 00:01:12.598 practice on on a day-to-day basis.

NOTE Confidence: 0.83330727

00:01:12.600 --> 00:01:15.765 The abstracts will be grouped

NOTE Confidence: 0.83330727

00:01:15.765 --> 00:01:18.297 in areas of clinical.

NOTE Confidence: 0.83330727

00:01:18.300 --> 00:01:20.932 Unmet need and there are many other

NOTE Confidence: 0.83330727

00:01:20.932 --> 00:01:23.566 abstracts of course that are very good that

NOTE Confidence: 0.83330727

00:01:23.566 --> 00:01:26.440 we do not have the time to cover today.

NOTE Confidence: 0.83330727

00:01:26.440 --> 00:01:28.112 Important to note that

NOTE Confidence: 0.83330727

00:01:28.112 --> 00:01:29.366 these abstracts represent.

NOTE Confidence: 0.83330727

00:01:29.370 --> 00:01:30.806 Often preliminary presentations and  
NOTE Confidence: 0.83330727

00:01:30.806 --> 00:01:33.422 data that has not been yet completely  
NOTE Confidence: 0.83330727

00:01:33.422 --> 00:01:35.804 vetted or peer reviewed or finalized.  
NOTE Confidence: 0.83330727

00:01:35.810 --> 00:01:38.850 So we have to take that into consideration.  
NOTE Confidence: 0.83330727

00:01:38.850 --> 00:01:41.272 As we discussed the data we like  
NOTE Confidence: 0.83330727

00:01:41.272 --> 00:01:43.866 to thank the authors who shared  
NOTE Confidence: 0.83330727

00:01:43.866 --> 00:01:46.818 their presentations with us and the  
NOTE Confidence: 0.83330727

00:01:46.818 --> 00:01:49.583 recording of this session and the  
NOTE Confidence: 0.83330727

00:01:49.583 --> 00:01:51.773 other sessions will be available.  
NOTE Confidence: 0.83330727

00:01:51.780 --> 00:01:54.618 Over the next week or so,  
NOTE Confidence: 0.83330727

00:01:54.620 --> 00:01:57.805 for those who cannot attend the live  
NOTE Confidence: 0.83330727

00:01:57.805 --> 00:02:01.396 sessions and the CME credit will be  
NOTE Confidence: 0.83330727

00:02:01.396 --> 00:02:04.061 available after filling up receive  
NOTE Confidence: 0.83330727

00:02:04.061 --> 00:02:06.742 feedback on the seminars and how  
NOTE Confidence: 0.83330727

00:02:06.742 --> 00:02:09.210 we can improve him going forward.  
NOTE Confidence: 0.83330727

00:02:09.210 --> 00:02:12.410 So today it's a pleasure to be joined

NOTE Confidence: 0.83330727

00:02:12.410 --> 00:02:15.428 by my colleagues Sabrina Browning,

NOTE Confidence: 0.83330727

00:02:15.430 --> 00:02:18.316 who's our instructor in medicine and

NOTE Confidence: 0.83330727

00:02:18.316 --> 00:02:21.379 section of Hematology who will be

NOTE Confidence: 0.83330727

00:02:21.379 --> 00:02:23.499 covering bleeding and hemostasis.

NOTE Confidence: 0.83330727

00:02:23.500 --> 00:02:25.606 Sam Alexander Pienaar,

NOTE Confidence: 0.83330727

00:02:25.606 --> 00:02:28.414 associate professor of medicine.

NOTE Confidence: 0.83330727

00:02:28.420 --> 00:02:31.180 Who will be covering from bosses

NOTE Confidence: 0.83330727

00:02:31.180 --> 00:02:32.560 an antithrombotic therapy?

NOTE Confidence: 0.83330727

00:02:32.560 --> 00:02:35.020 Advances from ash and then our

NOTE Confidence: 0.83330727

00:02:35.020 --> 00:02:37.301 bright fellow George Joshua will

NOTE Confidence: 0.83330727

00:02:37.301 --> 00:02:38.999 finish their presentations,

NOTE Confidence: 0.83330727

00:02:39.000 --> 00:02:40.840 covering other important and

NOTE Confidence: 0.83330727

00:02:40.840 --> 00:02:42.680 relevant classical hematology topics.

NOTE Confidence: 0.83330727

00:02:42.680 --> 00:02:45.767 At the end we will have Professor

NOTE Confidence: 0.83330727

00:02:45.767 --> 00:02:48.199 of Medicine Doctor Robert Bona,

NOTE Confidence: 0.83330727

00:02:48.200 --> 00:02:50.960 and our Associate Professor of Medicine,  
NOTE Confidence: 0.83330727

00:02:50.960 --> 00:02:52.349 Doctor Alfred Lee,  
NOTE Confidence: 0.83330727

00:02:52.349 --> 00:02:54.664 who will moderate your questions  
NOTE Confidence: 0.83330727

00:02:54.664 --> 00:02:57.483 and also be available to help  
NOTE Confidence: 0.83330727

00:02:57.483 --> 00:02:59.295 the speakers in answering.  
NOTE Confidence: 0.83330727

00:02:59.300 --> 00:03:01.754 Any of the questions that are  
NOTE Confidence: 0.83330727

00:03:01.754 --> 00:03:04.210 relevant to the abstracts presented,  
NOTE Confidence: 0.83330727

00:03:04.210 --> 00:03:07.480 or any other abstracts from the  
NOTE Confidence: 0.83330727

00:03:07.480 --> 00:03:09.660 meeting that are important.  
NOTE Confidence: 0.83330727

00:03:09.660 --> 00:03:12.635 So it's my pleasure to present our  
NOTE Confidence: 0.83330727

00:03:12.635 --> 00:03:14.804 first speaker, doctor Sabrina Browning,  
NOTE Confidence: 0.83330727

00:03:14.804 --> 00:03:16.994 who will discuss bleeding and  
NOTE Confidence: 0.83330727

00:03:16.994 --> 00:03:18.590 hemostasis without so Sabrina.  
NOTE Confidence: 0.83330727

00:03:18.590 --> 00:03:21.140 Feel free to share your screen.  
NOTE Confidence: 0.8116819

00:03:25.840 --> 00:03:30.215 Thank you Doctor Zayden and welcome everyone.  
NOTE Confidence: 0.8116819

00:03:30.220 --> 00:03:31.498 For those interested,

NOTE Confidence: 0.8116819

00:03:31.498 --> 00:03:33.628 we've included QR codes throughout

NOTE Confidence: 0.8116819

00:03:33.628 --> 00:03:35.491 our presentation that will link

NOTE Confidence: 0.8116819

00:03:35.491 --> 00:03:37.393 you directly to the ASH abstracts.

NOTE Confidence: 0.8116819

00:03:37.400 --> 00:03:40.015 You can access these by

NOTE Confidence: 0.8116819

00:03:40.015 --> 00:03:42.107 using your smartphone camera.

NOTE Confidence: 0.8116819

00:03:42.110 --> 00:03:45.140 I have no disclosures to report.

NOTE Confidence: 0.8116819

00:03:45.140 --> 00:03:46.874 So this slide outlines the abstracts

NOTE Confidence: 0.8116819

00:03:46.874 --> 00:03:49.166 that I will cover today which span

NOTE Confidence: 0.8116819

00:03:49.166 --> 00:03:50.961 disorders of platelet number or

NOTE Confidence: 0.8116819

00:03:50.961 --> 00:03:52.431 function disorders of coagulation

NOTE Confidence: 0.8116819

00:03:52.431 --> 00:03:54.171 and fibrinolysis and von Willebrand

NOTE Confidence: 0.8116819

00:03:54.171 --> 00:03:56.492 disease and at the end I will

NOTE Confidence: 0.8116819

00:03:56.492 --> 00:03:58.082 briefly touch upon abstracts that

NOTE Confidence: 0.8116819

00:03:58.082 --> 00:04:00.584 were presented at ASH on the role

NOTE Confidence: 0.8116819

00:04:00.584 --> 00:04:02.000 of convalescent plasma therapy

NOTE Confidence: 0.8116819

00:04:02.060 --> 00:04:04.004 in the management of COVID-19 and

NOTE Confidence: 0.8116819

00:04:04.004 --> 00:04:07.001 provide an update on where we stand

NOTE Confidence: 0.8116819

00:04:07.001 --> 00:04:09.269 with this treatment currently.

NOTE Confidence: 0.8116819

00:04:09.270 --> 00:04:10.347 So to begin,

NOTE Confidence: 0.8116819

00:04:10.347 --> 00:04:12.142 doctor Charlotte Bradbury from the

NOTE Confidence: 0.8116819

00:04:12.142 --> 00:04:14.431 University of Bristol in the United

NOTE Confidence: 0.8116819

00:04:14.431 --> 00:04:16.316 Kingdom presented a late breaking

NOTE Confidence: 0.8116819

00:04:16.316 --> 00:04:17.928 abstract on the flight trial,

NOTE Confidence: 0.8116819

00:04:17.930 --> 00:04:19.354 which is a multicenter,

NOTE Confidence: 0.8116819

00:04:19.354 --> 00:04:21.134 randomized trial evaluating the addition

NOTE Confidence: 0.8116819

00:04:21.134 --> 00:04:23.348 of mycophenolate to standard of care.

NOTE Confidence: 0.8116819

00:04:23.350 --> 00:04:24.622 Corticosteroids in the management

NOTE Confidence: 0.8116819

00:04:24.622 --> 00:04:26.212 of patients with newly diagnosed

NOTE Confidence: 0.8116819

00:04:26.212 --> 00:04:27.320 immune thrombocytopenia.

NOTE Confidence: 0.8116819

00:04:27.320 --> 00:04:30.071 This study was developed due to the

NOTE Confidence: 0.8116819

00:04:30.071 --> 00:04:32.073 heterogeneous responses in ITP to

NOTE Confidence: 0.8116819

00:04:32.073 --> 00:04:33.973 first line steroids and concerns

NOTE Confidence: 0.8116819

00:04:33.973 --> 00:04:36.319 regarding their long term side effects.

NOTE Confidence: 0.8116819

00:04:36.320 --> 00:04:38.456 Evidence for mycophenolate or MF and

NOTE Confidence: 0.8116819

00:04:38.456 --> 00:04:40.335 second line treatment and beyond

NOTE Confidence: 0.8116819

00:04:40.335 --> 00:04:42.290 really comes only from Russia's

NOTE Confidence: 0.8116819

00:04:42.290 --> 00:04:44.200 retrospective studies at this time.

NOTE Confidence: 0.8116819

00:04:44.200 --> 00:04:46.240 This study recruited adult patients

NOTE Confidence: 0.8116819

00:04:46.240 --> 00:04:49.573 with ITP and a platelet count of less

NOTE Confidence: 0.8116819

00:04:49.573 --> 00:04:52.015 than 30,000 who were requiring therapy.

NOTE Confidence: 0.8116819

00:04:52.020 --> 00:04:53.440 Subjects were then randomized

NOTE Confidence: 0.8116819

00:04:53.440 --> 00:04:54.505 to standard corticosteroids,

NOTE Confidence: 0.8116819

00:04:54.510 --> 00:04:57.358 which could be in the form of dexamethasone,

NOTE Confidence: 0.8116819

00:04:57.360 --> 00:05:00.208 pulsed, at 40 milligrams daily for four days,

NOTE Confidence: 0.8116819

00:05:00.210 --> 00:05:01.610 up to three cycles,

NOTE Confidence: 0.8116819

00:05:01.610 --> 00:05:03.010 or Prednisolone 1 milligram

NOTE Confidence: 0.8116819



00:05:03.010 --> 00:05:04.120 per kilogram daily,  
NOTE Confidence: 0.8116819

00:05:04.120 --> 00:05:05.900 followed by a taper or  
NOTE Confidence: 0.8116819

00:05:05.900 --> 00:05:06.968 corticosteroids plus MMF,  
NOTE Confidence: 0.8116819

00:05:06.970 --> 00:05:09.502 which was initially dosed at 500  
NOTE Confidence: 0.8116819

00:05:09.502 --> 00:05:11.586 milligrams twice daily and then  
NOTE Confidence: 0.8116819

00:05:11.586 --> 00:05:14.106 escalated to a Max dose of 1 gram  
NOTE Confidence: 0.8116819

00:05:14.106 --> 00:05:16.701 daily with a plan to taper and then  
NOTE Confidence: 0.8116819

00:05:16.701 --> 00:05:18.997 stop after six months of treatment.  
NOTE Confidence: 0.8116819

00:05:18.997 --> 00:05:20.793 The investigators from this  
NOTE Confidence: 0.8116819

00:05:20.793 --> 00:05:22.400 trial hypothesize that MF,  
NOTE Confidence: 0.8116819

00:05:22.400 --> 00:05:23.525 combined with steroids,  
NOTE Confidence: 0.8116819

00:05:23.525 --> 00:05:26.150 would be more effective than steroids alone,  
NOTE Confidence: 0.8116819

00:05:26.150 --> 00:05:28.565 and the primary outcome measured was time  
NOTE Confidence: 0.8116819

00:05:28.565 --> 00:05:30.650 from randomization to treatment failure,  
NOTE Confidence: 0.8116819

00:05:30.650 --> 00:05:32.235 defined as a platelet count  
NOTE Confidence: 0.8116819

00:05:32.235 --> 00:05:34.809 less than 30 and a clinical need

NOTE Confidence: 0.8116819

00:05:34.809 --> 00:05:36.645 for second line treatment.

NOTE Confidence: 0.8116819

00:05:36.650 --> 00:05:38.150 Secondary outcomes are outlined

NOTE Confidence: 0.8116819

00:05:38.150 --> 00:05:40.025 here and included bleeding events,

NOTE Confidence: 0.8116819

00:05:40.030 --> 00:05:40.758 side effects,

NOTE Confidence: 0.8116819

00:05:40.758 --> 00:05:42.942 and patient reported outcomes both at

NOTE Confidence: 0.8116819

00:05:42.942 --> 00:05:45.627 baseline and AT246 and 12 months as

NOTE Confidence: 0.8116819

00:05:45.627 --> 00:05:47.143 measured by validated questionnaires.

NOTE Confidence: 0.8653912

00:05:49.220 --> 00:05:51.719 120 patients were included in this study,

NOTE Confidence: 0.8653912

00:05:51.720 --> 00:05:54.272 with 59 on the MF ARM and 61

NOTE Confidence: 0.8653912

00:05:54.272 --> 00:05:55.999 patients receiving steroids alone.

NOTE Confidence: 0.8653912

00:05:56.000 --> 00:05:58.148 The median follow-up was 18 months.

NOTE Confidence: 0.8653912

00:05:58.150 --> 00:05:59.955 52.4% of patients were male

NOTE Confidence: 0.8653912

00:05:59.955 --> 00:06:02.070 with a median age of 54,

NOTE Confidence: 0.8653912

00:06:02.070 --> 00:06:04.541 so it was noted that more than

NOTE Confidence: 0.8653912

00:06:04.541 --> 00:06:06.737 1/4 of patients enrolled in the

NOTE Confidence: 0.8653912

00:06:06.737 --> 00:06:09.208 study were over the age of 70.  
NOTE Confidence: 0.8653912

00:06:09.210 --> 00:06:11.496 The primary outcome of proportion of  
NOTE Confidence: 0.8653912

00:06:11.496 --> 00:06:13.392 patients without treatment failure is  
NOTE Confidence: 0.8653912

00:06:13.392 --> 00:06:15.276 illustrated in the Kaplan Meier curve.  
NOTE Confidence: 0.8653912

00:06:15.280 --> 00:06:17.842 Here on the left of the slide  
NOTE Confidence: 0.8653912

00:06:17.842 --> 00:06:20.654 and favored the MF arm with an  
NOTE Confidence: 0.8653912

00:06:20.654 --> 00:06:22.689 adjusted hazard ratio of 0.41.  
NOTE Confidence: 0.8653912

00:06:22.690 --> 00:06:23.414 Interesting Lee.  
NOTE Confidence: 0.8653912

00:06:23.414 --> 00:06:24.862 Similar responses were observed  
NOTE Confidence: 0.8653912

00:06:24.862 --> 00:06:26.969 in the two groups at 2 weeks,  
NOTE Confidence: 0.8653912

00:06:26.970 --> 00:06:28.460 despite the less refractoriness that  
NOTE Confidence: 0.8653912

00:06:28.460 --> 00:06:31.111 was seen in the MF cohort and a  
NOTE Confidence: 0.8653912

00:06:31.111 --> 00:06:32.215 statistically significant increase  
NOTE Confidence: 0.8653912

00:06:32.215 --> 00:06:34.676 in plate in patients who reached a  
NOTE Confidence: 0.8653912

00:06:34.676 --> 00:06:36.530 platelet count greater than 100 before  
NOTE Confidence: 0.8653912

00:06:36.530 --> 00:06:39.510 they required in second line treatment.

NOTE Confidence: 0.8653912

00:06:39.510 --> 00:06:41.496 There were no differences observed in

NOTE Confidence: 0.8653912

00:06:41.496 --> 00:06:42.820 bleeding events or hospitalizations,

NOTE Confidence: 0.8653912

00:06:42.820 --> 00:06:44.776 and there were comparable rates of

NOTE Confidence: 0.8653912

00:06:44.776 --> 00:06:46.789 treatment side effects in both groups.

NOTE Confidence: 0.8653912

00:06:46.790 --> 00:06:47.180 However,

NOTE Confidence: 0.8653912

00:06:47.180 --> 00:06:49.520 there were some aspects on quality

NOTE Confidence: 0.8653912

00:06:49.520 --> 00:06:51.282 of life questionnaires that were

NOTE Confidence: 0.8653912

00:06:51.282 --> 00:06:53.410 observed to be worse in the MF arm,

NOTE Confidence: 0.8653912

00:06:53.410 --> 00:06:54.724 including both physical

NOTE Confidence: 0.8653912

00:06:54.724 --> 00:06:56.476 function and fatigue scores.

NOTE Confidence: 0.8653912

00:06:56.480 --> 00:06:58.380 So to summarize this abstract,

NOTE Confidence: 0.8653912

00:06:58.380 --> 00:07:00.642 this is the first randomized control

NOTE Confidence: 0.8653912

00:07:00.642 --> 00:07:02.920 trial using MF to treat ITP,

NOTE Confidence: 0.8653912

00:07:02.920 --> 00:07:04.740 and it illustrated good overall

NOTE Confidence: 0.8653912

00:07:04.740 --> 00:07:06.560 efficacy and tolerability when added

NOTE Confidence: 0.8653912

00:07:06.621 --> 00:07:08.229 to first line corticosteroids,  
NOTE Confidence: 0.8653912

00:07:08.230 --> 00:07:10.366 including in a cohort of patients  
NOTE Confidence: 0.8653912

00:07:10.366 --> 00:07:12.400 that had included elderly patients.  
NOTE Confidence: 0.8653912

00:07:12.400 --> 00:07:12.770 However,  
NOTE Confidence: 0.8653912

00:07:12.770 --> 00:07:14.990 there were some negative affects on  
NOTE Confidence: 0.8653912

00:07:14.990 --> 00:07:17.276 quality of life that were observed  
NOTE Confidence: 0.8653912

00:07:17.276 --> 00:07:19.496 in the treatment arm and the  
NOTE Confidence: 0.8653912

00:07:19.496 --> 00:07:21.084 investigator suggested that this  
NOTE Confidence: 0.8653912

00:07:21.084 --> 00:07:23.388 regimen could be considered in some,  
NOTE Confidence: 0.8653912

00:07:23.390 --> 00:07:25.594 but not necessarily all,  
NOTE Confidence: 0.8653912

00:07:25.594 --> 00:07:28.349 patients with newly diagnosed ITP.  
NOTE Confidence: 0.8653912

00:07:28.350 --> 00:07:30.102 The nest next abstract I'd like  
NOTE Confidence: 0.8653912

00:07:30.102 --> 00:07:32.114 to share was presented by Doctor  
NOTE Confidence: 0.8653912

00:07:32.114 --> 00:07:33.674 David Kuter from Massachusetts  
NOTE Confidence: 0.8653912

00:07:33.674 --> 00:07:35.646 General Hospital and highlights the  
NOTE Confidence: 0.8653912

00:07:35.646 --> 00:07:37.406 clinically active and the durable

NOTE Confidence: 0.8653912

00:07:37.406 --> 00:07:39.144 platelet response that were observed

NOTE Confidence: 0.8653912

00:07:39.144 --> 00:07:41.412 with the oral BTK inhibitor reels of

NOTE Confidence: 0.8653912

00:07:41.412 --> 00:07:43.568 Bruton IB in patients with heavily

NOTE Confidence: 0.8653912

00:07:43.568 --> 00:07:45.368 pretreated ITP as illustrated in

NOTE Confidence: 0.8653912

00:07:45.368 --> 00:07:46.499 the figure here.

NOTE Confidence: 0.8653912

00:07:46.500 --> 00:07:48.803 On the left rules ibrutinib is a

NOTE Confidence: 0.8653912

00:07:48.803 --> 00:07:50.191 reversible and selective inhibitor

NOTE Confidence: 0.8653912

00:07:50.191 --> 00:07:52.571 of BTK that aims to target the

NOTE Confidence: 0.8653912

00:07:52.571 --> 00:07:54.067 disease mechanisms leading to

NOTE Confidence: 0.8653912

00:07:54.067 --> 00:07:55.567 platelet destruction in ITP,

NOTE Confidence: 0.8653912

00:07:55.570 --> 00:07:57.766 though it's without the effects on

NOTE Confidence: 0.8653912

00:07:57.766 --> 00:07:59.880 platelet aggregation that we often see.

NOTE Confidence: 0.8653912

00:07:59.880 --> 00:08:02.760 In the drug ibrutinib the trial,

NOTE Confidence: 0.8653912

00:08:02.760 --> 00:08:04.840 this trial of Phase 1 two open label

NOTE Confidence: 0.8653912

00:08:04.840 --> 00:08:07.063 trial was a dose finding study and

NOTE Confidence: 0.8653912

00:08:07.063 --> 00:08:08.703 that enrolled adult patients with  
NOTE Confidence: 0.8653912

00:08:08.767 --> 00:08:10.669 relapsed or refractory ITP who had  
NOTE Confidence: 0.8653912

00:08:10.669 --> 00:08:12.546 responded to at least one prior  
NOTE Confidence: 0.8653912

00:08:12.546 --> 00:08:14.970 line of ITP therapy and had two or  
NOTE Confidence: 0.8653912

00:08:15.043 --> 00:08:17.107 more platelet counts that were less  
NOTE Confidence: 0.8653912

00:08:17.107 --> 00:08:19.937 than 30 at the time of study entry.  
NOTE Confidence: 0.8653912

00:08:19.940 --> 00:08:22.514 Subjects could be on stable doses  
NOTE Confidence: 0.8653912

00:08:22.514 --> 00:08:23.801 of concomitant corticosteroids  
NOTE Confidence: 0.8653912

00:08:23.801 --> 00:08:25.726 and or thrombopoietin receptor  
NOTE Confidence: 0.8653912

00:08:25.726 --> 00:08:27.634 agonist during this trial.  
NOTE Confidence: 0.8653912

00:08:27.640 --> 00:08:30.166 The dose escalation phase of this  
NOTE Confidence: 0.8653912

00:08:30.166 --> 00:08:32.281 study was previously reported at  
NOTE Confidence: 0.8653912

00:08:32.281 --> 00:08:34.447 ASH with a minimum effective dose  
NOTE Confidence: 0.8653912

00:08:34.447 --> 00:08:36.400 of 400 milligrams twice daily.  
NOTE Confidence: 0.8653912

00:08:36.400 --> 00:08:38.640 The primary endpoint of this part of  
NOTE Confidence: 0.8653912

00:08:38.640 --> 00:08:41.393 the study was achieving two or more

NOTE Confidence: 0.8653912

00:08:41.393 --> 00:08:43.113 consecutive platelet counts that

NOTE Confidence: 0.8653912

00:08:43.113 --> 00:08:45.398 were greater than 50,000 with an

NOTE Confidence: 0.8653912

00:08:45.398 --> 00:08:47.869 increase of more than 20,000 from the

NOTE Confidence: 0.8653912

00:08:47.869 --> 00:08:49.585 patients baseline without requiring

NOTE Confidence: 0.8653912

00:08:49.585 --> 00:08:51.730 any rescue or additional medications.

NOTE Confidence: 0.8653912

00:08:51.730 --> 00:08:54.050 The investigators also performed subgroup

NOTE Confidence: 0.8653912

00:08:54.050 --> 00:08:56.370 analysis to determine the impact

NOTE Confidence: 0.875766

00:08:56.435 --> 00:08:58.095 of certain prior treatments

NOTE Confidence: 0.875766

00:08:58.095 --> 00:08:59.755 on this primary endpoint.

NOTE Confidence: 0.875766

00:08:59.760 --> 00:09:01.972 A long term extension study was also

NOTE Confidence: 0.875766

00:09:01.972 --> 00:09:03.737 conducted to further assess safety

NOTE Confidence: 0.875766

00:09:03.737 --> 00:09:05.637 and durability of this medication,

NOTE Confidence: 0.875766

00:09:05.640 --> 00:09:07.390 and so this specific abstract

NOTE Confidence: 0.875766

00:09:07.390 --> 00:09:09.140 presented on 38 patients who

NOTE Confidence: 0.875766

00:09:09.201 --> 00:09:11.187 had received the dose of 400

NOTE Confidence: 0.875766



00:09:11.187 --> 00:09:13.268 milligrams twice daily and the 13  
NOTE Confidence: 0.875766

00:09:13.268 --> 00:09:15.332 patients who entered the long term  
NOTE Confidence: 0.875766

00:09:15.332 --> 00:09:17.408 extension study at this same dose.  
NOTE Confidence: 0.85495913

00:09:19.880 --> 00:09:22.174 So patients in the 400 milligram twice  
NOTE Confidence: 0.85495913

00:09:22.174 --> 00:09:24.503 daily cohort had a median duration of  
NOTE Confidence: 0.85495913

00:09:24.503 --> 00:09:27.080 ITP of six years and had received a  
NOTE Confidence: 0.85495913

00:09:27.080 --> 00:09:29.159 median of six prior lines of therapy.  
NOTE Confidence: 0.85495913

00:09:29.160 --> 00:09:31.915 Their median age was 50, with a little  
NOTE Confidence: 0.85495913

00:09:31.915 --> 00:09:34.610 more than half of patients being female.  
NOTE Confidence: 0.85495913

00:09:34.610 --> 00:09:36.506 At the time of data cutoff,  
NOTE Confidence: 0.85495913

00:09:36.510 --> 00:09:39.275 which was July of 2020, forty 2% of  
NOTE Confidence: 0.85495913

00:09:39.275 --> 00:09:41.645 patients had achieved the primary endpoint.  
NOTE Confidence: 0.85495913

00:09:41.650 --> 00:09:43.318 Furthermore, responses were relatively  
NOTE Confidence: 0.85495913

00:09:43.318 --> 00:09:45.820 similar whether or not these patients  
NOTE Confidence: 0.85495913

00:09:45.878 --> 00:09:47.578 had responded to prior therapy,  
NOTE Confidence: 0.85495913

00:09:47.580 --> 00:09:48.762 as outlined here,

NOTE Confidence: 0.85495913

00:09:48.762 --> 00:09:50.338 including thrombopoietin receptor agonist,

NOTE Confidence: 0.85495913

00:09:50.340 --> 00:09:51.525 rituximab, or fostamatinib,

NOTE Confidence: 0.85495913

00:09:51.525 --> 00:09:53.895 and notably responses were quite rapid,

NOTE Confidence: 0.85495913

00:09:53.900 --> 00:09:56.702 with 53% of patients achieving a

NOTE Confidence: 0.85495913

00:09:56.702 --> 00:10:00.109 platelet count of more than 30 by day 8.

NOTE Confidence: 0.85495913

00:10:00.110 --> 00:10:02.145 And and responses were also

NOTE Confidence: 0.85495913

00:10:02.145 --> 00:10:03.366 durable in nature.

NOTE Confidence: 0.85495913

00:10:03.370 --> 00:10:05.730 A real rose alot nib was generally well

NOTE Confidence: 0.85495913

00:10:05.730 --> 00:10:08.109 tolerated in all portions of the trial

NOTE Confidence: 0.85495913

00:10:08.109 --> 00:10:09.839 with approximately half of patients

NOTE Confidence: 0.85495913

00:10:09.900 --> 00:10:12.364 experiencing grade one or two side effects

NOTE Confidence: 0.85495913

00:10:12.364 --> 00:10:14.428 that were transient and mostly GI.

NOTE Confidence: 0.85495913

00:10:14.428 --> 00:10:15.100 In nature,

NOTE Confidence: 0.85495913

00:10:15.100 --> 00:10:17.158 though there were no serious adverse

NOTE Confidence: 0.85495913

00:10:17.158 --> 00:10:19.430 events or treatment related bleeding or

NOTE Confidence: 0.85495913

00:10:19.430 --> 00:10:21.535 thrombotic complications during this study.

NOTE Confidence: 0.85495913

00:10:21.540 --> 00:10:22.521 So, in conclusion,

NOTE Confidence: 0.85495913

00:10:22.521 --> 00:10:24.810 reels reels of Bruton AB therapy at

NOTE Confidence: 0.85495913

00:10:24.877 --> 00:10:27.551 a dose of 400 milligrams twice daily

NOTE Confidence: 0.85495913

00:10:27.551 --> 00:10:29.499 achieved significant rapid and long

NOTE Confidence: 0.85495913

00:10:29.499 --> 00:10:31.349 lasting platelet responses in about

NOTE Confidence: 0.85495913

00:10:31.349 --> 00:10:33.495 a slightly under half a percent

NOTE Confidence: 0.85495913

00:10:33.495 --> 00:10:35.220 percentage of this patient population

NOTE Confidence: 0.85495913

00:10:35.220 --> 00:10:37.189 with heavily treated pretreated ITP,

NOTE Confidence: 0.85495913

00:10:37.190 --> 00:10:39.668 and this was observed irrespective of the

NOTE Confidence: 0.85495913

00:10:39.668 --> 00:10:42.290 response to prior lines of treatment rules.

NOTE Confidence: 0.85495913

00:10:42.290 --> 00:10:44.105 Ibrutinib was granted fast track

NOTE Confidence: 0.85495913

00:10:44.105 --> 00:10:46.345 designation by the FDA in October

NOTE Confidence: 0.85495913

00:10:46.345 --> 00:10:48.523 of this past year and further

NOTE Confidence: 0.85495913

00:10:48.523 --> 00:10:50.300 clinical trials with this drug.

NOTE Confidence: 0.85495913

00:10:50.300 --> 00:10:51.820 That drug is current.

NOTE Confidence: 0.85495913

00:10:51.820 --> 00:10:52.960 Currently on going.

NOTE Confidence: 0.8092774

00:10:55.840 --> 00:10:57.264 In the plenary session,

NOTE Confidence: 0.8092774

00:10:57.264 --> 00:10:59.896 Doctor Terry Gurne Shime are from the

NOTE Confidence: 0.8092774

00:10:59.896 --> 00:11:02.464 University of Washington School of Medicine,

NOTE Confidence: 0.8092774

00:11:02.470 --> 00:11:04.864 presented the results of the American

NOTE Confidence: 0.8092774

00:11:04.864 --> 00:11:06.890 trial using tranexamic acid and

NOTE Confidence: 0.8092774

00:11:06.890 --> 00:11:09.098 thrombocytopenia or the a treat trial.

NOTE Confidence: 0.8092774

00:11:09.100 --> 00:11:10.536 This study specifically examined

NOTE Confidence: 0.8092774

00:11:10.536 --> 00:11:12.690 the effects of tranexamic acid or

NOTE Confidence: 0.8092774

00:11:12.747 --> 00:11:14.897 txa prophylaxis on bleeding outcomes

NOTE Confidence: 0.8092774

00:11:14.897 --> 00:11:16.617 in individuals with hematologic

NOTE Confidence: 0.8092774

00:11:16.617 --> 00:11:18.679 malignancy undergoing treatment therapy.

NOTE Confidence: 0.8092774

00:11:18.680 --> 00:11:20.936 And it was supported by understanding

NOTE Confidence: 0.8092774

00:11:20.936 --> 00:11:23.340 of the high incidence of bleeding

NOTE Confidence: 0.8092774

00:11:23.340 --> 00:11:25.000 in this patient population,

NOTE Confidence: 0.8092774

00:11:25.000 --> 00:11:27.828 even despite our evidence based use of  
NOTE Confidence: 0.8092774

00:11:27.828 --> 00:11:29.040 platelet transfusions prophylactically  
NOTE Confidence: 0.8092774

00:11:29.100 --> 00:11:30.780 and while anti fibrinolytic therapy  
NOTE Confidence: 0.8092774

00:11:30.780 --> 00:11:33.393 has certainly been used with pain in  
NOTE Confidence: 0.8092774

00:11:33.393 --> 00:11:35.145 patients with hematologic malignancy  
NOTE Confidence: 0.8092774

00:11:35.145 --> 00:11:36.459 undergoing treatment evidence,  
NOTE Confidence: 0.8092774

00:11:36.460 --> 00:11:38.830 evidence of its benefit has really  
NOTE Confidence: 0.8092774

00:11:38.830 --> 00:11:39.620 been lacking.  
NOTE Confidence: 0.8092774

00:11:39.620 --> 00:11:42.780 So the Atria trial was a multi center,  
NOTE Confidence: 0.8092774

00:11:42.780 --> 00:11:43.548 double blinded,  
NOTE Confidence: 0.8092774

00:11:43.548 --> 00:11:45.468 placebo controlled trial aimed to  
NOTE Confidence: 0.8092774

00:11:45.468 --> 00:11:47.988 assess the safety and efficacy of  
NOTE Confidence: 0.8092774

00:11:47.988 --> 00:11:49.724 prophylactic transit tranexamic acid.  
NOTE Confidence: 0.8092774

00:11:49.730 --> 00:11:52.070 Which is seen in this schematic,  
NOTE Confidence: 0.8092774

00:11:52.070 --> 00:11:54.478 here included on the left of the  
NOTE Confidence: 0.8092774

00:11:54.478 --> 00:11:56.876 slide block slicing binding site on

NOTE Confidence: 0.8092774

00:11:56.876 --> 00:11:59.474 plasminogen an inhibits and its activation,

NOTE Confidence: 0.8092774

00:11:59.480 --> 00:12:00.533 thus halting fibrinolysis.

NOTE Confidence: 0.8092774

00:12:00.533 --> 00:12:03.862 And the train exam IC acid was used as

NOTE Confidence: 0.8092774

00:12:03.862 --> 00:12:06.268 an adjunct to routine platelet transfusions.

NOTE Confidence: 0.8092774

00:12:06.270 --> 00:12:08.130 As was previously studied.

NOTE Confidence: 0.8092774

00:12:08.130 --> 00:12:09.990 Patients undergoing therapy for

NOTE Confidence: 0.8092774

00:12:09.990 --> 00:12:11.663 hematologic malignancy whom were

NOTE Confidence: 0.8092774

00:12:11.663 --> 00:12:13.358 expected to have platelet counts

NOTE Confidence: 0.8092774

00:12:13.358 --> 00:12:15.583 less than 10,000 for five or more

NOTE Confidence: 0.8092774

00:12:15.583 --> 00:12:17.305 days were eligible to be enrolled

NOTE Confidence: 0.8092774

00:12:17.310 --> 00:12:20.173 in the study and were randomized to

NOTE Confidence: 0.8092774

00:12:20.173 --> 00:12:22.173 receive either tranexamic acid at a

NOTE Confidence: 0.8092774

00:12:22.173 --> 00:12:24.610 dose of 1 gram Ivy or 1.3 grams opeo

NOTE Confidence: 0.8092774

00:12:24.610 --> 00:12:26.782 every eight hours or placebo with

NOTE Confidence: 0.8092774

00:12:26.782 --> 00:12:29.880 the start of the study drug after a

NOTE Confidence: 0.8092774

00:12:29.880 --> 00:12:32.229 platelet count had dropped below 30.  
NOTE Confidence: 0.8092774

00:12:32.230 --> 00:12:33.990 Tranexamic acid or placebo was  
NOTE Confidence: 0.8092774

00:12:33.990 --> 00:12:36.157 discontinued after 30 days or when  
NOTE Confidence: 0.8092774

00:12:36.157 --> 00:12:38.233 platelet counts had re platelet count  
NOTE Confidence: 0.8092774

00:12:38.233 --> 00:12:40.477 had recovered to more than 30,000  
NOTE Confidence: 0.8092774

00:12:40.477 --> 00:12:42.382 and the trans transfusion thresholds  
NOTE Confidence: 0.8092774

00:12:42.382 --> 00:12:44.614 used during the study where per  
NOTE Confidence: 0.8092774

00:12:44.614 --> 00:12:46.810 standard of care the primary endpoint  
NOTE Confidence: 0.8092774

00:12:46.876 --> 00:12:48.880 was the proportion of patients with  
NOTE Confidence: 0.8092774

00:12:48.880 --> 00:12:51.417 WHO grade two or above bleeding with  
NOTE Confidence: 0.8092774

00:12:51.417 --> 00:12:53.691 Grade 2 being moderate bleeding Grade  
NOTE Confidence: 0.8092774

00:12:53.691 --> 00:12:55.538 3 being severe bleeding requiring  
NOTE Confidence: 0.8092774

00:12:55.538 --> 00:12:57.740 transfusion of red blood cells or  
NOTE Confidence: 0.8092774

00:12:57.806 --> 00:13:00.212 other intervention and grade for being  
NOTE Confidence: 0.8092774

00:13:00.212 --> 00:13:02.559 life threatening or debilitating bleed bleed.  
NOTE Confidence: 0.8092774

00:13:02.560 --> 00:13:04.144 Additional secondary and safety

NOTE Confidence: 0.8092774

00:13:04.144 --> 00:13:06.520 endpoints are outlined on the slide

NOTE Confidence: 0.8092774

00:13:06.588 --> 00:13:08.718 here and include rate of thrombosis,

NOTE Confidence: 0.8092774

00:13:08.720 --> 00:13:10.650 vino occlusive disease and mortality.

NOTE Confidence: 0.85934526

00:13:14.810 --> 00:13:16.210 There were 330 patients,

NOTE Confidence: 0.85934526

00:13:16.210 --> 00:13:19.438 a valuable in the study with 165 on each arm,

NOTE Confidence: 0.85934526

00:13:19.440 --> 00:13:22.419 and the two groups were well balanced by age,

NOTE Confidence: 0.85934526

00:13:22.420 --> 00:13:24.080 gender, and type of therapy.

NOTE Confidence: 0.85934526

00:13:24.080 --> 00:13:26.042 Only 9% of the patients actually

NOTE Confidence: 0.85934526

00:13:26.042 --> 00:13:27.720 completed 30 days on drug,

NOTE Confidence: 0.85934526

00:13:27.720 --> 00:13:30.699 with an average of 12 days on train exam.

NOTE Confidence: 0.85934526

00:13:30.700 --> 00:13:31.956 IC acid or placebo.

NOTE Confidence: 0.85934526

00:13:31.956 --> 00:13:34.265 And as you can see in the

NOTE Confidence: 0.85934526

00:13:34.265 --> 00:13:35.990 table here on the left,

NOTE Confidence: 0.85934526

00:13:35.990 --> 00:13:37.730 the primary outcome of proportion of

NOTE Confidence: 0.85934526

00:13:37.730 --> 00:13:39.999 WHL grade two or higher bleeding was

NOTE Confidence: 0.85934526



00:13:39.999 --> 00:13:41.749 no different between the tranexamic

NOTE Confidence: 0.85934526

00:13:41.749 --> 00:13:43.678 acid and placebo, placebo arms,

NOTE Confidence: 0.85934526

00:13:43.678 --> 00:13:46.226 and this was also true irrespective of.

NOTE Confidence: 0.85934526

00:13:46.230 --> 00:13:48.066 The pre specified treatment

NOTE Confidence: 0.85934526

00:13:48.066 --> 00:13:49.902 subgroups that included allogeneic

NOTE Confidence: 0.85934526

00:13:49.902 --> 00:13:51.869 stencil stem cell transplant,

NOTE Confidence: 0.85934526

00:13:51.870 --> 00:13:53.090 autologous transplant,

NOTE Confidence: 0.85934526

00:13:53.090 --> 00:13:54.920 and chemotherapy alone.

NOTE Confidence: 0.85934526

00:13:54.920 --> 00:13:56.824 The time to 1st WH O2 or more

NOTE Confidence: 0.85934526

00:13:56.824 --> 00:13:59.122 two or higher bleeding or death

NOTE Confidence: 0.85934526

00:13:59.122 --> 00:14:00.874 was also remarkably similar,

NOTE Confidence: 0.85934526

00:14:00.880 --> 00:14:02.866 with the lines overlying each other

NOTE Confidence: 0.85934526

00:14:02.866 --> 00:14:06.480 in the graph, seen here on the right.

NOTE Confidence: 0.85934526

00:14:06.480 --> 00:14:07.816 Mean platelet transfusion mean

NOTE Confidence: 0.85934526

00:14:07.816 --> 00:14:10.288 days alive with WHO two or more

NOTE Confidence: 0.85934526

00:14:10.288 --> 00:14:12.748 bleeding an mean red blood cell

NOTE Confidence: 0.85934526

00:14:12.748 --> 00:14:13.978 transfusion per thrombocytopenia.

NOTE Confidence: 0.85934526

00:14:13.980 --> 00:14:16.530 Cdai were also not impacted by

NOTE Confidence: 0.85934526

00:14:16.530 --> 00:14:18.730 the use of tranexamic acid.

NOTE Confidence: 0.85934526

00:14:18.730 --> 00:14:19.442 There was,

NOTE Confidence: 0.85934526

00:14:19.442 --> 00:14:19.798 however,

NOTE Confidence: 0.85934526

00:14:19.798 --> 00:14:20.866 a statistically significant

NOTE Confidence: 0.85934526

00:14:20.866 --> 00:14:22.664 increase in the overall thrombotic

NOTE Confidence: 0.85934526

00:14:22.664 --> 00:14:24.596 events on the tranexamic acid arm,

NOTE Confidence: 0.85934526

00:14:24.600 --> 00:14:27.176 though this primarily was made up of

NOTE Confidence: 0.85934526

00:14:27.176 --> 00:14:29.638 line occlusions with a trend that was

NOTE Confidence: 0.85934526

00:14:29.638 --> 00:14:31.576 actually fewer in of non catheter

NOTE Confidence: 0.85934526

00:14:31.641 --> 00:14:34.155 thrombotic events in the treatment arm.

NOTE Confidence: 0.85934526

00:14:34.160 --> 00:14:36.379 There was no increase in Veno occlusive,

NOTE Confidence: 0.85934526

00:14:36.380 --> 00:14:36.705 disease,

NOTE Confidence: 0.85934526

00:14:36.705 --> 00:14:38.330 or all cause mortality

NOTE Confidence: 0.85934526

00:14:38.330 --> 00:14:40.179 at either 30 or 20 days,  
NOTE Confidence: 0.85934526

00:14:40.180 --> 00:14:42.065 and no deaths were observed  
NOTE Confidence: 0.85934526

00:14:42.065 --> 00:14:43.950 as the result of thrombosis.  
NOTE Confidence: 0.85934526

00:14:43.950 --> 00:14:46.038 So based on all of this,  
NOTE Confidence: 0.85934526

00:14:46.040 --> 00:14:47.780 train exam IC acid administered  
NOTE Confidence: 0.85934526

00:14:47.780 --> 00:14:48.128 prophylactically,  
NOTE Confidence: 0.85934526

00:14:48.130 --> 00:14:49.760 in addition to routine platelet  
NOTE Confidence: 0.85934526

00:14:49.760 --> 00:14:51.950 transfusion did not seem to increase,  
NOTE Confidence: 0.85934526

00:14:51.950 --> 00:14:53.924 decrease the rate of WHL grade 2  
NOTE Confidence: 0.85934526

00:14:53.924 --> 00:14:55.867 plus or bleeding in patients who  
NOTE Confidence: 0.85934526

00:14:55.867 --> 00:14:56.902 are severely thrombocytopenia  
NOTE Confidence: 0.85934526

00:14:56.902 --> 00:14:59.674 IK as a result of treatment for  
NOTE Confidence: 0.85934526

00:14:59.674 --> 00:15:01.000 their hematologic malignancy.  
NOTE Confidence: 0.85934526

00:15:01.000 --> 00:15:03.303 It also did not seem to alter  
NOTE Confidence: 0.85934526

00:15:03.303 --> 00:15:04.677 transfusion requirements and and  
NOTE Confidence: 0.85934526

00:15:04.677 --> 00:15:06.651 actually resulted in an increased rate

NOTE Confidence: 0.85934526  
00:15:06.651 --> 00:15:08.659 of central line occlusion events,  
NOTE Confidence: 0.85934526  
00:15:08.660 --> 00:15:10.400 and so the authors emphasize,  
NOTE Confidence: 0.85934526  
00:15:10.400 --> 00:15:11.372 despite these findings,  
NOTE Confidence: 0.85934526  
00:15:11.372 --> 00:15:12.992 that the utility of tranexamic  
NOTE Confidence: 0.85934526  
00:15:12.992 --> 00:15:14.947 acid in other settings with  
NOTE Confidence: 0.85934526  
00:15:14.947 --> 00:15:16.619 thrombocytopenia cannot be excluded.  
NOTE Confidence: 0.85934526  
00:15:16.620 --> 00:15:18.068 By this study alone.  
NOTE Confidence: 0.8342403  
00:15:20.300 --> 00:15:23.023 So moving on to an abstract presented  
NOTE Confidence: 0.8342403  
00:15:23.023 --> 00:15:25.433 by Doctor Steven Pipe from the  
NOTE Confidence: 0.8342403  
00:15:25.433 --> 00:15:28.156 University of Michigan on the long term,  
NOTE Confidence: 0.8342403  
00:15:28.160 --> 00:15:28.944 durability, safety,  
NOTE Confidence: 0.8342403  
00:15:28.944 --> 00:15:31.296 and efficacy of fat userin prophylaxis,  
NOTE Confidence: 0.8342403  
00:15:31.300 --> 00:15:32.828 prophylaxis in patients with  
NOTE Confidence: 0.8342403  
00:15:32.828 --> 00:15:35.592 hemophilia A or B with or without  
NOTE Confidence: 0.8342403  
00:15:35.592 --> 00:15:38.378 inhibitors as seen on the slide here.  
NOTE Confidence: 0.8342403

00:15:38.380 --> 00:15:41.521 So for twos are in is a small interfering  
NOTE Confidence: 0.8342403

00:15:41.521 --> 00:15:44.670 RNA that as described in the schematic,  
NOTE Confidence: 0.8342403

00:15:44.670 --> 00:15:46.380 blocks the production of anti  
NOTE Confidence: 0.8342403

00:15:46.380 --> 00:15:48.647 thrombin and as a result increases  
NOTE Confidence: 0.8342403

00:15:48.647 --> 00:15:51.077 or improves thrombin generation and.  
NOTE Confidence: 0.8342403

00:15:51.080 --> 00:15:53.324 Remote team of stasis and individuals  
NOTE Confidence: 0.8342403

00:15:53.324 --> 00:15:55.130 with hemophilia of phase one.  
NOTE Confidence: 0.8342403

00:15:55.130 --> 00:15:57.260 Study of monthly subcutaneous photographer  
NOTE Confidence: 0.8342403

00:15:57.260 --> 00:15:59.390 to Sarandos ING was previously  
NOTE Confidence: 0.8342403

00:15:59.453 --> 00:16:01.379 reported in the New England Journal  
NOTE Confidence: 0.8342403

00:16:01.379 --> 00:16:03.412 of Medicine in 2017 and demonstrated  
NOTE Confidence: 0.8342403

00:16:03.412 --> 00:16:05.820 that this drug was well tolerated and  
NOTE Confidence: 0.8342403

00:16:05.820 --> 00:16:07.169 also reliably lowered antithrombin  
NOTE Confidence: 0.8342403

00:16:07.169 --> 00:16:09.167 in a dose dependent manner resulting  
NOTE Confidence: 0.8342403

00:16:09.167 --> 00:16:10.948 in decreased bleeding frequency.  
NOTE Confidence: 0.8342403

00:16:10.950 --> 00:16:13.582 So in this trial adult male patients

NOTE Confidence: 0.8342403

00:16:13.582 --> 00:16:15.154 with moderate severe haemophilia

NOTE Confidence: 0.8342403

00:16:15.154 --> 00:16:17.374 moderate or severe hemophilia A or

NOTE Confidence: 0.8342403

00:16:17.374 --> 00:16:19.924 B who had tolerated for chooser in

NOTE Confidence: 0.8342403

00:16:19.924 --> 00:16:22.368 in the Phase one study were eligible

NOTE Confidence: 0.8342403

00:16:22.368 --> 00:16:24.258 to continue into this phase.

NOTE Confidence: 0.8342403

00:16:24.260 --> 00:16:24.966 A2 cohort,

NOTE Confidence: 0.8342403

00:16:24.966 --> 00:16:27.084 which was an open label extension

NOTE Confidence: 0.8342403

00:16:27.084 --> 00:16:29.118 portion and they receive photos,

NOTE Confidence: 0.8342403

00:16:29.120 --> 00:16:31.703 are in at a dose of 50 or 80

NOTE Confidence: 0.8342403

00:16:31.703 --> 00:16:33.610 milligrams subcutaneous monthly.

NOTE Confidence: 0.8342403

00:16:33.610 --> 00:16:35.102 The primary endpoints were

NOTE Confidence: 0.8342403

00:16:35.102 --> 00:16:36.594 safety and adverse events,

NOTE Confidence: 0.8342403

00:16:36.600 --> 00:16:38.796 and there were key secondary endpoints

NOTE Confidence: 0.8342403

00:16:38.796 --> 00:16:40.720 that included a calculated median.

NOTE Confidence: 0.8342403

00:16:40.720 --> 00:16:42.800 Analyze the annualized bleed rate

NOTE Confidence: 0.8342403

00:16:42.800 --> 00:16:44.464 pharmacokinetics in quality of  
NOTE Confidence: 0.8342403

00:16:44.464 --> 00:16:46.700 life in the in the patient cohort.  
NOTE Confidence: 0.9159124

00:16:49.070 --> 00:16:52.214 34 patients were included in this portion of  
NOTE Confidence: 0.9159124

00:16:52.214 --> 00:16:55.409 the study with a median age of 35.4 years.  
NOTE Confidence: 0.9159124

00:16:55.410 --> 00:16:57.726 And this included 27 individuals with  
NOTE Confidence: 0.9159124

00:16:57.726 --> 00:16:59.505 hemophilia A, A7 individuals with  
NOTE Confidence: 0.9159124

00:16:59.505 --> 00:17:02.378 hemophilia B and 15 out of the group  
NOTE Confidence: 0.9159124

00:17:02.378 --> 00:17:04.668 had inhibitors with 19 individuals.  
NOTE Confidence: 0.9159124

00:17:04.670 --> 00:17:06.350 Not having an inhibitor.  
NOTE Confidence: 0.9159124

00:17:06.350 --> 00:17:09.578 Patients received a median of 3.1 years of  
NOTE Confidence: 0.9159124

00:17:09.578 --> 00:17:12.490 a tutor inducing as of the data cut off,  
NOTE Confidence: 0.9159124

00:17:12.490 --> 00:17:14.758 which was September of 2020 and 12  
NOTE Confidence: 0.9159124

00:17:14.758 --> 00:17:17.117 individuals were on the 50 milligram dose,  
NOTE Confidence: 0.9159124

00:17:17.120 --> 00:17:20.376 with 22 being on the 80 milligram dose.  
NOTE Confidence: 0.9159124

00:17:20.380 --> 00:17:22.612 But user and was noted in this study  
NOTE Confidence: 0.9159124

00:17:22.612 --> 00:17:24.442 to decrease antithrombin levels quickly

NOTE Confidence: 0.9159124

00:17:24.442 --> 00:17:26.854 with sustained levels that remained at

NOTE Confidence: 0.9159124

00:17:26.854 --> 00:17:29.096 or below 20% in individuals who remained

NOTE Confidence: 0.9159124

00:17:29.096 --> 00:17:31.909 on the drug and so this was confirmed.

NOTE Confidence: 0.9159124

00:17:31.910 --> 00:17:34.724 The findings of the Phase one portion

NOTE Confidence: 0.9159124

00:17:34.724 --> 00:17:35.930 of the study.

NOTE Confidence: 0.9159124

00:17:35.930 --> 00:17:37.910 Immediate analyzed bleed rate was

NOTE Confidence: 0.9159124

00:17:37.910 --> 00:17:39.890 calculated for this cohort after

NOTE Confidence: 0.9159124

00:17:39.954 --> 00:17:41.634 achieving antithrombin knockdown an

NOTE Confidence: 0.9159124

00:17:41.634 --> 00:17:44.154 was zero for treated bleeds during

NOTE Confidence: 0.9159124

00:17:44.219 --> 00:17:45.479 the follow up period.

NOTE Confidence: 0.9159124

00:17:45.480 --> 00:17:48.091 The figure included here on this slide

NOTE Confidence: 0.9159124

00:17:48.091 --> 00:17:51.124 is a result from a post hoc analysis

NOTE Confidence: 0.9159124

00:17:51.124 --> 00:17:53.929 of 258 treated bleeds in 15 subjects,

NOTE Confidence: 0.9159124

00:17:53.930 --> 00:17:56.228 with each separate graph showing data

NOTE Confidence: 0.9159124

00:17:56.228 --> 00:17:58.090 on bleed causality, bleed location,

NOTE Confidence: 0.9159124



00:17:58.090 --> 00:18:00.575 an bleeds severity and from left to  
NOTE Confidence: 0.9159124

00:18:00.575 --> 00:18:02.635 right in patients with hemophilia  
NOTE Confidence: 0.9159124

00:18:02.635 --> 00:18:04.680 A with no inhibitor hemophilia.  
NOTE Confidence: 0.9159124

00:18:04.680 --> 00:18:07.110 A patients with an inhibitor hemophilia  
NOTE Confidence: 0.9159124

00:18:07.110 --> 00:18:09.697 B patients without an inhibitor and  
NOTE Confidence: 0.9159124

00:18:09.697 --> 00:18:12.385 hemophilia B patients with an inhibitor.  
NOTE Confidence: 0.9159124

00:18:12.390 --> 00:18:15.400 So while this is a bit of a busy figure,  
NOTE Confidence: 0.9159124

00:18:15.400 --> 00:18:17.512 the takeaway is really that breakaway  
NOTE Confidence: 0.9159124

00:18:17.512 --> 00:18:18.920 breakthrough bleeds occurred mostly  
NOTE Confidence: 0.9159124

00:18:18.974 --> 00:18:20.514 in the joints or mild in nature,  
NOTE Confidence: 0.9159124

00:18:20.520 --> 00:18:22.774 and tended to be more spontaneous in  
NOTE Confidence: 0.9159124

00:18:22.774 --> 00:18:24.400 those individuals with inhibitors.  
NOTE Confidence: 0.9159124

00:18:24.400 --> 00:18:26.770 These breakthrough bleeds were managed  
NOTE Confidence: 0.9159124

00:18:26.770 --> 00:18:29.140 with factor replacement or bypassing  
NOTE Confidence: 0.9159124

00:18:29.206 --> 00:18:31.366 agent per the study management guidelines  
NOTE Confidence: 0.9159124

00:18:31.366 --> 00:18:34.489 with a focus on reduced doses to try

NOTE Confidence: 0.9159124

00:18:34.489 --> 00:18:36.913 and minimize the potential thrombotic risk.

NOTE Confidence: 0.9159124

00:18:36.920 --> 00:18:37.316 However,

NOTE Confidence: 0.9159124

00:18:37.316 --> 00:18:40.088 in the safety analysis of this study,

NOTE Confidence: 0.9159124

00:18:40.090 --> 00:18:42.532 97% of patients experienced at least

NOTE Confidence: 0.9159124

00:18:42.532 --> 00:18:45.334 one adverse event with 38% having a

NOTE Confidence: 0.9159124

00:18:45.334 --> 00:18:47.569 serious adverse event which included

NOTE Confidence: 0.9159124

00:18:47.569 --> 00:18:50.130 the events such as an arterial

NOTE Confidence: 0.9159124

00:18:50.130 --> 00:18:52.797 thrombosis in one patient and a death

NOTE Confidence: 0.9159124

00:18:52.873 --> 00:18:55.281 that actually occurred in 2017 as a

NOTE Confidence: 0.9159124

00:18:55.281 --> 00:18:57.730 result of a cerebral vein thrombosis.

NOTE Confidence: 0.9159124

00:18:57.730 --> 00:19:00.080 So in October of 2020,

NOTE Confidence: 0.9159124

00:19:00.080 --> 00:19:01.616 Sanofi voluntarily paused enrollment,

NOTE Confidence: 0.9159124

00:19:01.616 --> 00:19:02.768 inducing with Catoosa,

NOTE Confidence: 0.9159124

00:19:02.770 --> 00:19:05.014 ran to further investigate these adverse

NOTE Confidence: 0.9159124

00:19:05.014 --> 00:19:07.359 events and the rate of thrombotic

NOTE Confidence: 0.9159124

00:19:07.359 --> 00:19:09.319 events in the clinical trials,  
NOTE Confidence: 0.9159124

00:19:09.320 --> 00:19:11.582 these trials have now resumed with  
NOTE Confidence: 0.9159124

00:19:11.582 --> 00:19:13.550 reduced dosing of Fatou Suran,  
NOTE Confidence: 0.9159124

00:19:13.550 --> 00:19:15.490 initially at 50 milligrams every  
NOTE Confidence: 0.9159124

00:19:15.490 --> 00:19:18.244 other month in order to target and  
NOTE Confidence: 0.9159124

00:19:18.244 --> 00:19:20.476 antithrombin level of 15 to 35%,  
NOTE Confidence: 0.9159124

00:19:20.480 --> 00:19:23.483 which was found to be less associated  
NOTE Confidence: 0.9159124

00:19:23.483 --> 00:19:25.380 with the thrombotic events.  
NOTE Confidence: 0.9159124

00:19:25.380 --> 00:19:26.463 So in summary,  
NOTE Confidence: 0.9159124

00:19:26.463 --> 00:19:28.629 for chooser and is an investigational  
NOTE Confidence: 0.9159124

00:19:28.629 --> 00:19:30.160 small interfering RNA therapeutic  
NOTE Confidence: 0.9159124

00:19:30.160 --> 00:19:33.168 and it has the potential use as a  
NOTE Confidence: 0.9159124

00:19:33.168 --> 00:19:34.636 prophylactic treatment in patients  
NOTE Confidence: 0.9159124

00:19:34.636 --> 00:19:37.140 with hemophilia A or B with or  
NOTE Confidence: 0.9159124

00:19:37.140 --> 00:19:39.120 without inhibitors in order to try  
NOTE Confidence: 0.9159124

00:19:39.120 --> 00:19:40.920 and reestablish hemostatic balance.

NOTE Confidence: 0.9159124  
00:19:40.920 --> 00:19:41.290 However,  
NOTE Confidence: 0.9159124  
00:19:41.290 --> 00:19:43.140 further evaluation of its safety  
NOTE Confidence: 0.9159124  
00:19:43.140 --> 00:19:43.880 is imperative,  
NOTE Confidence: 0.9159124  
00:19:43.880 --> 00:19:45.926 and phase three trials of this  
NOTE Confidence: 0.9159124  
00:19:45.926 --> 00:19:47.950 drug are are now ongoing.  
NOTE Confidence: 0.85483044  
00:19:50.040 --> 00:19:52.152 And so I'll switch gears a bit with  
NOTE Confidence: 0.85483044  
00:19:52.152 --> 00:19:54.228 this abstract that was presented by  
NOTE Confidence: 0.85483044  
00:19:54.228 --> 00:19:56.088 Doctor Brooks Sadler from Washington  
NOTE Confidence: 0.85483044  
00:19:56.088 --> 00:19:58.140 University School of Medicine on Geno  
NOTE Confidence: 0.85483044  
00:19:58.140 --> 00:20:00.232 type analysis of adolescents with low.  
NOTE Confidence: 0.85483044  
00:20:00.232 --> 00:20:01.648 One willibrand factor,  
NOTE Confidence: 0.85483044  
00:20:01.648 --> 00:20:03.536 an heavy menstrual bleeding.  
NOTE Confidence: 0.85483044  
00:20:03.540 --> 00:20:05.592 She noted that heavy menstrual bleeding  
NOTE Confidence: 0.85483044  
00:20:05.592 --> 00:20:07.673 occurs in about 1/3 of adolescent  
NOTE Confidence: 0.85483044  
00:20:07.673 --> 00:20:09.948 women and accounts for 2/3 of patients  
NOTE Confidence: 0.85483044

00:20:09.948 --> 00:20:12.127 who require hysterectomy and the  
NOTE Confidence: 0.85483044

00:20:12.127 --> 00:20:13.923 prevalence of bleeding disorders,  
NOTE Confidence: 0.85483044

00:20:13.930 --> 00:20:16.012 including von Willebrand disease in this  
NOTE Confidence: 0.85483044

00:20:16.012 --> 00:20:18.748 cohort is higher than the general population.  
NOTE Confidence: 0.85483044

00:20:18.750 --> 00:20:19.444 However, no,  
NOTE Confidence: 0.85483044

00:20:19.444 --> 00:20:21.526 no one has looked or evaluated  
NOTE Confidence: 0.85483044

00:20:21.526 --> 00:20:23.454 at other genetic hemostatic risk  
NOTE Confidence: 0.85483044

00:20:23.454 --> 00:20:26.163 factors that may play a role here.  
NOTE Confidence: 0.85483044

00:20:26.170 --> 00:20:27.642 So in this study,  
NOTE Confidence: 0.85483044

00:20:27.642 --> 00:20:29.850 86 adolescent patients who met criteria  
NOTE Confidence: 0.85483044

00:20:29.919 --> 00:20:32.992 for heavy menstrual bleeding and had von  
NOTE Confidence: 0.85483044

00:20:32.992 --> 00:20:35.090 Willebrand activity between 30 and 50%.  
NOTE Confidence: 0.85483044

00:20:35.090 --> 00:20:37.575 Were enrolled in the study and underwent  
NOTE Confidence: 0.85483044

00:20:37.575 --> 00:20:39.828 whole exome sequencing that was compared  
NOTE Confidence: 0.85483044

00:20:39.828 --> 00:20:41.698 to 600 unrelated in-house controls.  
NOTE Confidence: 0.85483044

00:20:41.700 --> 00:20:43.625 The sequencing interesting Lee revealed

NOTE Confidence: 0.85483044

00:20:43.625 --> 00:20:46.767 in excess of rare stop gain and stop

NOTE Confidence: 0.85483044

00:20:46.767 --> 00:20:48.692 loss mutations in genes associated

NOTE Confidence: 0.85483044

00:20:48.692 --> 00:20:50.662 with bleeding or haematologic diseases

NOTE Confidence: 0.85483044

00:20:50.662 --> 00:20:52.936 as outlined in the slide here.

NOTE Confidence: 0.85483044

00:20:52.940 --> 00:20:55.677 There was also an excess of rare

NOTE Confidence: 0.85483044

00:20:55.677 --> 00:20:57.317 pathogenic variants that were

NOTE Confidence: 0.85483044

00:20:57.317 --> 00:20:59.663 observed in jeans that cause anemia

NOTE Confidence: 0.85483044

00:20:59.663 --> 00:21:02.408 or cause disease with anemia as a

NOTE Confidence: 0.85483044

00:21:02.408 --> 00:21:04.278 major symptoms of major symptom.

NOTE Confidence: 0.85483044

00:21:04.280 --> 00:21:07.017 This included variance in Adams TS 13,

NOTE Confidence: 0.85483044

00:21:07.020 --> 00:21:07.435 Fink,

NOTE Confidence: 0.85483044

00:21:07.435 --> 00:21:10.340 CA and G6PD and the other jeans

NOTE Confidence: 0.85483044

00:21:10.340 --> 00:21:12.350 that are listed here.

NOTE Confidence: 0.85483044

00:21:12.350 --> 00:21:14.360 There was analysis Additionally for

NOTE Confidence: 0.85483044

00:21:14.360 --> 00:21:15.968 common single nucleotide polymorphism's

NOTE Confidence: 0.85483044

00:21:15.968 --> 00:21:18.078 or snips that were that identified,  
NOTE Confidence: 0.85483044

00:21:18.080 --> 00:21:19.990 3 common snips infirm too,  
NOTE Confidence: 0.85483044

00:21:19.990 --> 00:21:22.755 and this past genome wide significance as  
NOTE Confidence: 0.85483044

00:21:22.755 --> 00:21:26.475 seen in the figure here on the right firm T2,  
NOTE Confidence: 0.85483044

00:21:26.480 --> 00:21:28.008 encodes a cytoskeletal protein  
NOTE Confidence: 0.85483044

00:21:28.008 --> 00:21:29.918 that is important in hemostasis,  
NOTE Confidence: 0.85483044

00:21:29.920 --> 00:21:31.444 angiogenesis and blood vessel,  
NOTE Confidence: 0.85483044

00:21:31.444 --> 00:21:32.936 home homeostasis, and so.  
NOTE Confidence: 0.85483044

00:21:32.936 --> 00:21:35.114 This was the first whole exome  
NOTE Confidence: 0.85483044

00:21:35.114 --> 00:21:37.572 sequencing study in patients with heavy  
NOTE Confidence: 0.85483044

00:21:37.572 --> 00:21:39.652 menstrual bleeding and suggest there  
NOTE Confidence: 0.85483044

00:21:39.652 --> 00:21:42.379 may be some Association in this group.  
NOTE Confidence: 0.85483044

00:21:42.380 --> 00:21:44.240 With both rare and common  
NOTE Confidence: 0.85483044

00:21:44.240 --> 00:21:46.100 variants in hemostasis and anemia,  
NOTE Confidence: 0.85483044

00:21:46.100 --> 00:21:47.588 genes that warrant further  
NOTE Confidence: 0.85483044

00:21:47.588 --> 00:21:49.076 validation in larger studies.

NOTE Confidence: 0.8524265

00:21:52.370 --> 00:21:54.750 And Lastly, I wanted to touch upon

NOTE Confidence: 0.8524265

00:21:54.750 --> 00:21:56.565 the abstracts that presented data

NOTE Confidence: 0.8524265

00:21:56.565 --> 00:21:59.120 on the use of kobid 19 convalescent

NOTE Confidence: 0.8524265

00:21:59.120 --> 00:22:00.839 plasma convalescent plasma,

NOTE Confidence: 0.8524265

00:22:00.840 --> 00:22:02.765 which is collected from individuals

NOTE Confidence: 0.8524265

00:22:02.765 --> 00:22:04.690 who have recovered from infection,

NOTE Confidence: 0.8524265

00:22:04.690 --> 00:22:06.520 is a therapeutic modality that's

NOTE Confidence: 0.8524265

00:22:06.520 --> 00:22:08.803 actually been used for over a

NOTE Confidence: 0.8524265

00:22:08.803 --> 00:22:11.143 century with the aim to transfer

NOTE Confidence: 0.8524265

00:22:11.143 --> 00:22:12.767 virus neutralizing antibodies to

NOTE Confidence: 0.8524265

00:22:12.767 --> 00:22:14.697 patients who have active infection.

NOTE Confidence: 0.8524265

00:22:14.700 --> 00:22:17.689 However, data on its use in COVID-19

NOTE Confidence: 0.8524265

00:22:17.689 --> 00:22:20.349 has been limited and quite mixed.

NOTE Confidence: 0.8524265

00:22:20.350 --> 00:22:22.678 And so I'll highlight here again,

NOTE Confidence: 0.8524265

00:22:22.680 --> 00:22:24.630 the five abstracts that presented

NOTE Confidence: 0.8524265



00:22:24.630 --> 00:22:25.800 some additional data.  
NOTE Confidence: 0.8524265

00:22:25.800 --> 00:22:27.630 So in our institutional experience  
NOTE Confidence: 0.8524265

00:22:27.630 --> 00:22:30.202 with 105 patients with severe or life  
NOTE Confidence: 0.8524265

00:22:30.202 --> 00:22:31.892 threatening COVID-19 who were transfuse  
NOTE Confidence: 0.8524265

00:22:31.892 --> 00:22:34.359 one unit of convalescent plasma through  
NOTE Confidence: 0.8524265

00:22:34.359 --> 00:22:36.684 the national Expanded Access program,  
NOTE Confidence: 0.8524265

00:22:36.690 --> 00:22:39.308 we saw that 42.9% of patients had  
NOTE Confidence: 0.8524265

00:22:39.308 --> 00:22:41.750 improvement in their WHO ordinal scale,  
NOTE Confidence: 0.8524265

00:22:41.750 --> 00:22:44.078 which is a score comprised of  
NOTE Confidence: 0.8524265

00:22:44.078 --> 00:22:46.024 functional status, level of care,  
NOTE Confidence: 0.8524265

00:22:46.024 --> 00:22:47.576 and oxygen supplement Tatian.  
NOTE Confidence: 0.8524265

00:22:47.580 --> 00:22:48.019 Interestingly,  
NOTE Confidence: 0.8524265

00:22:48.019 --> 00:22:50.653 we observed a correlation between D  
NOTE Confidence: 0.8524265

00:22:50.653 --> 00:22:53.472 dimer level more than five at 2448  
NOTE Confidence: 0.8524265

00:22:53.472 --> 00:22:55.257 and 72 hours after transfusion.  
NOTE Confidence: 0.8524265

00:22:55.260 --> 00:22:57.380 Convalescent, plasma, and mortality.

NOTE Confidence: 0.8524265

00:22:57.380 --> 00:22:59.500 Ibrahim and colleagues shared

NOTE Confidence: 0.8524265

00:22:59.500 --> 00:23:01.499 data on 17 patients,

NOTE Confidence: 0.8524265

00:23:01.500 --> 00:23:04.050 six of whom were being treated

NOTE Confidence: 0.8524265

00:23:04.050 --> 00:23:05.750 for a hematologic malignancy,

NOTE Confidence: 0.8524265

00:23:05.750 --> 00:23:07.505 and these individuals were transfused

NOTE Confidence: 0.8524265

00:23:07.505 --> 00:23:09.814 one to two units of COVID-19

NOTE Confidence: 0.8524265

00:23:09.814 --> 00:23:12.274 convalescent plasma that had concert

NOTE Confidence: 0.8524265

00:23:12.274 --> 00:23:14.242 confirmed positive antibody titer,

NOTE Confidence: 0.8524265

00:23:14.250 --> 00:23:16.632 and they also observed a decrease

NOTE Confidence: 0.8524265

00:23:16.632 --> 00:23:19.577 in the mean WHO ordinal score by

NOTE Confidence: 0.8524265

00:23:19.577 --> 00:23:22.531 two points at the time of discharge

NOTE Confidence: 0.8524265

00:23:22.615 --> 00:23:25.243 of multi center phase two trial

NOTE Confidence: 0.8524265

00:23:25.243 --> 00:23:27.483 presented by Doctor Al Hashmi

NOTE Confidence: 0.8524265

00:23:27.483 --> 00:23:29.898 compared 178 covid convalescent plasma

NOTE Confidence: 0.8524265

00:23:29.898 --> 00:23:32.520 recipients to 391 matched controls.

NOTE Confidence: 0.8524265

00:23:32.520 --> 00:23:34.176 Is a significant reduction in 30  
NOTE Confidence: 0.8524265

00:23:34.176 --> 00:23:36.069 day mortality in the treatment arm.  
NOTE Confidence: 0.8524265

00:23:36.070 --> 00:23:37.111 In this study,  
NOTE Confidence: 0.8524265

00:23:37.111 --> 00:23:38.846 though Interestingly they observed that  
NOTE Confidence: 0.8524265

00:23:38.846 --> 00:23:40.766 the hospital and ICU length of stay  
NOTE Confidence: 0.8524265

00:23:40.766 --> 00:23:42.582 as well as duration of intubation was  
NOTE Confidence: 0.8524265

00:23:42.582 --> 00:23:44.358 longer and that was actually longer  
NOTE Confidence: 0.8524265

00:23:44.358 --> 00:23:46.264 in the convalescent Plasma Group.  
NOTE Confidence: 0.8524265

00:23:46.264 --> 00:23:47.140 Another phase,  
NOTE Confidence: 0.8524265

00:23:47.140 --> 00:23:49.084 two matched case control study looked  
NOTE Confidence: 0.8524265

00:23:49.084 --> 00:23:51.232 at a smaller number of hospitalized  
NOTE Confidence: 0.8524265

00:23:51.232 --> 00:23:53.590 COVID-19 patients who received 2 units  
NOTE Confidence: 0.8524265

00:23:53.590 --> 00:23:55.916 of transfusion and there was a trend  
NOTE Confidence: 0.8524265

00:23:55.916 --> 00:23:57.742 in this group towards improved survival,  
NOTE Confidence: 0.8524265

00:23:57.742 --> 00:23:59.110 though this was not  
NOTE Confidence: 0.8524265

00:23:59.110 --> 00:23:59.794 statistically significant,

NOTE Confidence: 0.8524265

00:23:59.800 --> 00:24:02.128 it was noted in this study that the

NOTE Confidence: 0.8524265

00:24:02.128 --> 00:24:04.238 donor plasma was quite heterogeneous,

NOTE Confidence: 0.8524265

00:24:04.240 --> 00:24:05.950 with an increase in antibody

NOTE Confidence: 0.8524265

00:24:05.950 --> 00:24:07.318 activity observed in some,

NOTE Confidence: 0.8524265

00:24:07.320 --> 00:24:08.346 but not all,

NOTE Confidence: 0.8524265

00:24:08.346 --> 00:24:10.740 of the patients included in the study,

NOTE Confidence: 0.8524265

00:24:10.740 --> 00:24:11.721 and interesting Lee,

NOTE Confidence: 0.8524265

00:24:11.721 --> 00:24:14.010 those who had undergone anti CD 20

NOTE Confidence: 0.8524265

00:24:14.069 --> 00:24:16.589 treatment in the last year had a demo

NOTE Confidence: 0.8524265

00:24:16.589 --> 00:24:18.350 demonstrated an impaired response.

NOTE Confidence: 0.8524265

00:24:18.350 --> 00:24:20.200 In regards to antibody activity

NOTE Confidence: 0.8524265

00:24:20.200 --> 00:24:22.754 and Lastly a multi center Phase 1

NOTE Confidence: 0.8524265

00:24:22.754 --> 00:24:24.980 two trial of 70 patients who had

NOTE Confidence: 0.8524265

00:24:24.980 --> 00:24:26.237 received COVID-19 convalescent

NOTE Confidence: 0.8524265

00:24:26.237 --> 00:24:28.847 plasma found that 30 day overall

NOTE Confidence: 0.8524265

00:24:28.847 --> 00:24:30.917 survival was improved in those  
NOTE Confidence: 0.8524265

00:24:30.917 --> 00:24:32.912 patients who had severe acute  
NOTE Confidence: 0.8524265

00:24:32.912 --> 00:24:34.812 respiratory distress syndrome as a  
NOTE Confidence: 0.8524265

00:24:34.812 --> 00:24:36.537 part of their COVID-19 infection,  
NOTE Confidence: 0.8524265

00:24:36.540 --> 00:24:39.186 though there was an adverse event rate  
NOTE Confidence: 0.8524265

00:24:39.186 --> 00:24:41.605 of 3.65% and there was one patient  
NOTE Confidence: 0.8524265

00:24:41.605 --> 00:24:44.120 who was observed to have transfusion,  
NOTE Confidence: 0.8524265

00:24:44.120 --> 00:24:45.772 associated circulatory overload and  
NOTE Confidence: 0.8524265

00:24:45.772 --> 00:24:48.759 a second that was observed to have a.  
NOTE Confidence: 0.8524265

00:24:48.760 --> 00:24:51.140 A venous thromboembolic event.  
NOTE Confidence: 0.8445773

00:24:53.740 --> 00:24:56.064 So the QR code included here on  
NOTE Confidence: 0.8445773

00:24:56.064 --> 00:24:58.429 this slide links to a section of  
NOTE Confidence: 0.8445773

00:24:58.429 --> 00:25:00.379 the ash website that discuss is  
NOTE Confidence: 0.8445773

00:25:00.449 --> 00:25:02.869 our available evidence on COVID-19.  
NOTE Confidence: 0.8445773

00:25:02.870 --> 00:25:04.690 Convalescent Plasma provides a summary.  
NOTE Confidence: 0.8445773

00:25:04.690 --> 00:25:06.880 As you can see, just from

NOTE Confidence: 0.8445773

00:25:06.880 --> 00:25:08.340 the data presented today,

NOTE Confidence: 0.8445773

00:25:08.340 --> 00:25:09.716 information on its effectiveness

NOTE Confidence: 0.8445773

00:25:09.716 --> 00:25:11.436 has been somewhat mixed and

NOTE Confidence: 0.8445773

00:25:11.436 --> 00:25:13.370 we're really awaiting data from

NOTE Confidence: 0.8445773

00:25:13.370 --> 00:25:14.906 larger randomized control trials.

NOTE Confidence: 0.8445773

00:25:14.910 --> 00:25:17.465 There are some themes that have emerged,

NOTE Confidence: 0.8445773

00:25:17.470 --> 00:25:19.290 and they include the importance

NOTE Confidence: 0.8445773

00:25:19.290 --> 00:25:20.746 of both antibody titer,

NOTE Confidence: 0.8445773

00:25:20.750 --> 00:25:23.126 but more notably neutralizing function in

NOTE Confidence: 0.8445773

00:25:23.126 --> 00:25:25.150 the donor COVID-19 convalescent plasma.

NOTE Confidence: 0.8445773

00:25:25.150 --> 00:25:28.166 As well as the benefit of providing this

NOTE Confidence: 0.8445773

00:25:28.166 --> 00:25:30.159 treatment earlier in disease course,

NOTE Confidence: 0.8445773

00:25:30.160 --> 00:25:32.162 there has been concern raised by our

NOTE Confidence: 0.8445773

00:25:32.162 --> 00:25:33.968 group and others regarding whether

NOTE Confidence: 0.8445773

00:25:33.968 --> 00:25:35.756 COVID-19 convalescent plasma may

NOTE Confidence: 0.8445773

00:25:35.756 --> 00:25:37.544 actually potentiates the already  
NOTE Confidence: 0.8445773

00:25:37.607 --> 00:25:39.008 increased thrombotic risk.  
NOTE Confidence: 0.8445773

00:25:39.010 --> 00:25:41.514 An end to Ophelia Opathy that we now  
NOTE Confidence: 0.8445773

00:25:41.514 --> 00:25:44.041 know occurs with COVID-19 and further  
NOTE Confidence: 0.8445773

00:25:44.041 --> 00:25:46.326 investigation into this is warranted.  
NOTE Confidence: 0.8445773

00:25:46.330 --> 00:25:48.610 So taking this all into account  
NOTE Confidence: 0.8445773

00:25:48.610 --> 00:25:50.949 as of just actually last week,  
NOTE Confidence: 0.8445773

00:25:50.950 --> 00:25:53.194 the FDA has updated their emergency  
NOTE Confidence: 0.8445773

00:25:53.194 --> 00:25:54.690 use authorization for COVID-19  
NOTE Confidence: 0.8445773

00:25:54.747 --> 00:25:55.879 convalescent plasma.  
NOTE Confidence: 0.8445773

00:25:55.880 --> 00:25:57.819 Really limiting it to use of high  
NOTE Confidence: 0.8445773

00:25:57.819 --> 00:25:59.067 titer plasma for hospitalized  
NOTE Confidence: 0.8445773

00:25:59.067 --> 00:26:01.197 patients that are early in their  
NOTE Confidence: 0.8445773

00:26:01.197 --> 00:26:03.392 disease course and those who may  
NOTE Confidence: 0.8445773

00:26:03.392 --> 00:26:04.820 have impaired humoral immunity.  
NOTE Confidence: 0.8751028

00:26:07.060 --> 00:26:10.000 Thank you and I'll turn it over to Alex now.

NOTE Confidence: 0.668146  
00:26:14.400 --> 00:26:18.680 Thank you Sabrina. I'm just.  
NOTE Confidence: 0.86815625  
00:26:33.060 --> 00:26:36.686 OK, hopefully everybody can see the screen.  
NOTE Confidence: 0.6899577  
00:26:39.910 --> 00:26:44.214 Alright, wanted to say thank you to decide  
NOTE Confidence: 0.6899577  
00:26:44.214 --> 00:26:48.893 and Megadeth for putting all this together  
NOTE Confidence: 0.6899577  
00:26:48.893 --> 00:26:52.613 and everybody who's contributed else.  
NOTE Confidence: 0.6899577  
00:26:52.620 --> 00:26:55.434 Um, exciting, serious, and learning a lot.  
NOTE Confidence: 0.6899577  
00:26:55.440 --> 00:26:58.296 So I am going to see if I  
NOTE Confidence: 0.6899577  
00:26:58.296 --> 00:27:00.683 can move the slides. Yes,  
NOTE Confidence: 0.6899577  
00:27:00.683 --> 00:27:06.360 I'm just going to touch upon a few guests. 3.  
NOTE Confidence: 0.6899577  
00:27:06.360 --> 00:27:09.727 The abstracts that that that and identified,  
NOTE Confidence: 0.6899577  
00:27:09.730 --> 00:27:11.714 and specifically about cancer,  
NOTE Confidence: 0.6899577  
00:27:11.714 --> 00:27:13.202 associated venous thromboembolism  
NOTE Confidence: 0.6899577  
00:27:13.202 --> 00:27:16.586 and one of the new exciting agent  
NOTE Confidence: 0.6899577  
00:27:16.586 --> 00:27:18.406 for reversal of anticoagulation.  
NOTE Confidence: 0.6899577  
00:27:18.410 --> 00:27:21.980 And then I'm going to touch  
NOTE Confidence: 0.6899577



00:27:21.980 --> 00:27:25.180 base and our own work.

NOTE Confidence: 0.6899577

00:27:25.180 --> 00:27:27.250 Thrombosis and COVID-19.

NOTE Confidence: 0.6899577

00:27:27.250 --> 00:27:31.780 How it actually. Informed us about

NOTE Confidence: 0.6899577

00:27:31.780 --> 00:27:35.060 in conditions beyond COVID-19.

NOTE Confidence: 0.6899577

00:27:35.060 --> 00:27:37.830 No disclosures on my end.

NOTE Confidence: 0.6899577

00:27:37.830 --> 00:27:39.267 Um, so the.

NOTE Confidence: 0.6899577

00:27:39.267 --> 00:27:42.141 One of the first highlight the

NOTE Confidence: 0.6899577

00:27:42.141 --> 00:27:44.912 this abstract about machine

NOTE Confidence: 0.6899577

00:27:44.912 --> 00:27:48.547 learning for prediction of cancer.

NOTE Confidence: 0.6899577

00:27:48.550 --> 00:27:49.578 Social verbalism,

NOTE Confidence: 0.6899577

00:27:49.578 --> 00:27:52.662 especially in the setting of new

NOTE Confidence: 0.6899577

00:27:52.662 --> 00:27:54.805 guidelines that ash guidelines

NOTE Confidence: 0.6899577

00:27:54.805 --> 00:27:57.375 that have been just released

NOTE Confidence: 0.6899577

00:27:57.375 --> 00:27:59.550 about cancer regarding cancer.

NOTE Confidence: 0.6899577

00:27:59.550 --> 00:28:01.236 Associated venous thromboembolism

NOTE Confidence: 0.6899577

00:28:01.236 --> 00:28:05.777 just the other day and as you all

NOTE Confidence: 0.6899577

00:28:05.777 --> 00:28:08.879 know we there are several clinical

NOTE Confidence: 0.6899577

00:28:08.879 --> 00:28:12.129 prediction rules of which comma score.

NOTE Confidence: 0.6899577

00:28:12.130 --> 00:28:15.406 Is most validated and had been.

NOTE Confidence: 0.6899577

00:28:15.410 --> 00:28:21.218 Used to stratify the risk in multiple trials,

NOTE Confidence: 0.6899577

00:28:21.220 --> 00:28:25.000 including most recently a PERT and

NOTE Confidence: 0.6899577

00:28:25.000 --> 00:28:28.499 Cassini RCT S42 Deluxe prophylactic

NOTE Confidence: 0.6899577

00:28:28.499 --> 00:28:32.829 regimen versus placebo and recall.

NOTE Confidence: 0.6899577

00:28:32.830 --> 00:28:37.345 It's pretty simple score to

NOTE Confidence: 0.6899577

00:28:37.345 --> 00:28:40.957 to use the questions.

NOTE Confidence: 0.6899577

00:28:40.960 --> 00:28:43.634 We have been raised over the over

NOTE Confidence: 0.6899577

00:28:43.634 --> 00:28:45.960 over the years is exactly where

NOTE Confidence: 0.6899577

00:28:45.960 --> 00:28:48.522 the draw the line in terms of

NOTE Confidence: 0.6899577

00:28:48.606 --> 00:28:52.044 prophylaxis versus which group to sort

NOTE Confidence: 0.6899577

00:28:52.044 --> 00:28:54.336 of start prophylactic production,

NOTE Confidence: 0.6899577

00:28:54.340 --> 00:28:55.678 if at all.

NOTE Confidence: 0.6899577

00:28:55.678 --> 00:28:56.570 And Furthermore,  
NOTE Confidence: 0.6899577

00:28:56.570 --> 00:28:59.246 since Corona score as anybody know,  
NOTE Confidence: 0.6899577

00:28:59.250 --> 00:29:01.255 several other scores have been  
NOTE Confidence: 0.6899577

00:29:01.255 --> 00:29:03.260 released that had also been  
NOTE Confidence: 0.6899577

00:29:03.330 --> 00:29:05.750 addressing certain features that had  
NOTE Confidence: 0.6899577

00:29:05.750 --> 00:29:08.170 not been including current score.  
NOTE Confidence: 0.6899577

00:29:08.170 --> 00:29:11.334 But unfortunately all of them have been.  
NOTE Confidence: 0.6899577

00:29:11.340 --> 00:29:15.834 Not so useful in terms of prediction  
NOTE Confidence: 0.6899577

00:29:15.834 --> 00:29:18.421 because their predicted power  
NOTE Confidence: 0.6899577

00:29:18.421 --> 00:29:22.243 was not was in moderate mild to  
NOTE Confidence: 0.6899577

00:29:22.243 --> 00:29:25.332 moderate sort of territory with  
NOTE Confidence: 0.6899577

00:29:25.332 --> 00:29:28.477 statistics between .6 and .7.  
NOTE Confidence: 0.6899577

00:29:28.480 --> 00:29:31.540 So for Corona score itself,  
NOTE Confidence: 0.6899577

00:29:31.540 --> 00:29:36.428 there's a three categories so long to medium,  
NOTE Confidence: 0.6899577

00:29:36.430 --> 00:29:38.958 high and specifically in  
NOTE Confidence: 0.6899577

00:29:38.958 --> 00:29:41.486 high in the original.

NOTE Confidence: 0.6899577

00:29:41.490 --> 00:29:44.778 An original paper by Doctor Corona.

NOTE Confidence: 0.6899577

00:29:44.780 --> 00:29:49.172 We know that the rate of DTE was

NOTE Confidence: 0.6899577

00:29:49.172 --> 00:29:52.306 about 7% in high risk cohort,

NOTE Confidence: 0.6899577

00:29:52.306 --> 00:29:56.713 so the authors of this app start from

NOTE Confidence: 0.6899577

00:29:56.713 --> 00:29:59.864 Libor Sloan, Kettering, US Sameta and.

NOTE Confidence: 0.6899577

00:29:59.864 --> 00:30:02.720 Microsoft Group they sought to use

NOTE Confidence: 0.6899577

00:30:02.807 --> 00:30:05.711 to to utilize the machine learning

NOTE Confidence: 0.6899577

00:30:05.711 --> 00:30:08.701 algorithms to inform about the which

NOTE Confidence: 0.6899577

00:30:08.701 --> 00:30:11.121 features actually would be more

NOTE Confidence: 0.6899577

00:30:11.121 --> 00:30:13.765 productive in there for create a

NOTE Confidence: 0.6899577

00:30:13.765 --> 00:30:16.135 score or update the current score

NOTE Confidence: 0.6899577

00:30:16.135 --> 00:30:18.335 that potentially could increase

NOTE Confidence: 0.6899577

00:30:18.335 --> 00:30:20.635 the its predictive power.

NOTE Confidence: 0.6899577

00:30:20.640 --> 00:30:23.995 So they positive that they

NOTE Confidence: 0.6899577

00:30:23.995 --> 00:30:26.679 would use known predictors.

NOTE Confidence: 0.6899577

00:30:26.680 --> 00:30:28.364 It from Corona score.  
NOTE Confidence: 0.6899577

00:30:28.364 --> 00:30:30.469 They would utilize too much  
NOTE Confidence: 0.6899577

00:30:30.469 --> 00:30:32.809 genomic information that they they  
NOTE Confidence: 0.6899577

00:30:32.809 --> 00:30:35.563 collect it in their preferred their  
NOTE Confidence: 0.6899577

00:30:35.637 --> 00:30:38.433 profiling assay with 341 uncle gene  
NOTE Confidence: 0.6899577

00:30:38.433 --> 00:30:40.297 and tumor suppressor genes.  
NOTE Confidence: 0.6899577

00:30:40.300 --> 00:30:40.897 Overall,  
NOTE Confidence: 0.6899577

00:30:40.897 --> 00:30:45.076 they had a significant number of patients  
NOTE Confidence: 0.6899577

00:30:45.076 --> 00:30:49.559 at 12,000 out of those they had about 850.  
NOTE Confidence: 0.6899577

00:30:49.560 --> 00:30:52.152 It's something about like events in  
NOTE Confidence: 0.6899577

00:30:52.152 --> 00:30:55.679 the span of six months from from  
NOTE Confidence: 0.6899577

00:30:55.679 --> 00:30:57.955 the diagnosis from enrollment,  
NOTE Confidence: 0.6899577

00:30:57.960 --> 00:31:00.430 and most frequent cancer along  
NOTE Confidence: 0.6899577

00:31:00.430 --> 00:31:01.418 Bryson colorectal.  
NOTE Confidence: 0.6899577

00:31:01.420 --> 00:31:04.384 They did not include upper extremity  
NOTE Confidence: 0.6899577

00:31:04.384 --> 00:31:06.360 DVT's and their collected.

NOTE Confidence: 0.6899577

00:31:06.360 --> 00:31:09.204 This is amazing that they collected

NOTE Confidence: 0.6899577

00:31:09.204 --> 00:31:11.695 all these events from clinic

NOTE Confidence: 0.6899577

00:31:11.695 --> 00:31:14.255 from review of clinical notes,

NOTE Confidence: 0.802935

00:31:14.260 --> 00:31:16.730 radiology reports and text search,

NOTE Confidence: 0.802935

00:31:16.730 --> 00:31:20.286 which itself is very valiant effort knowing.

NOTE Confidence: 0.802935

00:31:20.290 --> 00:31:25.270 Anne. From now, from my from my

NOTE Confidence: 0.802935

00:31:25.270 --> 00:31:27.550 own experience doing similar work.

NOTE Confidence: 0.802935

00:31:27.550 --> 00:31:31.230 So as far as the predictors that they

NOTE Confidence: 0.802935

00:31:31.230 --> 00:31:35.148 put that they use in the in the model,

NOTE Confidence: 0.802935

00:31:35.150 --> 00:31:38.272 which was not really clear how they

NOTE Confidence: 0.802935

00:31:38.272 --> 00:31:41.145 selected it, but it seemed like it

NOTE Confidence: 0.802935

00:31:41.145 --> 00:31:44.090 was some sort of manual selection.

NOTE Confidence: 0.802935

00:31:44.090 --> 00:31:45.766 Not unbiased informed selection,

NOTE Confidence: 0.802935

00:31:45.766 --> 00:31:48.280 at least based on their abstract

NOTE Confidence: 0.802935

00:31:48.352 --> 00:31:49.450 and presentation.

NOTE Confidence: 0.802935

00:31:49.450 --> 00:31:52.579 So the tumor type status of metastases,  
NOTE Confidence: 0.802935

00:31:52.580 --> 00:31:54.815 age, cytotoxic chemotherapy time since  
NOTE Confidence: 0.802935

00:31:54.815 --> 00:31:56.656 cancer diagnosis, tumor sampling,  
NOTE Confidence: 0.802935

00:31:56.656 --> 00:31:58.548 and they included interesting  
NOTE Confidence: 0.802935

00:31:58.548 --> 00:32:00.440 without the blood counts.  
NOTE Confidence: 0.802935

00:32:00.440 --> 00:32:01.730 In the prior three months.  
NOTE Confidence: 0.750427

00:32:04.110 --> 00:32:08.432 Indices of calculation be my end. Of course.  
NOTE Confidence: 0.750427

00:32:08.432 --> 00:32:10.962 Those somatic genetic alterations on  
NOTE Confidence: 0.750427

00:32:10.962 --> 00:32:14.598 the jeans in tumor suppression genes,  
NOTE Confidence: 0.750427

00:32:14.600 --> 00:32:18.410 of which they include 56.  
NOTE Confidence: 0.750427

00:32:18.410 --> 00:32:20.834 And so when they put it all together  
NOTE Confidence: 0.750427

00:32:20.834 --> 00:32:22.929 and they used this fancy math,  
NOTE Confidence: 0.750427

00:32:22.930 --> 00:32:24.666 the random survival forest  
NOTE Confidence: 0.750427

00:32:24.666 --> 00:32:27.270 basically to create a model to  
NOTE Confidence: 0.750427

00:32:27.353 --> 00:32:29.866 fit the model using all of these.  
NOTE Confidence: 0.750427

00:32:29.870 --> 00:32:32.789 Various sets of permutations of the features,

NOTE Confidence: 0.750427  
00:32:32.790 --> 00:32:36.126 the predictors and what they come up with.  
NOTE Confidence: 0.750427  
00:32:36.130 --> 00:32:38.315 It came up with basically  
NOTE Confidence: 0.750427  
00:32:38.315 --> 00:32:41.130 that if you include all of it,  
NOTE Confidence: 0.750427  
00:32:41.130 --> 00:32:44.007 that gives usage statistics of .7 is  
NOTE Confidence: 0.750427  
00:32:44.007 --> 00:32:47.379 just the kind of worry and people here.  
NOTE Confidence: 0.750427  
00:32:47.380 --> 00:32:50.716 If it's insisted 6.5 is a coin toss,  
NOTE Confidence: 0.750427  
00:32:50.720 --> 00:32:52.840 so basically it doesn't predict  
NOTE Confidence: 0.750427  
00:32:52.840 --> 00:32:55.310 anything and see statistics of one.  
NOTE Confidence: 0.750427  
00:32:55.310 --> 00:32:56.978 It's the perfect sensitivity,  
NOTE Confidence: 0.750427  
00:32:56.978 --> 00:33:00.070 specificity of 5%, of course is unreachable.  
NOTE Confidence: 0.750427  
00:33:00.070 --> 00:33:02.370 So somewhere in between that,  
NOTE Confidence: 0.750427  
00:33:02.370 --> 00:33:04.882 the higher the better.  
NOTE Confidence: 0.750427  
00:33:04.882 --> 00:33:08.022 But .7 ISM is it.  
NOTE Confidence: 0.750427  
00:33:08.030 --> 00:33:08.934 Legitimate number,  
NOTE Confidence: 0.750427  
00:33:08.934 --> 00:33:12.550 and as I would like to remind everybody,  
NOTE Confidence: 0.750427



00:33:12.550 --> 00:33:15.230 the original credit score  
NOTE Confidence: 0.750427

00:33:15.230 --> 00:33:18.580 system tistic was also .7.  
NOTE Confidence: 0.750427

00:33:18.580 --> 00:33:21.115 They also then separated their  
NOTE Confidence: 0.750427

00:33:21.115 --> 00:33:23.143 population into five groups,  
NOTE Confidence: 0.750427

00:33:23.150 --> 00:33:26.156 although how they get it not  
NOTE Confidence: 0.750427

00:33:26.156 --> 00:33:28.740 clearly was outlined as well,  
NOTE Confidence: 0.750427

00:33:28.740 --> 00:33:32.796 and it's five risk groups based on the.  
NOTE Confidence: 0.78821117

00:33:36.460 --> 00:33:38.810 Incidence of VTE I presume,  
NOTE Confidence: 0.78821117

00:33:38.810 --> 00:33:42.982 and so then they validated this with  
NOTE Confidence: 0.78821117

00:33:42.982 --> 00:33:47.580 the model in the said that that is.  
NOTE Confidence: 0.78821117

00:33:47.580 --> 00:33:50.670 Per their validation metric that was  
NOTE Confidence: 0.78821117

00:33:50.670 --> 00:33:55.110 validated, model was performed well.  
NOTE Confidence: 0.78821117

00:33:55.110 --> 00:33:56.865 With, Interestingly enough,  
NOTE Confidence: 0.78821117

00:33:56.865 --> 00:33:59.790 when they looked at which  
NOTE Confidence: 0.78821117

00:33:59.790 --> 00:34:02.937 predictors had been most predictive  
NOTE Confidence: 0.78821117

00:34:02.937 --> 00:34:05.445 of the venous thromboembolism,

NOTE Confidence: 0.78821117

00:34:05.450 --> 00:34:10.306 they found that it's a cancer type came,

NOTE Confidence: 0.78821117

00:34:10.310 --> 00:34:13.830 whether patient received chemotherapy,

NOTE Confidence: 0.78821117

00:34:13.830 --> 00:34:15.590 platelet count.

NOTE Confidence: 0.78821117

00:34:15.590 --> 00:34:19.790 PT White count and so on was interesting.

NOTE Confidence: 0.78821117

00:34:19.790 --> 00:34:24.806 This is out of these features.

NOTE Confidence: 0.78821117

00:34:24.810 --> 00:34:27.450 Where this is not a selection,

NOTE Confidence: 0.78821117

00:34:27.450 --> 00:34:29.650 so these features were determined.

NOTE Confidence: 0.78821117

00:34:29.650 --> 00:34:32.452 The importance of these features was

NOTE Confidence: 0.78821117

00:34:32.452 --> 00:34:35.369 determined in in sort of post hoc.

NOTE Confidence: 0.78821117

00:34:35.370 --> 00:34:38.676 These are not the features that

NOTE Confidence: 0.78821117

00:34:38.676 --> 00:34:42.620 were selected to go into the model.

NOTE Confidence: 0.78821117

00:34:42.620 --> 00:34:45.056 That's it, that's a key issue,

NOTE Confidence: 0.78821117

00:34:45.060 --> 00:34:48.870 because in my opinion, because.

NOTE Confidence: 0.78821117

00:34:48.870 --> 00:34:52.398 If the if you if you if the features

NOTE Confidence: 0.78821117

00:34:52.398 --> 00:34:55.339 are included in a biased way,

NOTE Confidence: 0.78821117

00:34:55.340 --> 00:34:58.020 the prediction of course would  
NOTE Confidence: 0.78821117

00:34:58.020 --> 00:35:00.164 potentially suffer as well.  
NOTE Confidence: 0.78821117

00:35:00.170 --> 00:35:04.850 And so out of all the genes that they pulled.  
NOTE Confidence: 0.78821117

00:35:04.850 --> 00:35:08.270 As you can see this STK 11 was found  
NOTE Confidence: 0.78821117

00:35:08.270 --> 00:35:12.172 to be significant and only one of them  
NOTE Confidence: 0.78821117

00:35:12.172 --> 00:35:16.080 based on value of false detection rate.  
NOTE Confidence: 0.78821117

00:35:16.080 --> 00:35:18.888 So every every other one gene  
NOTE Confidence: 0.78821117

00:35:18.888 --> 00:35:20.760 was not considered significant.  
NOTE Confidence: 0.78821117

00:35:20.760 --> 00:35:23.100 And as people probably know,  
NOTE Confidence: 0.78821117

00:35:23.100 --> 00:35:26.190 STK 11 is actually tumor suppressor  
NOTE Confidence: 0.78821117

00:35:26.190 --> 00:35:29.870 gene out of all possible jeans.  
NOTE Confidence: 0.78821117

00:35:29.870 --> 00:35:32.470 So question on my end that I sort  
NOTE Confidence: 0.78821117

00:35:32.470 --> 00:35:35.428 of would like to one of wanted to  
NOTE Confidence: 0.78821117

00:35:35.428 --> 00:35:37.598 clarify was unclear how initial  
NOTE Confidence: 0.78821117

00:35:37.598 --> 00:35:39.398 features were selected,  
NOTE Confidence: 0.78821117

00:35:39.400 --> 00:35:41.722 and again that's important because the

NOTE Confidence: 0.78821117

00:35:41.722 --> 00:35:45.172 biased it will be by a set of features

NOTE Confidence: 0.78821117

00:35:45.172 --> 00:35:47.511 if it manually manually selected and

NOTE Confidence: 0.78821117

00:35:47.511 --> 00:35:50.115 similar to other clinical scoring tools.

NOTE Confidence: 0.78821117

00:35:50.120 --> 00:35:52.538 So there are some robust methods

NOTE Confidence: 0.78821117

00:35:52.538 --> 00:35:54.630 exist that feature feature selection

NOTE Confidence: 0.78821117

00:35:54.630 --> 00:35:57.048 algorithm that you know existed prior

NOTE Confidence: 0.78821117

00:35:57.048 --> 00:36:00.179 that can be used to to select features

NOTE Confidence: 0.78821117

00:36:00.179 --> 00:36:02.420 prior to including into the model.

NOTE Confidence: 0.78821117

00:36:02.420 --> 00:36:03.980 That would be very,

NOTE Confidence: 0.78821117

00:36:03.980 --> 00:36:05.420 very helpful in China.

NOTE Confidence: 0.79679555

00:36:09.630 --> 00:36:11.534 Something something like this.

NOTE Confidence: 0.79679555

00:36:11.534 --> 00:36:14.889 We were actually thinking of doing the

NOTE Confidence: 0.79679555

00:36:14.889 --> 00:36:16.979 VA and another interesting component

NOTE Confidence: 0.79679555

00:36:16.979 --> 00:36:20.001 was prior vtu is not included although

NOTE Confidence: 0.79679555

00:36:20.001 --> 00:36:22.976 has it has a racial quoted somewhere

NOTE Confidence: 0.79679555

00:36:22.980 --> 00:36:27.444 in between two to three which is not  
NOTE Confidence: 0.79679555

00:36:27.444 --> 00:36:30.799 insignificant risk factor and of course.  
NOTE Confidence: 0.79679555

00:36:30.800 --> 00:36:32.990 Current score is not the dynamic  
NOTE Confidence: 0.79679555

00:36:32.990 --> 00:36:35.894 score and would be interested to know  
NOTE Confidence: 0.79679555

00:36:35.894 --> 00:36:38.174 how variability of the features,  
NOTE Confidence: 0.79679555

00:36:38.180 --> 00:36:40.230 specifically of CBC features assessed.  
NOTE Confidence: 0.79679555

00:36:40.230 --> 00:36:42.911 So overall it's I think it's important  
NOTE Confidence: 0.79679555

00:36:42.911 --> 00:36:45.800 work and I think it's a interesting  
NOTE Confidence: 0.79679555

00:36:45.800 --> 00:36:48.840 how the field of all because again,  
NOTE Confidence: 0.79679555

00:36:48.840 --> 00:36:51.300 even the guidelines have been released,  
NOTE Confidence: 0.79679555

00:36:51.300 --> 00:36:52.368 their sort of,  
NOTE Confidence: 0.79679555

00:36:52.368 --> 00:36:54.860 they still leave a lot of uncertainty  
NOTE Confidence: 0.79679555

00:36:54.933 --> 00:36:57.908 into who which group needs to be  
NOTE Confidence: 0.79679555

00:36:57.908 --> 00:36:59.730 anticoagulated versus whether it's  
NOTE Confidence: 0.79679555

00:36:59.730 --> 00:37:02.125 intermediate group versus high Group.  
NOTE Confidence: 0.79679555

00:37:02.130 --> 00:37:05.066 Um patients for should be inside quite late.

NOTE Confidence: 0.79679555

00:37:05.070 --> 00:37:06.542 It's still not clear.

NOTE Confidence: 0.79679555

00:37:06.542 --> 00:37:08.382 I think uncertainties still exist,

NOTE Confidence: 0.79679555

00:37:08.390 --> 00:37:10.959 and so the the better we have,

NOTE Confidence: 0.79679555

00:37:10.960 --> 00:37:13.624 the better method we have in terms of

NOTE Confidence: 0.79679555

00:37:13.624 --> 00:37:15.750 determining which features are important,

NOTE Confidence: 0.79679555

00:37:15.750 --> 00:37:19.534 I think that's going to be very helpful.

NOTE Confidence: 0.79679555

00:37:19.540 --> 00:37:20.098 Alright,

NOTE Confidence: 0.79679555

00:37:20.098 --> 00:37:24.004 so moving on are also an interesting

NOTE Confidence: 0.79679555

00:37:24.004 --> 00:37:26.049 abstract about than you.

NOTE Confidence: 0.79679555

00:37:26.050 --> 00:37:31.030 A reversal agent for anticoagulation.

NOTE Confidence: 0.79679555

00:37:31.030 --> 00:37:34.338 This is really interesting.

NOTE Confidence: 0.79679555

00:37:34.340 --> 00:37:37.130 Abstract the work has been going

NOTE Confidence: 0.79679555

00:37:37.130 --> 00:37:40.659 on for quite awhile and I found

NOTE Confidence: 0.79679555

00:37:40.659 --> 00:37:42.755 references going quite badly.

NOTE Confidence: 0.79679555

00:37:42.760 --> 00:37:45.286 Even just doesn't 14 but essentially

NOTE Confidence: 0.79679555

00:37:45.286 --> 00:37:48.093 pseudoprime tag is a small molecule  
NOTE Confidence: 0.79679555

00:37:48.093 --> 00:37:50.713 that was initially designed through  
NOTE Confidence: 0.79679555

00:37:50.713 --> 00:37:53.412 very rational design to reversibly  
NOTE Confidence: 0.79679555

00:37:53.412 --> 00:37:56.032 bind to fractionated heparin low  
NOTE Confidence: 0.79679555

00:37:56.032 --> 00:37:58.107 molecular weight heparin through  
NOTE Confidence: 0.79679555

00:37:58.107 --> 00:38:00.095 noncovalent charge charge interaction  
NOTE Confidence: 0.79679555

00:38:00.095 --> 00:38:02.580 with it was interesting that  
NOTE Confidence: 0.79679555

00:38:02.651 --> 00:38:04.599 they unexpectedly they found.  
NOTE Confidence: 0.79679555

00:38:04.600 --> 00:38:07.168 That it also binds the DOAX,  
NOTE Confidence: 0.79679555

00:38:07.170 --> 00:38:08.882 which prevents their Association  
NOTE Confidence: 0.79679555

00:38:08.882 --> 00:38:11.450 with factor 10 factor to rain,  
NOTE Confidence: 0.79679555

00:38:11.450 --> 00:38:14.460 but it doesn't bind to a lot  
NOTE Confidence: 0.79679555

00:38:14.460 --> 00:38:17.440 of things at a lot of drugs.  
NOTE Confidence: 0.79679555

00:38:17.440 --> 00:38:19.852 It doesn't bind to albumin and  
NOTE Confidence: 0.79679555

00:38:19.852 --> 00:38:22.150 doesn't bind to actual factors,  
NOTE Confidence: 0.79679555

00:38:22.150 --> 00:38:24.290 and so they say uh-huh.

NOTE Confidence: 0.79679555

00:38:24.290 --> 00:38:26.090 Let's try to reverse.

NOTE Confidence: 0.79679555

00:38:26.090 --> 00:38:29.380 Let's try to use their parents like

NOTE Confidence: 0.79679555

00:38:29.380 --> 00:38:32.894 to reverse do act like apixaban oral

NOTE Confidence: 0.79679555

00:38:32.894 --> 00:38:35.368 molecular weight heparin so they.

NOTE Confidence: 0.79679555

00:38:35.370 --> 00:38:39.938 They've done that in animals and in humans.

NOTE Confidence: 0.79679555

00:38:39.940 --> 00:38:42.964 So here you can see that for

NOTE Confidence: 0.79679555

00:38:42.964 --> 00:38:44.850 instance on the left.

NOTE Confidence: 0.79679555

00:38:44.850 --> 00:38:49.618 A pain where you can see that several

NOTE Confidence: 0.79679555

00:38:49.618 --> 00:38:54.219 hours after administration of edoxaban.

NOTE Confidence: 0.79679555

00:38:54.220 --> 00:38:58.620 Sorry for typo the.

NOTE Confidence: 0.79679555

00:38:58.620 --> 00:39:00.666 After the silicone flag was administered,

NOTE Confidence: 0.79679555

00:39:00.670 --> 00:39:03.680 there was a very rapid.

NOTE Confidence: 0.79679555

00:39:03.680 --> 00:39:07.646 Reversal a curd that actually stayed.

NOTE Confidence: 0.79679555

00:39:07.650 --> 00:39:09.906 Plateaued for a number of hours

NOTE Confidence: 0.79679555

00:39:09.906 --> 00:39:13.226 and then on the right side the same

NOTE Confidence: 0.79679555



00:39:13.226 --> 00:39:15.386 idea with low molecular weights  
NOTE Confidence: 0.79679555

00:39:15.386 --> 00:39:17.746 in same sort of data that,  
NOTE Confidence: 0.79679555

00:39:17.750 --> 00:39:22.118 with different doses of Sopron tags.  
NOTE Confidence: 0.79679555

00:39:22.120 --> 00:39:24.640 The universal was fairly complete.  
NOTE Confidence: 0.79679555

00:39:24.640 --> 00:39:26.644 Below 10% of baseline.  
NOTE Confidence: 0.79679555

00:39:26.644 --> 00:39:29.650 Now the metric that's being used  
NOTE Confidence: 0.79679555

00:39:29.749 --> 00:39:32.725 to determine this is a whole  
NOTE Confidence: 0.79679555

00:39:32.725 --> 00:39:34.213 blood clotting time,  
NOTE Confidence: 0.79679555

00:39:34.220 --> 00:39:37.238 and that's and that's actually important,  
NOTE Confidence: 0.79679555

00:39:37.240 --> 00:39:39.760 because apparently I cannot activity  
NOTE Confidence: 0.79679555

00:39:39.760 --> 00:39:42.280 of Sharon Cycle rather reversal.  
NOTE Confidence: 0.76944727

00:39:44.600 --> 00:39:46.900 Enter calculation cannot be determined  
NOTE Confidence: 0.76944727

00:39:46.900 --> 00:39:48.740 using regular typical methods.  
NOTE Confidence: 0.76944727

00:39:48.740 --> 00:39:51.470 For instance using PT PTT  
NOTE Confidence: 0.76944727

00:39:51.470 --> 00:39:54.655 because your parent act would be  
NOTE Confidence: 0.76944727

00:39:54.655 --> 00:39:57.479 in in the in the in the tube,

NOTE Confidence: 0.76944727  
00:39:57.480 --> 00:40:00.480 in the inner tube of blood.  
NOTE Confidence: 0.76944727  
00:40:00.480 --> 00:40:02.900 It would be pulled competitively  
NOTE Confidence: 0.76944727  
00:40:02.900 --> 00:40:04.836 inhibited by like say,  
NOTE Confidence: 0.76944727  
00:40:04.840 --> 00:40:07.255 citrate or ETA that already  
NOTE Confidence: 0.76944727  
00:40:07.255 --> 00:40:09.187 present in the tube,  
NOTE Confidence: 0.76944727  
00:40:09.190 --> 00:40:11.605 so therefore they used whole  
NOTE Confidence: 0.76944727  
00:40:11.605 --> 00:40:13.054 blood clotting time.  
NOTE Confidence: 0.76944727  
00:40:13.060 --> 00:40:16.276 So now the abstract itself actually  
NOTE Confidence: 0.76944727  
00:40:16.276 --> 00:40:19.391 presents the two studies to phase  
NOTE Confidence: 0.76944727  
00:40:19.391 --> 00:40:21.581 two will see what controlled  
NOTE Confidence: 0.76944727  
00:40:21.581 --> 00:40:24.357 RCT one for Apixaban and the  
NOTE Confidence: 0.76944727  
00:40:24.357 --> 00:40:27.099 other one for rear axle band,  
NOTE Confidence: 0.76944727  
00:40:27.100 --> 00:40:30.289 where they actually.  
NOTE Confidence: 0.76944727  
00:40:30.290 --> 00:40:33.465 Looked at reversal Cedar parents  
NOTE Confidence: 0.76944727  
00:40:33.465 --> 00:40:36.640 like versus placebo and it's  
NOTE Confidence: 0.76944727

00:40:36.747 --> 00:40:40.077 very simple design in both arms.  
NOTE Confidence: 0.76944727

00:40:40.080 --> 00:40:41.444 Both studies.  
NOTE Confidence: 0.76944727

00:40:41.444 --> 00:40:45.536 Essentially they used doac to reach  
NOTE Confidence: 0.76944727

00:40:45.536 --> 00:40:50.085 a steady state and then they gave  
NOTE Confidence: 0.76944727

00:40:50.085 --> 00:40:54.019 patients Sera parent tag on different  
NOTE Confidence: 0.76944727

00:40:54.019 --> 00:40:58.555 doses and contract the whole blood.  
NOTE Confidence: 0.76944727

00:40:58.560 --> 00:40:59.910 A cloud.  
NOTE Confidence: 0.76944727

00:40:59.910 --> 00:41:03.960 Including time and again because the  
NOTE Confidence: 0.76944727

00:41:03.960 --> 00:41:07.060 other parameters cannot be used.  
NOTE Confidence: 0.76944727

00:41:07.060 --> 00:41:10.120 And in point was that WBC  
NOTE Confidence: 0.76944727

00:41:10.120 --> 00:41:12.760 T should be below 10%,  
NOTE Confidence: 0.76944727

00:41:12.760 --> 00:41:16.379 and so how fast that actually happens.  
NOTE Confidence: 0.76944727

00:41:16.380 --> 00:41:19.488 And So what they showed again,  
NOTE Confidence: 0.76944727

00:41:19.490 --> 00:41:23.178 that in both cases for the Pixel banner  
NOTE Confidence: 0.76944727

00:41:23.178 --> 00:41:26.323 over oxygen that indeed within hours  
NOTE Confidence: 0.76944727

00:41:26.323 --> 00:41:29.521 within actually minutes the for in

NOTE Confidence: 0.76944727

00:41:29.615 --> 00:41:32.957 different doses of shared parent tag,

NOTE Confidence: 0.76944727

00:41:32.960 --> 00:41:36.640 the reversal was rather.

NOTE Confidence: 0.76944727

00:41:36.640 --> 00:41:38.071 Especially in this,

NOTE Confidence: 0.76944727

00:41:38.071 --> 00:41:41.410 in higher doses like syntax 60 milligrams,

NOTE Confidence: 0.76944727

00:41:41.410 --> 00:41:45.674 220 milligrams in takes a band and higher

NOTE Confidence: 0.76944727

00:41:45.674 --> 00:41:49.630 doses in rivaroxaban group as well.

NOTE Confidence: 0.76944727

00:41:49.630 --> 00:41:54.265 Then they also looked at how fast in again,

NOTE Confidence: 0.76944727

00:41:54.270 --> 00:41:56.840 how long the reversal remained.

NOTE Confidence: 0.76944727

00:41:56.840 --> 00:41:57.870 And again,

NOTE Confidence: 0.76944727

00:41:57.870 --> 00:42:00.445 in both groups fix again,

NOTE Confidence: 0.76944727

00:42:00.450 --> 00:42:03.540 but were actually in the high

NOTE Confidence: 0.76944727

00:42:03.540 --> 00:42:05.600 dose single parent tag.

NOTE Confidence: 0.76944727

00:42:05.600 --> 00:42:09.720 The highest dose children tag in each group.

NOTE Confidence: 0.76944727

00:42:09.720 --> 00:42:12.225 River traversal was rather fast

NOTE Confidence: 0.76944727

00:42:12.225 --> 00:42:14.730 within within 660 minutes in

NOTE Confidence: 0.76944727

00:42:14.814 --> 00:42:16.954 apixaban 100% patients have  
NOTE Confidence: 0.76944727

00:42:16.954 --> 00:42:19.589 been reversed to the target.  
NOTE Confidence: 0.76944727

00:42:19.590 --> 00:42:22.075 Of less than 10% of baseline for  
NOTE Confidence: 0.76944727

00:42:22.075 --> 00:42:24.375 a whole bottle of whole blood  
NOTE Confidence: 0.76944727

00:42:24.375 --> 00:42:26.685 clotting time and in Russia ban  
NOTE Confidence: 0.76944727

00:42:26.685 --> 00:42:29.118 even even faster in 30 minutes.  
NOTE Confidence: 0.76944727

00:42:29.120 --> 00:42:31.922 So it's an interesting concept is  
NOTE Confidence: 0.76944727

00:42:31.922 --> 00:42:34.328 interesting new molecule which product  
NOTE Confidence: 0.76944727

00:42:34.328 --> 00:42:36.628 which is undergoing studies like  
NOTE Confidence: 0.76944727

00:42:36.628 --> 00:42:39.199 phase two and probably would be.  
NOTE Confidence: 0.76944727

00:42:39.200 --> 00:42:41.984 Can soon enter phase three with  
NOTE Confidence: 0.76944727

00:42:41.984 --> 00:42:43.840 a very exciting profile.  
NOTE Confidence: 0.76944727

00:42:43.840 --> 00:42:46.368 There's no prothrombotic signal,  
NOTE Confidence: 0.76944727

00:42:46.368 --> 00:42:50.734 no evidence to promote it signaled they  
NOTE Confidence: 0.76944727

00:42:50.734 --> 00:42:54.038 actually looked at the D dimer and.  
NOTE Confidence: 0.76944727

00:42:54.040 --> 00:42:57.340 Uh, and that was not affected.

NOTE Confidence: 0.76944727

00:42:57.340 --> 00:42:58.526 There's potential.

NOTE Confidence: 0.76944727

00:42:58.526 --> 00:43:01.491 The interesting question that could

NOTE Confidence: 0.76944727

00:43:01.491 --> 00:43:04.603 be raised that whether magnesium

NOTE Confidence: 0.76944727

00:43:04.603 --> 00:43:07.522 and calcium in Vivo could could

NOTE Confidence: 0.76944727

00:43:07.522 --> 00:43:10.613 have any effect on sort of pulling

NOTE Confidence: 0.76944727

00:43:10.613 --> 00:43:13.038 setup Ramtek out of the.

NOTE Confidence: 0.76944727

00:43:13.040 --> 00:43:16.365 Interaction with the aid with the agents.

NOTE Confidence: 0.76944727

00:43:16.370 --> 00:43:18.218 Anticoagulation agents but it

NOTE Confidence: 0.76944727

00:43:18.218 --> 00:43:20.066 probably in molar concentration

NOTE Confidence: 0.76944727

00:43:20.066 --> 00:43:22.498 such that probably not really

NOTE Confidence: 0.76944727

00:43:22.498 --> 00:43:24.422 likely an interesting concept

NOTE Confidence: 0.76944727

00:43:24.422 --> 00:43:25.865 that an anticoagulation,

NOTE Confidence: 0.76944727

00:43:25.870 --> 00:43:29.342 if necessary can be re stored and re

NOTE Confidence: 0.76944727

00:43:29.342 --> 00:43:32.519 established 24 hour reversal without any.

NOTE Confidence: 0.8165076

00:43:35.300 --> 00:43:37.715 In effect cost, of course the issue,

NOTE Confidence: 0.8165076

00:43:37.720 --> 00:43:39.604 and I'm sure George some point  
NOTE Confidence: 0.8165076

00:43:39.604 --> 00:43:41.530 will do the cost analysis.  
NOTE Confidence: 0.8165076

00:43:41.530 --> 00:43:45.122 I hope if that comes to that and  
NOTE Confidence: 0.8165076

00:43:45.122 --> 00:43:48.057 then with that I'll move to.  
NOTE Confidence: 0.8165076

00:43:48.060 --> 00:43:52.556 To our to my final discussion of the  
NOTE Confidence: 0.8165076

00:43:52.556 --> 00:43:57.589 work that we sort of we presented at ASH.  
NOTE Confidence: 0.8165076

00:43:57.590 --> 00:44:00.360 That in form has been  
NOTE Confidence: 0.8165076

00:44:00.360 --> 00:44:02.576 informing us beyond COVID-19,  
NOTE Confidence: 0.8165076

00:44:02.580 --> 00:44:05.350 which is quite interesting discussion.  
NOTE Confidence: 0.8165076

00:44:05.350 --> 00:44:09.110 So what we wanted to.  
NOTE Confidence: 0.8165076

00:44:09.110 --> 00:44:12.870 Look at is a weather items test 13.  
NOTE Confidence: 0.8165076

00:44:12.870 --> 00:44:15.985 Another imbalance of atoms TS 13 an  
NOTE Confidence: 0.8165076

00:44:15.985 --> 00:44:18.275 Fonville burn factor could potentially  
NOTE Confidence: 0.8165076

00:44:18.275 --> 00:44:20.897 serve as a marker of uniform  
NOTE Confidence: 0.8165076

00:44:20.897 --> 00:44:23.679 doses in patients with COVID-19,  
NOTE Confidence: 0.8165076

00:44:23.680 --> 00:44:26.030 that was our initial goal,

NOTE Confidence: 0.8165076

00:44:26.030 --> 00:44:30.118 so we last year we right in the

NOTE Confidence: 0.8165076

00:44:30.118 --> 00:44:33.636 beginning of pandemic we sort of

NOTE Confidence: 0.8165076

00:44:33.636 --> 00:44:37.660 have this lack of having number of.

NOTE Confidence: 0.8165076

00:44:37.660 --> 00:44:39.922 Great researchers working,

NOTE Confidence: 0.8165076

00:44:39.922 --> 00:44:43.692 collaborating with George Washago shoe

NOTE Confidence: 0.8165076

00:44:43.692 --> 00:44:48.236 and Enchong after deadly and math mileage.

NOTE Confidence: 0.8165076

00:44:48.240 --> 00:44:49.650 And we.

NOTE Confidence: 0.77607673

00:44:51.860 --> 00:44:53.432 Show that one from

NOTE Confidence: 0.77607673

00:44:53.432 --> 00:44:55.004 building factor, of course.

NOTE Confidence: 0.77607673

00:44:55.004 --> 00:44:57.356 It's been shown since then many,

NOTE Confidence: 0.77607673

00:44:57.360 --> 00:44:59.325 many times is quite elevated

NOTE Confidence: 0.77607673

00:44:59.325 --> 00:45:01.290 in patients with coded 19,

NOTE Confidence: 0.77607673

00:45:01.290 --> 00:45:03.576 and this specifically much more elevated

NOTE Confidence: 0.77607673

00:45:03.576 --> 00:45:05.620 in patients with critical disease.

NOTE Confidence: 0.77607673

00:45:05.620 --> 00:45:07.828 We also know from other studies

NOTE Confidence: 0.77607673



00:45:07.828 --> 00:45:10.216 from studies so far not related  
NOTE Confidence: 0.77607673

00:45:10.216 --> 00:45:11.900 to coordinating at all,  
NOTE Confidence: 0.77607673

00:45:11.900 --> 00:45:13.480 that Adams TS13 deficiency.  
NOTE Confidence: 0.68871737

00:45:16.470 --> 00:45:18.924 13 is reduced in inflammatory states  
NOTE Confidence: 0.68871737

00:45:18.924 --> 00:45:21.120 like cancer stroke and sepsis.  
NOTE Confidence: 0.68871737

00:45:21.120 --> 00:45:21.968 Interestingly enough,  
NOTE Confidence: 0.68871737

00:45:21.968 --> 00:45:23.662 in animal models, Adams,  
NOTE Confidence: 0.68871737

00:45:23.662 --> 00:45:25.350 tutti and efficiency increases.  
NOTE Confidence: 0.68871737

00:45:25.350 --> 00:45:27.658 Release of from building  
NOTE Confidence: 0.68871737

00:45:27.658 --> 00:45:29.966 factor from from platelets.  
NOTE Confidence: 0.68871737

00:45:29.970 --> 00:45:34.518 It increases increases adhesion to white.  
NOTE Confidence: 0.68871737

00:45:34.520 --> 00:45:34.864 Neutrophils,  
NOTE Confidence: 0.68871737

00:45:34.864 --> 00:45:37.272 white count white cells to the civilian  
NOTE Confidence: 0.68871737

00:45:37.272 --> 00:45:39.340 and enhances neutrophil extravasation.  
NOTE Confidence: 0.68871737

00:45:39.340 --> 00:45:42.220 So what we then looked we going back  
NOTE Confidence: 0.68871737

00:45:42.220 --> 00:45:45.131 to the to the cohort to our data

NOTE Confidence: 0.68871737

00:45:45.131 --> 00:45:48.534 and we will look at what kind of

NOTE Confidence: 0.68871737

00:45:48.534 --> 00:45:50.919 relationship exists between Adams test

NOTE Confidence: 0.68871737

00:45:50.919 --> 00:45:53.818 13 an from villain factor antigen activity.

NOTE Confidence: 0.68871737

00:45:53.820 --> 00:45:56.988 We found that indeed.

NOTE Confidence: 0.68871737

00:45:56.990 --> 00:45:59.200 In critical disease in patients

NOTE Confidence: 0.68871737

00:45:59.200 --> 00:46:00.526 with critical disease,

NOTE Confidence: 0.68871737

00:46:00.530 --> 00:46:02.249 it's indeed lower.

NOTE Confidence: 0.68871737

00:46:02.249 --> 00:46:07.330 The balance is such that this ratio is lower.

NOTE Confidence: 0.68871737

00:46:07.330 --> 00:46:09.832 We also showed earlier this year

NOTE Confidence: 0.68871737

00:46:09.832 --> 00:46:11.500 that there's several markers

NOTE Confidence: 0.68871737

00:46:11.575 --> 00:46:13.459 of neutrophil activation that

NOTE Confidence: 0.68871737

00:46:13.459 --> 00:46:15.814 been associated with ICU status,

NOTE Confidence: 0.68871737

00:46:15.820 --> 00:46:18.502 and we collaborate with this with

NOTE Confidence: 0.68871737

00:46:18.502 --> 00:46:20.290 adjacency Cheyenne David Friend.

NOTE Confidence: 0.65678453

00:46:22.400 --> 00:46:24.717 \*\*\*\* and what we can infer that

NOTE Confidence: 0.65678453

00:46:24.717 --> 00:46:27.257 we show that at the absolute  
NOTE Confidence: 0.65678453

00:46:27.257 --> 00:46:29.702 neutrophil count and image resized  
NOTE Confidence: 0.65678453

00:46:29.702 --> 00:46:32.230 to neutrophils have been associated  
NOTE Confidence: 0.65678453

00:46:32.230 --> 00:46:34.675 and could discriminate mortality and  
NOTE Confidence: 0.65678453

00:46:34.675 --> 00:46:38.988 we used our Dom Kodiaks database.  
NOTE Confidence: 0.65678453

00:46:38.990 --> 00:46:42.482 For that so then when we went to Adams  
NOTE Confidence: 0.65678453

00:46:42.482 --> 00:46:45.670 just watching from Wilburton ratio,  
NOTE Confidence: 0.65678453

00:46:45.670 --> 00:46:48.806 we also showed that that he had  
NOTE Confidence: 0.65678453

00:46:48.806 --> 00:46:51.241 actually inversely related to neutrophil  
NOTE Confidence: 0.65678453

00:46:51.241 --> 00:46:53.776 and initial to lymphocyte ratio,  
NOTE Confidence: 0.65678453

00:46:53.780 --> 00:46:56.874 and Furthermore we when we looked at  
NOTE Confidence: 0.65678453

00:46:56.874 --> 00:46:59.296 whether this disbalance also associated  
NOTE Confidence: 0.65678453

00:46:59.296 --> 00:47:01.836 with the the neutrophil markers  
NOTE Confidence: 0.65678453

00:47:01.836 --> 00:47:03.907 markers of neutrophil activation  
NOTE Confidence: 0.65678453

00:47:03.907 --> 00:47:06.691 is GF resistant Lipo Callanan I'll  
NOTE Confidence: 0.65678453

00:47:06.691 --> 00:47:10.235 eight that indeed we found that.

NOTE Confidence: 0.65678453

00:47:10.235 --> 00:47:13.810 All those markers were associated

NOTE Confidence: 0.65678453

00:47:13.810 --> 00:47:15.240 with worsening.

NOTE Confidence: 0.65678453

00:47:15.240 --> 00:47:18.166 Reducing the rate reduce the ratio for

NOTE Confidence: 0.65678453

00:47:18.166 --> 00:47:21.289 Adams Tester team to fund building factor,

NOTE Confidence: 0.65678453

00:47:21.290 --> 00:47:23.445 which again could indicate the

NOTE Confidence: 0.65678453

00:47:23.445 --> 00:47:24.738 potential prothrombotic process.

NOTE Confidence: 0.65678453

00:47:24.740 --> 00:47:25.320 Furthermore,

NOTE Confidence: 0.65678453

00:47:25.320 --> 00:47:30.540 we also looked at the same exact idea about.

NOTE Confidence: 0.65678453

00:47:30.540 --> 00:47:33.220 L Association with the ratio

NOTE Confidence: 0.65678453

00:47:33.220 --> 00:47:34.828 with Taiwan with.

NOTE Confidence: 0.65678453

00:47:34.830 --> 00:47:37.890 Fabulous inhibitor and again the

NOTE Confidence: 0.65678453

00:47:37.890 --> 00:47:41.545 same situation with where Adams just

NOTE Confidence: 0.65678453

00:47:41.545 --> 00:47:44.497 looking for the ratio is lower.

NOTE Confidence: 0.65678453

00:47:44.500 --> 00:47:46.831 So overall we show that lower so

NOTE Confidence: 0.65678453

00:47:46.831 --> 00:47:49.327 Adam Sistine Info Bill from building

NOTE Confidence: 0.65678453

00:47:49.327 --> 00:47:50.758 factor Disbalance exist.  
NOTE Confidence: 0.65678453

00:47:50.760 --> 00:47:53.100 So shaded with inhibitor for lysis,  
NOTE Confidence: 0.65678453

00:47:53.100 --> 00:47:54.552 markers of neutrophil activation  
NOTE Confidence: 0.65678453

00:47:54.552 --> 00:47:56.730 and there are four its potential  
NOTE Confidence: 0.65678453

00:47:56.787 --> 00:47:58.862 email somebody in uniform biotic  
NOTE Confidence: 0.65678453

00:47:58.862 --> 00:48:00.522 market foreign botic complication.  
NOTE Confidence: 0.65678453

00:48:00.530 --> 00:48:02.140 What's really interesting now is  
NOTE Confidence: 0.65678453

00:48:02.140 --> 00:48:05.020 that what we do now is actually we're  
NOTE Confidence: 0.65678453

00:48:05.020 --> 00:48:07.030 looking specifically at people at  
NOTE Confidence: 0.65678453

00:48:07.030 --> 00:48:09.224 patients with COVID-19 and without  
NOTE Confidence: 0.65678453

00:48:09.224 --> 00:48:11.864 coordinating but who had actual thrombosis.  
NOTE Confidence: 0.65678453

00:48:11.870 --> 00:48:15.198 So now we actually will be able to.  
NOTE Confidence: 0.65678453

00:48:15.200 --> 00:48:17.230 Tying this with this ratio  
NOTE Confidence: 0.65678453

00:48:17.230 --> 00:48:18.448 with thrombosis itself,  
NOTE Confidence: 0.65678453

00:48:18.450 --> 00:48:20.880 and of course going beyond COVID-19,  
NOTE Confidence: 0.65678453

00:48:20.880 --> 00:48:22.504 all of it applies.

NOTE Confidence: 0.65678453

00:48:22.504 --> 00:48:24.940 This platform can be scaled up.

NOTE Confidence: 0.65678453

00:48:24.940 --> 00:48:27.579 This idea can be scaled up to

NOTE Confidence: 0.65678453

00:48:27.579 --> 00:48:29.819 basically any uniform body disorder,

NOTE Confidence: 0.65678453

00:48:29.820 --> 00:48:31.624 an also synthetic malignancies,

NOTE Confidence: 0.65678453

00:48:31.624 --> 00:48:35.096 which we would like to explore as well

NOTE Confidence: 0.65678453

00:48:35.096 --> 00:48:37.525 and with that will yield the floor.

NOTE Confidence: 0.89763653

00:48:42.980 --> 00:48:46.286 Thank you so much, Alex and.

NOTE Confidence: 0.89763653

00:48:46.290 --> 00:48:48.929 For the last part of the talk.

NOTE Confidence: 0.89763653

00:48:48.930 --> 00:48:51.072 I am going to talk about other

NOTE Confidence: 0.89763653

00:48:51.072 --> 00:48:52.670 topics in classical mythology.

NOTE Confidence: 0.89763653

00:48:52.670 --> 00:48:53.702 Good afternoon everybody.

NOTE Confidence: 0.89763653

00:48:53.702 --> 00:48:56.110 My name is George Joshua and one

NOTE Confidence: 0.89763653

00:48:56.174 --> 00:48:58.834 of the senior fellows in the Yale

NOTE Confidence: 0.89763653

00:48:58.834 --> 00:49:00.510 Hematology Oncology Fellowship program.

NOTE Confidence: 0.89763653

00:49:00.510 --> 00:49:02.472 And it is a pleasure to

NOTE Confidence: 0.89763653

00:49:02.472 --> 00:49:04.340 be talking to you today.  
NOTE Confidence: 0.89763653

00:49:04.340 --> 00:49:05.730 I have no disclosures.  
NOTE Confidence: 0.89763653

00:49:05.730 --> 00:49:08.035 There are four apps we're going to  
NOTE Confidence: 0.89763653

00:49:08.035 --> 00:49:10.599 cover and I will speak through this,  
NOTE Confidence: 0.89763653

00:49:10.600 --> 00:49:12.777 so we finish on time and we're  
NOTE Confidence: 0.89763653

00:49:12.777 --> 00:49:15.129 going to talk about gene editing.  
NOTE Confidence: 0.89763653

00:49:15.130 --> 00:49:17.212 And we're going to talk about  
NOTE Confidence: 0.89763653

00:49:17.212 --> 00:49:18.253 complement system performance,  
NOTE Confidence: 0.89763653

00:49:18.260 --> 00:49:19.541 health outcomes, research.  
NOTE Confidence: 0.89763653

00:49:19.541 --> 00:49:22.103 And a little bit of coping.  
NOTE Confidence: 0.89763653

00:49:22.110 --> 00:49:23.720 19 So to start off.  
NOTE Confidence: 0.89763653

00:49:23.720 --> 00:49:25.514 First abstract #4 entitled CRISPR CAS  
NOTE Confidence: 0.89763653

00:49:25.514 --> 00:49:27.804 9 gene editing for sickle cell disease  
NOTE Confidence: 0.89763653

00:49:27.804 --> 00:49:29.539 and beta thalassemia by doctors.  
NOTE Confidence: 0.89763653

00:49:29.540 --> 00:49:30.344 Frangou and colleagues.  
NOTE Confidence: 0.89763653

00:49:30.344 --> 00:49:31.952 Miss was a plenary talk and

NOTE Confidence: 0.89763653  
00:49:31.952 --> 00:49:33.081 also simultaneously published  
NOTE Confidence: 0.89763653  
00:49:33.081 --> 00:49:34.705 in human Journal Medicine.  
NOTE Confidence: 0.89763653  
00:49:34.710 --> 00:49:36.325 For context to the reason  
NOTE Confidence: 0.89763653  
00:49:36.325 --> 00:49:37.940 why the study is important.  
NOTE Confidence: 0.095846444  
00:49:40.090 --> 00:49:41.450 Football.  
NOTE Confidence: 0.409799  
00:49:44.520 --> 00:49:44.910 Emma.  
NOTE Confidence: 0.15843415  
00:49:46.940 --> 00:49:50.830 Bo team. Both.  
NOTE Confidence: 0.51197803  
00:49:53.540 --> 00:49:57.290 Valve should have.  
NOTE Confidence: 0.51197803  
00:49:57.290 --> 00:50:03.299 What is speed? Your line is.  
NOTE Confidence: 0.51197803  
00:50:03.300 --> 00:50:09.050 Is script more than one?  
NOTE Confidence: 0.51197803  
00:50:09.050 --> 00:50:10.349 For the intervention,  
NOTE Confidence: 0.51197803  
00:50:10.349 --> 00:50:12.514 here is analogous selling 001,  
NOTE Confidence: 0.51197803  
00:50:12.520 --> 00:50:14.260 and it is edited.  
NOTE Confidence: 0.6017649  
00:50:19.190 --> 00:50:19.570 Speak.  
NOTE Confidence: 0.81746113  
00:50:31.180 --> 00:50:34.936 OK, I suppose we disconnected there.  
NOTE Confidence: 0.81746113



00:50:34.940 --> 00:50:37.543 Alright. Alright,  
NOTE Confidence: 0.81746113

00:50:37.543 --> 00:50:40.810 so back to the figure as it was saying.  
NOTE Confidence: 0.81746113

00:50:40.810 --> 00:50:42.922 So this is crisper cast 9  
NOTE Confidence: 0.81746113

00:50:42.922 --> 00:50:44.800 technology on the X axis.  
NOTE Confidence: 0.81746113

00:50:44.800 --> 00:50:46.642 You see months before birth and  
NOTE Confidence: 0.81746113

00:50:46.642 --> 00:50:49.503 after birth and on the Y axis globin  
NOTE Confidence: 0.81746113

00:50:49.503 --> 00:50:51.075 synthesis and percentage fetal  
NOTE Confidence: 0.81746113

00:50:51.075 --> 00:50:53.149 hemoglobin goes to adult hemoglobin.  
NOTE Confidence: 0.81746113

00:50:53.150 --> 00:50:55.530 BCL 11 is an important  
NOTE Confidence: 0.81746113

00:50:55.530 --> 00:50:56.958 transcription factor so.  
NOTE Confidence: 0.81746113

00:50:56.960 --> 00:50:59.996 If you take a look at.  
NOTE Confidence: 0.81746113

00:51:00.000 --> 00:51:01.878 The nucleus and the guide RNA.  
NOTE Confidence: 0.81746113

00:51:01.880 --> 00:51:03.902 The target is in the Erythroid  
NOTE Confidence: 0.81746113

00:51:03.902 --> 00:51:05.704 Enhancer region and by disrupting  
NOTE Confidence: 0.81746113

00:51:05.704 --> 00:51:08.032 that with gene editing we can  
NOTE Confidence: 0.81746113

00:51:08.032 --> 00:51:09.959 alter the expression of BCL 11A.

NOTE Confidence: 0.81746113

00:51:09.960 --> 00:51:13.749 Effectively shutting down.

NOTE Confidence: 0.81746113

00:51:13.750 --> 00:51:16.015 The production of globin and

NOTE Confidence: 0.81746113

00:51:16.015 --> 00:51:17.374 increasing fetal hemoglobin.

NOTE Confidence: 0.81746113

00:51:17.380 --> 00:51:19.364 So you will see the results here in

NOTE Confidence: 0.81746113

00:51:19.364 --> 00:51:21.272 the first 2 patients presented by

NOTE Confidence: 0.81746113

00:51:21.272 --> 00:51:22.957 Doctor Strangle and colleagues on

NOTE Confidence: 0.81746113

00:51:22.957 --> 00:51:25.088 the left you have a patient with data

NOTE Confidence: 0.81746113

00:51:25.088 --> 00:51:27.250 file on the X axis you have months.

NOTE Confidence: 0.81746113

00:51:27.250 --> 00:51:28.096 After CTX user,

NOTE Confidence: 0.81746113

00:51:28.096 --> 00:51:29.788 one infusion on the Y axis,

NOTE Confidence: 0.81746113

00:51:29.790 --> 00:51:31.332 hemoglobin in grams per deciliter and

NOTE Confidence: 0.81746113

00:51:31.332 --> 00:51:33.631 on the and on the right panel you

NOTE Confidence: 0.81746113

00:51:33.631 --> 00:51:35.146 have patients sickle cell disease.

NOTE Confidence: 0.81746113

00:51:35.150 --> 00:51:36.949 Pay attention to the areas in the

NOTE Confidence: 0.81746113

00:51:36.949 --> 00:51:38.689 blue as they expand that's fetal

NOTE Confidence: 0.81746113

00:51:38.689 --> 00:51:40.501 hemoglobin and you see that in  
NOTE Confidence: 0.81746113

00:51:40.501 --> 00:51:42.509 the case of beta Thal the last  
NOTE Confidence: 0.81746113

00:51:42.509 --> 00:51:43.870 transfusion was at one month.  
NOTE Confidence: 0.81746113

00:51:43.870 --> 00:51:45.950 Prior Post 2 CTX 01 infusion and in  
NOTE Confidence: 0.81746113

00:51:45.950 --> 00:51:48.135 the case of sickle cell disease the  
NOTE Confidence: 0.81746113

00:51:48.135 --> 00:51:49.889 last transfusion was at 19 days.  
NOTE Confidence: 0.81746113

00:51:49.890 --> 00:51:53.208 Status Post ETF 001 infusion the  
NOTE Confidence: 0.81746113

00:51:53.208 --> 00:51:55.987 adverse events are listed here  
NOTE Confidence: 0.81746113

00:51:55.987 --> 00:51:58.765 and all of them were treated.  
NOTE Confidence: 0.81746113

00:51:58.770 --> 00:52:00.450 Abstract number 445 is entitled very  
NOTE Confidence: 0.81746113

00:52:00.450 --> 00:52:01.983 inherited defects of the complement  
NOTE Confidence: 0.81746113

00:52:01.983 --> 00:52:03.419 system and poor performance.  
NOTE Confidence: 0.81746113

00:52:03.420 --> 00:52:05.232 This was presented by Doctor Bendapudi  
NOTE Confidence: 0.81746113

00:52:05.232 --> 00:52:07.450 and colleagues out of the Harvard system.  
NOTE Confidence: 0.81746113

00:52:07.450 --> 00:52:09.925 The context here is that PF is on the  
NOTE Confidence: 0.81746113

00:52:09.925 --> 00:52:12.409 extreme thrombotic end of the GIC spectrum,

NOTE Confidence: 0.81746113  
00:52:12.410 --> 00:52:14.100 and elucidating PF quite gladly  
NOTE Confidence: 0.81746113  
00:52:14.100 --> 00:52:16.724 may pave the way for a better  
NOTE Confidence: 0.81746113  
00:52:16.724 --> 00:52:18.456 understanding of DIC including.  
NOTE Confidence: 0.81746113  
00:52:18.460 --> 00:52:22.258 Are you asking in this subset?  
NOTE Confidence: 0.81746113  
00:52:22.260 --> 00:52:29.340 Peach boss Richmond Cody, their competitor.  
NOTE Confidence: 0.81746113  
00:52:29.340 --> 00:52:32.679 This with this from the NHL VR.  
NOTE Confidence: 0.70531815  
00:52:34.980 --> 00:52:37.038 And you will see violin plots  
NOTE Confidence: 0.70531815  
00:52:37.038 --> 00:52:39.640 on the left and the right on  
NOTE Confidence: 0.70531815  
00:52:39.640 --> 00:52:41.550 the left is the compliment.  
NOTE Confidence: 0.70531815  
00:52:41.550 --> 00:52:43.888 You can set the enrichment in PFS  
NOTE Confidence: 0.70531815  
00:52:43.888 --> 00:52:45.765 compared to an slips patients  
NOTE Confidence: 0.70531815  
00:52:45.765 --> 00:52:47.755 and on the right quality.  
NOTE Confidence: 0.774716963478261  
00:52:50.430 --> 00:52:52.010 At the doctor \*\*\*\*\*.  
NOTE Confidence: 0.774716963478261  
00:52:52.010 --> 00:52:54.380 Global in the slides looking at  
NOTE Confidence: 0.774716963478261  
00:52:54.461 --> 00:52:57.053 all the unique variants that the  
NOTE Confidence: 0.774716963478261

00:52:57.053 --> 00:52:59.758 researchers have found so far to date,  
NOTE Confidence: 0.774716963478261

00:52:59.760 --> 00:53:01.788 but let me summarize it here.  
NOTE Confidence: 0.774716963478261

00:53:01.790 --> 00:53:04.149 26 out of have one or more  
NOTE Confidence: 0.774716963478261

00:53:04.149 --> 00:53:05.160 rare putatively delete,  
NOTE Confidence: 0.774716963478261

00:53:05.160 --> 00:53:06.168 delete serious mutations.  
NOTE Confidence: 0.8488677

00:53:18.990 --> 00:53:20.974 Sorry for the audio difficulties.  
NOTE Confidence: 0.8488677

00:53:20.974 --> 00:53:22.558 I think George you  
NOTE Confidence: 0.8488677

00:53:22.560 --> 00:53:24.945 might wanna like hide your camera.  
NOTE Confidence: 0.8488677

00:53:24.945 --> 00:53:27.716 Maybe that will help the audio connection.  
NOTE Confidence: 0.8488677

00:53:27.720 --> 00:53:30.108 It might be a connectivity issue.  
NOTE Confidence: 0.72921765

00:53:30.940 --> 00:53:32.505 Um, I wouldn't having connectivity  
NOTE Confidence: 0.72921765

00:53:32.505 --> 00:53:34.799 issues at all and all prior talks.  
NOTE Confidence: 0.72921765

00:53:34.800 --> 00:53:37.054 Can you see this summer right now?  
NOTE Confidence: 0.8479782

00:53:39.080 --> 00:53:41.050 Or no, we can. We see you,  
NOTE Confidence: 0.8479782

00:53:41.050 --> 00:53:43.010 but it keeps freezing, yet it keeps  
NOTE Confidence: 0.8568507

00:53:43.010 --> 00:53:46.598 freezing. Not quite. Sorry bout that.

NOTE Confidence: 0.8568507

00:53:46.600 --> 00:53:49.410 Um? Let me try this again.

NOTE Confidence: 0.9230279

00:53:54.520 --> 00:53:55.700 Can you see this here?

NOTE Confidence: 0.845912

00:53:58.080 --> 00:54:00.798 Yeah, we can see, but probably better if you

NOTE Confidence: 0.845912

00:54:00.798 --> 00:54:03.380 hide your camera so that it flows nicely.

NOTE Confidence: 0.85032344

00:54:06.730 --> 00:54:08.627 Sorry, I'm not sure what you mean

NOTE Confidence: 0.85032344

00:54:08.627 --> 00:54:10.688 by hide the camera 'cause all I'm

NOTE Confidence: 0.85032344

00:54:10.688 --> 00:54:12.950 seeing is the screen on the screen.

NOTE Confidence: 0.85032344

00:54:12.950 --> 00:54:14.670 Let's see here OK.

NOTE Confidence: 0.8047364

00:54:18.500 --> 00:54:21.076 Alright, just let me know if we get

NOTE Confidence: 0.8047364

00:54:21.080 --> 00:54:23.330 disconnected again. You can go ahead. I

NOTE Confidence: 0.8047364

00:54:23.330 --> 00:54:24.618 think we're good now.

NOTE Confidence: 0.8047364

00:54:24.618 --> 00:54:26.280 OK, sounds good. Thank you.

NOTE Confidence: 0.8047364

00:54:26.280 --> 00:54:27.955 So with regards to the

NOTE Confidence: 0.8047364

00:54:27.955 --> 00:54:29.129 bendapudi at all study,

NOTE Confidence: 0.8047364

00:54:29.130 --> 00:54:31.130 they found that six of the 8 CR

NOTE Confidence: 0.8047364

00:54:31.130 --> 00:54:33.305 3 variants were loss of function  
NOTE Confidence: 0.8047364

00:54:33.305 --> 00:54:34.913 and these are anti-inflammatory,  
NOTE Confidence: 0.8047364

00:54:34.920 --> 00:54:36.750 while three of seven CR 4  
NOTE Confidence: 0.8047364

00:54:36.750 --> 00:54:37.970 variants are gaining function  
NOTE Confidence: 0.8047364

00:54:38.029 --> 00:54:39.749 and these are pro inflammatory.  
NOTE Confidence: 0.8047364

00:54:39.750 --> 00:54:41.742 So overall supporting very  
NOTE Confidence: 0.8047364

00:54:41.742 --> 00:54:44.232 inflammatory milieu in these patients.  
NOTE Confidence: 0.8047364

00:54:44.240 --> 00:54:45.548 Abstract 47 cost effectiveness  
NOTE Confidence: 0.8047364

00:54:45.548 --> 00:54:47.183 of capitalism had been acquired.  
NOTE Confidence: 0.8047364

00:54:47.190 --> 00:54:48.498 Thrombotic thrombocytopenia purpura was  
NOTE Confidence: 0.8047364

00:54:48.498 --> 00:54:50.133 presented by Joshua and colleagues.  
NOTE Confidence: 0.8047364

00:54:50.140 --> 00:54:51.886 The context for this study is  
NOTE Confidence: 0.8047364

00:54:51.886 --> 00:54:53.893 that complexes map is the first  
NOTE Confidence: 0.8047364

00:54:53.893 --> 00:54:55.716 FDA approved medication. In TTP.  
NOTE Confidence: 0.8047364

00:54:55.716 --> 00:54:57.356 It's endorsed in ITP guidelines,  
NOTE Confidence: 0.8047364

00:54:57.360 --> 00:54:59.496 recently approved in the context of

NOTE Confidence: 0.8047364

00:54:59.496 --> 00:55:00.920 confidential patient access schemes

NOTE Confidence: 0.8047364

00:55:00.979 --> 00:55:02.939 for use in the National Health Service,

NOTE Confidence: 0.8047364

00:55:02.940 --> 00:55:04.705 both discomfort in England has

NOTE Confidence: 0.8047364

00:55:04.705 --> 00:55:06.948 a high list price of 270,000

NOTE Confidence: 0.8047364

00:55:06.948 --> 00:55:08.968 US dollars per TCP episode.

NOTE Confidence: 0.8047364

00:55:08.970 --> 00:55:10.692 Here is a cartoon schematic on

NOTE Confidence: 0.8047364

00:55:10.692 --> 00:55:12.394 the bottom you see the summary

NOTE Confidence: 0.8047364

00:55:12.394 --> 00:55:14.362 of the two of the phase two in

NOTE Confidence: 0.8047364

00:55:14.424 --> 00:55:16.299 the Phase three clinical trials.

NOTE Confidence: 0.8047364

00:55:16.300 --> 00:55:18.636 You have a patient with the disease state,

NOTE Confidence: 0.8047364

00:55:18.640 --> 00:55:19.928 the hospitalization for TCP,

NOTE Confidence: 0.8047364

00:55:19.928 --> 00:55:21.538 who then receive treatment with

NOTE Confidence: 0.8047364

00:55:21.538 --> 00:55:22.746 their capitalism admin standard

NOTE Confidence: 0.8047364

00:55:22.746 --> 00:55:24.692 of care labeled as a or placebo

NOTE Confidence: 0.8047364

00:55:24.744 --> 00:55:26.352 standard care labeled as B and

NOTE Confidence: 0.8047364



00:55:26.352 --> 00:55:28.014 they can either progress to death  
NOTE Confidence: 0.8047364

00:55:28.014 --> 00:55:29.766 or they can go into remission.  
NOTE Confidence: 0.8047364

00:55:29.770 --> 00:55:31.814 Once in remission they can again relapse.  
NOTE Confidence: 0.8047364

00:55:31.820 --> 00:55:33.843 The total cost for each arm are  
NOTE Confidence: 0.8047364

00:55:33.843 --> 00:55:35.634 in front of you, 324 thousand.  
NOTE Confidence: 0.8047364

00:55:35.634 --> 00:55:37.386 For the campuses in my bar,  
NOTE Confidence: 0.8047364

00:55:37.390 --> 00:55:41.030 84,000 for the standard of care arm.  
NOTE Confidence: 0.8047364

00:55:41.030 --> 00:55:43.406 The five year time Horizon incremental  
NOTE Confidence: 0.8047364

00:55:43.406 --> 00:55:45.638 cost effectiveness ratio here was \$1.5  
NOTE Confidence: 0.8047364

00:55:45.638 --> 00:55:47.384 million for the use of capitalism  
NOTE Confidence: 0.8047364

00:55:47.384 --> 00:55:49.143 have in addition to the standard  
NOTE Confidence: 0.8047364

00:55:49.143 --> 00:55:50.868 of care with a 95% confidence  
NOTE Confidence: 0.8047364

00:55:50.868 --> 00:55:53.125 interval of 1.3 to \$1.7 million.  
NOTE Confidence: 0.8047364

00:55:53.125 --> 00:55:54.085 Of note,  
NOTE Confidence: 0.8047364

00:55:54.085 --> 00:55:56.500 this is the sensitivity analysis and I'll  
NOTE Confidence: 0.8047364

00:55:56.500 --> 00:55:58.529 just highlight one specific area here.

NOTE Confidence: 0.8047364

00:55:58.530 --> 00:55:59.898 Researchers looked at parameters

NOTE Confidence: 0.8047364

00:55:59.898 --> 00:56:01.950 that affect the icier for capitalism,

NOTE Confidence: 0.8047364

00:56:01.950 --> 00:56:04.742 AB and the one that affected the most

NOTE Confidence: 0.8047364

00:56:04.742 --> 00:56:07.986 by far is capitalism that cost itself.

NOTE Confidence: 0.8047364

00:56:07.990 --> 00:56:08.451 Finally,

NOTE Confidence: 0.8047364

00:56:08.451 --> 00:56:10.756 abstract 529 entitled intermediate dose

NOTE Confidence: 0.8047364

00:56:10.756 --> 00:56:12.600 anticoagulation and aspirin COVID-19

NOTE Confidence: 0.8047364

00:56:12.655 --> 00:56:14.280 and Propensity Score match analysis

NOTE Confidence: 0.8047364

00:56:14.280 --> 00:56:16.560 by not this mindless and colleagues.

NOTE Confidence: 0.8047364

00:56:16.560 --> 00:56:19.241 The context here is the current active

NOTE Confidence: 0.8047364

00:56:19.241 --> 00:56:20.894 for preliminary an unadjudicated

NOTE Confidence: 0.8047364

00:56:20.894 --> 00:56:23.486 data which shows 2 main things.

NOTE Confidence: 0.8047364

00:56:23.490 --> 00:56:25.530 One that therapeutic versus prophylactic

NOTE Confidence: 0.8047364

00:56:25.530 --> 00:56:27.570 dose anticoagulation in severely ill,

NOTE Confidence: 0.8047364

00:56:27.570 --> 00:56:27.940 i.e.

NOTE Confidence: 0.8047364

00:56:27.940 --> 00:56:29.790 Critically ill patients was halted  
NOTE Confidence: 0.8047364

00:56:29.790 --> 00:56:32.170 utility in December and then January  
NOTE Confidence: 0.8047364

00:56:32.170 --> 00:56:33.838 pre specified security boundary  
NOTE Confidence: 0.8047364

00:56:33.838 --> 00:56:36.419 was achieved in moderately elii non  
NOTE Confidence: 0.8047364

00:56:36.419 --> 00:56:38.534 critically ill patients on therapeutic  
NOTE Confidence: 0.8047364

00:56:38.534 --> 00:56:40.134 versus prophylactic dose anticoagulation.  
NOTE Confidence: 0.8047364

00:56:40.134 --> 00:56:42.402 So it is in this background that  
NOTE Confidence: 0.8047364

00:56:42.402 --> 00:56:43.688 optimization colleagues published their  
NOTE Confidence: 0.8047364

00:56:43.688 --> 00:56:45.760 study in the American Journal of Hematology.  
NOTE Confidence: 0.8047364

00:56:45.760 --> 00:56:47.404 This is an observation ULL study  
NOTE Confidence: 0.8047364

00:56:47.404 --> 00:56:48.860 looking at about 2800 patients  
NOTE Confidence: 0.8047364

00:56:48.860 --> 00:56:50.660 with the primary outcome being time  
NOTE Confidence: 0.8047364

00:56:50.660 --> 00:56:51.920 to in hospital death.  
NOTE Confidence: 0.8047364

00:56:51.920 --> 00:56:53.380 The competing risk of discharge.  
NOTE Confidence: 0.8047364

00:56:53.380 --> 00:56:55.092 I'm showing only a portion of the Yale  
NOTE Confidence: 0.8047364

00:56:55.092 --> 00:56:56.109 guidelines for thromboprophylaxis

NOTE Confidence: 0.8047364

00:56:56.109 --> 00:56:57.189 for hospitalizations.

NOTE Confidence: 0.8047364

00:56:57.190 --> 00:56:58.660 COVID-19 on the top right,

NOTE Confidence: 0.8047364

00:56:58.660 --> 00:57:01.228 and you see that there was a D

NOTE Confidence: 0.8047364

00:57:01.228 --> 00:57:03.728 dimer cut off that was utilized.

NOTE Confidence: 0.8047364

00:57:03.730 --> 00:57:05.879 This is the overall study design in

NOTE Confidence: 0.8047364

00:57:05.879 --> 00:57:07.960 overall cohort of some 2800 patients.

NOTE Confidence: 0.8047364

00:57:07.960 --> 00:57:09.328 Researchers identified risk factors

NOTE Confidence: 0.8047364

00:57:09.328 --> 00:57:11.380 for in hospital death and then

NOTE Confidence: 0.8047364

00:57:11.435 --> 00:57:13.457 created two nested cohorts on the

NOTE Confidence: 0.8047364

00:57:13.457 --> 00:57:14.805 left anticoagulation court that

NOTE Confidence: 0.7165097

00:57:14.858 --> 00:57:16.568 were Ben City scored matched for

NOTE Confidence: 0.7165097

00:57:16.568 --> 00:57:18.685 those risk factors and on the right.

NOTE Confidence: 0.7165097

00:57:18.685 --> 00:57:19.660 Aspirin versus NASCAR,

NOTE Confidence: 0.7165097

00:57:19.660 --> 00:57:21.610 notably on patients who were not

NOTE Confidence: 0.7165097

00:57:21.610 --> 00:57:22.910 on home antiplatelet therapy.

NOTE Confidence: 0.7165097

00:57:22.910 --> 00:57:25.016 And finally the results of the  
NOTE Confidence: 0.7165097

00:57:25.016 --> 00:57:26.069 multiple analysis following  
NOTE Confidence: 0.7165097

00:57:26.069 --> 00:57:27.958 the propensity score matching.  
NOTE Confidence: 0.7165097

00:57:27.960 --> 00:57:30.540 You will see the hazard ratio for  
NOTE Confidence: 0.7165097

00:57:30.540 --> 00:57:32.988 death for the use of intermediate  
NOTE Confidence: 0.7165097

00:57:32.988 --> 00:57:34.620 dose anticoagulation as compared  
NOTE Confidence: 0.7165097

00:57:34.684 --> 00:57:36.610 to prophylactic is .5 two and  
NOTE Confidence: 0.7165097

00:57:36.610 --> 00:57:37.894 again for in hospital.  
NOTE Confidence: 0.7165097

00:57:37.900 --> 00:57:39.368 Aspirin compared to and  
NOTE Confidence: 0.7165097

00:57:39.368 --> 00:57:41.203 no aspirin again .5 two.  
NOTE Confidence: 0.7165097

00:57:41.210 --> 00:57:43.779 So take homes gene editing in Dallas,  
NOTE Confidence: 0.7165097

00:57:43.780 --> 00:57:45.620 EMEA and sickle cell disease  
NOTE Confidence: 0.7165097

00:57:45.620 --> 00:57:49.270 can alter the disease scorers.  
NOTE Confidence: 0.7165097

00:57:49.270 --> 00:57:50.694 Target gene discoveries facility  
NOTE Confidence: 0.7165097

00:57:50.694 --> 00:57:52.118 genomic studies of breakfast  
NOTE Confidence: 0.7165097

00:57:52.118 --> 00:57:53.769 acquisition by bending colleagues,

NOTE Confidence: 0.7165097

00:57:53.770 --> 00:57:54.895 capitalism, app costs,

NOTE Confidence: 0.7165097

00:57:54.895 --> 00:57:56.770 and ATP is quite expensive.

NOTE Confidence: 0.7165097

00:57:56.770 --> 00:57:58.924 And finally we randomized trial data

NOTE Confidence: 0.7165097

00:57:58.924 --> 00:58:00.360 on intermediate dose anticoagulation

NOTE Confidence: 0.7165097

00:58:00.418 --> 00:58:01.648 and antiplatelet therapy.

NOTE Confidence: 0.7165097

00:58:01.650 --> 00:58:02.786 Thank you.

NOTE Confidence: 0.7165097

00:58:02.786 --> 00:58:06.194 Look forward to taking your questions.

NOTE Confidence: 0.7165097

00:58:06.200 --> 00:58:06.660 Yeah,

NOTE Confidence: 0.8676868

00:58:06.660 --> 00:58:08.970 thank you so much George,

NOTE Confidence: 0.8676868

00:58:08.970 --> 00:58:11.730 and apologies about the

NOTE Confidence: 0.8676868

00:58:11.730 --> 00:58:13.110 technical difficulties.

NOTE Confidence: 0.8676868

00:58:13.110 --> 00:58:15.130 For the next 10 minutes,

NOTE Confidence: 0.8676868

00:58:15.130 --> 00:58:17.728 doctor Bone and hopefully will moderate

NOTE Confidence: 0.8676868

00:58:17.728 --> 00:58:20.788 questions for those of you have to leave.

NOTE Confidence: 0.8676868

00:58:20.790 --> 00:58:23.226 As mentioned, this will be recorded

NOTE Confidence: 0.8676868

00:58:23.226 --> 00:58:25.303 and should be available for  
NOTE Confidence: 0.8676868

00:58:25.303 --> 00:58:27.250 you for subsequent full option.  
NOTE Confidence: 0.8676868

00:58:27.250 --> 00:58:28.870 Doctor Bone and Alfred.  
NOTE Confidence: 0.8386467

00:58:30.500 --> 00:58:32.200 Great, thank you everybody.  
NOTE Confidence: 0.91464174

00:58:37.690 --> 00:58:39.410 So maybe I can start with a  
NOTE Confidence: 0.91464174

00:58:39.410 --> 00:58:41.996 question that came in through the.  
NOTE Confidence: 0.91464174

00:58:42.000 --> 00:58:45.590 Through the chat room so you Sabrina.  
NOTE Confidence: 0.91464174

00:58:45.590 --> 00:58:48.605 How robust or how good do you feel  
NOTE Confidence: 0.91464174

00:58:48.605 --> 00:58:50.900 about the mycophenolate? In addition to  
NOTE Confidence: 0.876151

00:58:50.900 --> 00:58:51.908 corticosteroids that it  
NOTE Confidence: 0.876151

00:58:51.910 --> 00:58:52.930 might begin to  
NOTE Confidence: 0.876151

00:58:52.930 --> 00:58:55.640 alter practice at this point. Yeah,  
NOTE Confidence: 0.7826892

00:58:55.640 --> 00:58:58.377 you know, I I I have pause.  
NOTE Confidence: 0.7826892

00:58:58.380 --> 00:59:00.335 I don't think it's practice  
NOTE Confidence: 0.7826892

00:59:00.335 --> 00:59:01.899 changing at this point.  
NOTE Confidence: 0.7826892

00:59:01.900 --> 00:59:04.270 You know, I think it's interesting

NOTE Confidence: 0.7826892

00:59:04.270 --> 00:59:06.677 that there were some decrease in

NOTE Confidence: 0.7826892

00:59:06.677 --> 00:59:08.939 quality of life in the mpharm.

NOTE Confidence: 0.7826892

00:59:08.940 --> 00:59:11.836 I think it's important to kind of recognize

NOTE Confidence: 0.7826892

00:59:11.836 --> 00:59:14.692 that clinical response and kind of patient

NOTE Confidence: 0.7826892

00:59:14.692 --> 00:59:16.757 experience may not always correlate.

NOTE Confidence: 0.7826892

00:59:16.760 --> 00:59:18.715 You know, the this steroid

NOTE Confidence: 0.7826892

00:59:18.715 --> 00:59:20.670 alone arm more than 50%?

NOTE Confidence: 0.7826892

00:59:20.670 --> 00:59:22.795 About 56% of patients actually

NOTE Confidence: 0.7826892

00:59:22.795 --> 00:59:25.260 at the end of follow up.

NOTE Confidence: 0.7826892

00:59:25.260 --> 00:59:26.700 Which was about two years,

NOTE Confidence: 0.7826892

00:59:26.700 --> 00:59:28.416 had not required second line treatment,

NOTE Confidence: 0.7826892

00:59:28.420 --> 00:59:30.240 so they did well as in addition

NOTE Confidence: 0.7826892

00:59:30.240 --> 00:59:31.859 and better than prior studies.

NOTE Confidence: 0.7826892

00:59:31.860 --> 00:59:33.869 So you know, I think it's interesting,

NOTE Confidence: 0.7826892

00:59:33.870 --> 00:59:36.078 but I I think we need more data

NOTE Confidence: 0.7826892



00:59:36.078 --> 00:59:38.457 before we move it to the first line.  
NOTE Confidence: 0.7826892

00:59:39.400 --> 00:59:39.870 Thank you.  
NOTE Confidence: 0.78495073

00:59:42.110 --> 00:59:44.005 To be a payment, go ahead.  
NOTE Confidence: 0.78495073

00:59:44.005 --> 00:59:46.210 At the Harford, I figured we could.  
NOTE Confidence: 0.78495073

00:59:46.210 --> 00:59:47.470 We could like pick,  
NOTE Confidence: 0.78495073

00:59:47.470 --> 00:59:49.042 introduce some of the questions  
NOTE Confidence: 0.78495073

00:59:49.042 --> 00:59:50.926 that are are added in there.  
NOTE Confidence: 0.78495073

00:59:50.930 --> 00:59:52.825 Sabrina. Can you also talk a  
NOTE Confidence: 0.78495073

00:59:52.825 --> 00:59:54.712 bit about tranexamic acid in he  
NOTE Confidence: 0.78495073

00:59:54.712 --> 00:59:55.660 malignancy's and thrombocytopenia?  
NOTE Confidence: 0.78495073

00:59:55.660 --> 00:59:58.486 You know there is positive data for its use.  
NOTE Confidence: 0.78495073

00:59:58.490 --> 01:00:00.433 It's been completely lifesaving in trauma.  
NOTE Confidence: 0.78495073

01:00:00.433 --> 01:00:01.426 In postpartum hemorrhage,  
NOTE Confidence: 0.78495073

01:00:01.430 --> 01:00:02.686 particularly in Third World  
NOTE Confidence: 0.78495073

01:00:02.686 --> 01:00:04.256 countries and under resourced areas,  
NOTE Confidence: 0.78495073

01:00:04.260 --> 01:00:07.095 do any comments on why you think it didn't

NOTE Confidence: 0.78495073

01:00:07.095 --> 01:00:08.985 work in the setting of hematologic,

NOTE Confidence: 0.78495073

01:00:08.990 --> 01:00:09.932 malignancy, and thrombocytopenia?

NOTE Confidence: 0.78495073

01:00:09.932 --> 01:00:11.190 Yeah things, but I

NOTE Confidence: 0.82867736

01:00:11.190 --> 01:00:13.694 think that's a great great question and a

NOTE Confidence: 0.82867736

01:00:13.694 --> 01:00:15.916 question that came up for the presenters.

NOTE Confidence: 0.82867736

01:00:15.920 --> 01:00:17.180 The authors as well.

NOTE Confidence: 0.82867736

01:00:17.180 --> 01:00:20.008 You know, I think what they they spoke to,

NOTE Confidence: 0.82867736

01:00:20.010 --> 01:00:21.590 which makes sense to me,

NOTE Confidence: 0.82867736

01:00:21.590 --> 01:00:23.414 is kind of the complexity of

NOTE Confidence: 0.82867736

01:00:23.414 --> 01:00:25.050 microvascular and India theal damage.

NOTE Confidence: 0.82867736

01:00:25.050 --> 01:00:27.255 That happens as a rolls result of

NOTE Confidence: 0.82867736

01:00:27.255 --> 01:00:29.142 chemotherapy, 'cause all of these

NOTE Confidence: 0.82867736

01:00:29.142 --> 01:00:30.714 patients were getting treatment.

NOTE Confidence: 0.82867736

01:00:30.720 --> 01:00:33.380 You know, we know that while prophylactic

NOTE Confidence: 0.82867736

01:00:33.380 --> 01:00:34.914 platelet transfusions has helped

NOTE Confidence: 0.82867736

01:00:34.914 --> 01:00:36.906 in terms of of bleeding incidents,  
NOTE Confidence: 0.82867736

01:00:36.910 --> 01:00:38.950 there are still a good proportion  
NOTE Confidence: 0.82867736

01:00:38.950 --> 01:00:41.280 of patients that do have bleeding.  
NOTE Confidence: 0.82867736

01:00:41.280 --> 01:00:42.153 So you know,  
NOTE Confidence: 0.82867736

01:00:42.153 --> 01:00:44.719 I think there may just be more complex  
NOTE Confidence: 0.82867736

01:00:44.719 --> 01:00:47.443 pathophysiology in terms of why these  
NOTE Confidence: 0.82867736

01:00:47.443 --> 01:00:50.330 patients believe that is beyond low  
NOTE Confidence: 0.82867736

01:00:50.330 --> 01:00:52.266 platelets and impaired fibrinolysis.  
NOTE Confidence: 0.82867736

01:00:52.270 --> 01:00:54.654 But I agree that I think there are  
NOTE Confidence: 0.82867736

01:00:54.654 --> 01:00:56.080 definitely rules and you know,  
NOTE Confidence: 0.82867736

01:00:56.080 --> 01:00:57.838 I think even within this population,  
NOTE Confidence: 0.82867736

01:00:57.840 --> 01:00:59.840 there may be a role for this in  
NOTE Confidence: 0.82867736

01:00:59.840 --> 01:01:01.883 patients who are bleeding or who need  
NOTE Confidence: 0.82867736

01:01:01.883 --> 01:01:03.990 procedures or other kind of subgroups.  
NOTE Confidence: 0.77241987

01:01:05.400 --> 01:01:06.856 Great Bob, do you want to just sort of  
NOTE Confidence: 0.77241987

01:01:06.856 --> 01:01:09.210 tag team back and forth? Uh, sure, in

NOTE Confidence: 0.83646846  
01:01:09.210 --> 01:01:10.500 less anyone in the audience  
NOTE Confidence: 0.83646846  
01:01:10.500 --> 01:01:12.051 has a question, you could raise  
NOTE Confidence: 0.83646846  
01:01:12.051 --> 01:01:13.600 your hand and will unmute you.  
NOTE Confidence: 0.8548884  
01:01:15.760 --> 01:01:17.520 But still waiting for  
NOTE Confidence: 0.8548884  
01:01:17.520 --> 01:01:21.040 that. I I had a question for Alex.  
NOTE Confidence: 0.8548884  
01:01:21.040 --> 01:01:24.120 So Alex, the data on Adams 13  
NOTE Confidence: 0.8548884  
01:01:24.120 --> 01:01:26.760 and BWF levels. Do you think  
NOTE Confidence: 0.8548884  
01:01:26.760 --> 01:01:29.400 that could be the basis for  
NOTE Confidence: 0.8548884  
01:01:29.400 --> 01:01:31.600 identifying high risk patients who  
NOTE Confidence: 0.8548884  
01:01:31.600 --> 01:01:34.922 then might be part of a randomized  
NOTE Confidence: 0.8548884  
01:01:34.922 --> 01:01:39.014 control trial of anticoagulation or not?  
NOTE Confidence: 0.8548884  
01:01:39.020 --> 01:01:41.660 In in COVID-19 and perhaps other  
NOTE Confidence: 0.8548884  
01:01:41.660 --> 01:01:43.860 people who are severely infected.  
NOTE Confidence: 0.77955836  
01:01:45.670 --> 01:01:47.462 Yes, but thank you.  
NOTE Confidence: 0.77955836  
01:01:47.462 --> 01:01:49.259 Thanks for question. Indeed.  
NOTE Confidence: 0.77955836

01:01:49.259 --> 01:01:51.504 I actually have great hopes  
NOTE Confidence: 0.77955836

01:01:51.504 --> 01:01:53.300 until data shows otherwise,  
NOTE Confidence: 0.77955836

01:01:53.300 --> 01:01:56.191 but I have great hopes that this  
NOTE Confidence: 0.77955836

01:01:56.191 --> 01:01:58.490 imbalance Adams just routine for  
NOTE Confidence: 0.77955836

01:01:58.490 --> 01:02:00.940 Willebrand factor in balance is,  
NOTE Confidence: 0.77955836

01:02:00.940 --> 01:02:04.076 you know for the lack of a better  
NOTE Confidence: 0.77955836

01:02:04.076 --> 01:02:07.669 word may be fundamental to Infosys it.  
NOTE Confidence: 0.77955836

01:02:07.670 --> 01:02:11.254 Whether it is a marker or A cause,  
NOTE Confidence: 0.77955836

01:02:11.260 --> 01:02:15.124 that's I think it remains to be.  
NOTE Confidence: 0.77955836

01:02:15.130 --> 01:02:17.470 Is to be seen.  
NOTE Confidence: 0.77955836

01:02:17.470 --> 01:02:19.290 But from from Pathophysiologic  
NOTE Confidence: 0.77955836

01:02:19.290 --> 01:02:21.565 understanding of how Infosys happens,  
NOTE Confidence: 0.77955836

01:02:21.570 --> 01:02:25.371 I think this two markers would be  
NOTE Confidence: 0.77955836

01:02:25.371 --> 01:02:28.095 potentially could have that that  
NOTE Confidence: 0.77955836

01:02:28.095 --> 01:02:31.077 could have that fill that role.  
NOTE Confidence: 0.77955836

01:02:31.080 --> 01:02:31.550 Thank you.

NOTE Confidence: 0.8076803  
01:02:34.200 --> 01:02:36.016 Another question for you Alex again,  
NOTE Confidence: 0.8076803  
01:02:36.016 --> 01:02:37.204 great session, great summaries.  
NOTE Confidence: 0.8076803  
01:02:37.204 --> 01:02:38.956 All of you guys you know  
NOTE Confidence: 0.8076803  
01:02:38.956 --> 01:02:39.960 for predicting cancer,  
NOTE Confidence: 0.8076803  
01:02:39.960 --> 01:02:40.562 associated thrombosis.  
NOTE Confidence: 0.8076803  
01:02:40.562 --> 01:02:42.985 You kind of mentioned this that you know  
NOTE Confidence: 0.8076803  
01:02:42.985 --> 01:02:45.108 the Corona score has been around awhile.  
NOTE Confidence: 0.8076803  
01:02:45.108 --> 01:02:46.316 There been other scores.  
NOTE Confidence: 0.8076803  
01:02:46.320 --> 01:02:48.136 There's been positive data to support  
NOTE Confidence: 0.8076803  
01:02:48.136 --> 01:02:49.652 the use of prophylactic integration  
NOTE Confidence: 0.8076803  
01:02:49.652 --> 01:02:51.470 for years and years and years,  
NOTE Confidence: 0.8076803  
01:02:51.470 --> 01:02:53.591 but an even most recently with doacs  
NOTE Confidence: 0.8076803  
01:02:53.591 --> 01:02:55.714 and yet no major consensus group has  
NOTE Confidence: 0.8076803  
01:02:55.714 --> 01:02:57.526 come down to support that practice.  
NOTE Confidence: 0.8076803  
01:02:57.530 --> 01:02:59.954 So so do you feel that this machine  
NOTE Confidence: 0.8076803

01:02:59.954 --> 01:03:01.169 learning algorithm will change  
NOTE Confidence: 0.8076803

01:03:01.170 --> 01:03:02.680 clinical practice in that regard?  
NOTE Confidence: 0.8076803

01:03:02.680 --> 01:03:05.176 Or do you still feel that we need?  
NOTE Confidence: 0.8076803

01:03:05.180 --> 01:03:08.042 Better tools to predict who will  
NOTE Confidence: 0.8076803

01:03:08.042 --> 01:03:09.950 actually get cancer thrombosis.  
NOTE Confidence: 0.8076803

01:03:09.950 --> 01:03:12.918 So I'm a big believer in machine  
NOTE Confidence: 0.8076803

01:03:12.918 --> 01:03:15.175 learning just because it make it  
NOTE Confidence: 0.8076803

01:03:15.175 --> 01:03:17.740 can crunch a lot of data in that.  
NOTE Confidence: 0.8076803

01:03:17.740 --> 01:03:18.607 From that perspective,  
NOTE Confidence: 0.8076803

01:03:18.607 --> 01:03:20.630 I think as a data generator and  
NOTE Confidence: 0.8076803

01:03:20.688 --> 01:03:22.940 hypothesis generator generating technique,  
NOTE Confidence: 0.8076803

01:03:22.940 --> 01:03:25.280 I think it's very important tool  
NOTE Confidence: 0.8076803

01:03:25.280 --> 01:03:27.958 in we should not shy from it  
NOTE Confidence: 0.8076803

01:03:27.958 --> 01:03:30.359 and utilized as much as we can.  
NOTE Confidence: 0.8076803

01:03:30.360 --> 01:03:32.520 The question becomes sort of whether  
NOTE Confidence: 0.8076803

01:03:32.520 --> 01:03:34.776 it's become sort of garbage in

NOTE Confidence: 0.8076803

01:03:34.776 --> 01:03:36.656 garbage out kind of situation.

NOTE Confidence: 0.8076803

01:03:36.660 --> 01:03:40.164 If we feed something that biased to this.

NOTE Confidence: 0.8076803

01:03:40.170 --> 01:03:41.750 So the machine learning algorithms

NOTE Confidence: 0.8076803

01:03:41.750 --> 01:03:43.330 algorithms we're going to get

NOTE Confidence: 0.8076803

01:03:43.384 --> 01:03:44.668 something totally useless,

NOTE Confidence: 0.8076803

01:03:44.670 --> 01:03:46.934 so we have to be very careful about

NOTE Confidence: 0.8076803

01:03:46.934 --> 01:03:49.178 what we really feed these algorithms

NOTE Confidence: 0.8076803

01:03:49.178 --> 01:03:51.590 and how we use these algorithms.

NOTE Confidence: 0.8076803

01:03:51.590 --> 01:03:53.529 And I think we need to collaborate

NOTE Confidence: 0.8076803

01:03:53.529 --> 01:03:56.088 with a lot of artificial intelligence,

NOTE Confidence: 0.8076803

01:03:56.090 --> 01:03:57.845 machine learning people to to

NOTE Confidence: 0.8076803

01:03:57.845 --> 01:03:59.890 get the best out of it.

NOTE Confidence: 0.8076803

01:03:59.890 --> 01:04:01.286 But yes, I agree,

NOTE Confidence: 0.8076803

01:04:01.286 --> 01:04:02.682 that's actually could be

NOTE Confidence: 0.8076803

01:04:02.682 --> 01:04:03.700 absolutely indispensable tool.

NOTE Confidence: 0.8837805



01:04:06.730 --> 01:04:10.730 So George question for you if I may.  
NOTE Confidence: 0.8678143

01:04:12.380 --> 01:04:16.240 Do you think that the data for complement  
NOTE Confidence: 0.8678143

01:04:16.240 --> 01:04:18.660 abnormalities in purpura fulminans has,  
NOTE Confidence: 0.8678143

01:04:18.660 --> 01:04:21.560 or will have any therapeutic implications?  
NOTE Confidence: 0.8234763

01:04:25.040 --> 01:04:28.604 Thank you Bob, really fascinating question.  
NOTE Confidence: 0.8234763

01:04:28.604 --> 01:04:30.980 Really hard question too,  
NOTE Confidence: 0.8234763

01:04:30.980 --> 01:04:34.140 especially because we worry about  
NOTE Confidence: 0.8234763

01:04:34.140 --> 01:04:38.130 performance often in the infectious setting.  
NOTE Confidence: 0.8234763

01:04:38.130 --> 01:04:40.517 One of the first patients that this  
NOTE Confidence: 0.8234763

01:04:40.517 --> 01:04:43.790 study was based off of was a patient  
NOTE Confidence: 0.8234763

01:04:43.790 --> 01:04:45.095 with Capnocytophaga bacteremia,  
NOTE Confidence: 0.8234763

01:04:45.100 --> 01:04:48.188 who ended up having purple foam and ends.  
NOTE Confidence: 0.8234763

01:04:48.190 --> 01:04:50.125 So I think that that's  
NOTE Confidence: 0.8234763

01:04:50.125 --> 01:04:51.673 that's that's that stuff.  
NOTE Confidence: 0.8234763

01:04:51.680 --> 01:04:54.464 At the same time we have utilized compliment  
NOTE Confidence: 0.8234763

01:04:54.464 --> 01:04:57.479 in vision therapy when necessary in patients,

NOTE Confidence: 0.8234763

01:04:57.480 --> 01:04:59.420 for example, with catastrophic APS.

NOTE Confidence: 0.8234763

01:04:59.420 --> 01:05:00.968 The difficulty, of course,

NOTE Confidence: 0.8234763

01:05:00.968 --> 01:05:03.290 because when there's a common infection,

NOTE Confidence: 0.8234763

01:05:03.290 --> 01:05:05.408 so I think that becomes a

NOTE Confidence: 0.8234763

01:05:05.408 --> 01:05:07.540 discussion of risks and benefits,

NOTE Confidence: 0.8234763

01:05:07.540 --> 01:05:09.220 including with our infectious

NOTE Confidence: 0.8234763

01:05:09.220 --> 01:05:10.060 disease specialists.

NOTE Confidence: 0.8234763

01:05:10.060 --> 01:05:10.837 Beyond of course,

NOTE Confidence: 0.8234763

01:05:10.837 --> 01:05:12.132 the vaccination and the use

NOTE Confidence: 0.8234763

01:05:12.132 --> 01:05:13.299 of amoxicillin or penicillin,

NOTE Confidence: 0.8234763

01:05:13.300 --> 01:05:15.190 or something like that to be able

NOTE Confidence: 0.8234763

01:05:15.190 --> 01:05:17.860 to cover the next serial organisms.

NOTE Confidence: 0.8234763

01:05:17.860 --> 01:05:20.280 Thank you.

NOTE Confidence: 0.83295316

01:05:20.280 --> 01:05:22.248 Question for Sabrina the convalescent plasma.

NOTE Confidence: 0.83295316

01:05:22.250 --> 01:05:24.266 The most recent recovery is a

NOTE Confidence: 0.83295316

01:05:24.266 --> 01:05:25.870 recovery truck from the UK.  
NOTE Confidence: 0.83295316

01:05:25.870 --> 01:05:27.182 Was a negative study,  
NOTE Confidence: 0.83295316

01:05:27.182 --> 01:05:28.822 but there's many positive ones,  
NOTE Confidence: 0.83295316

01:05:28.830 --> 01:05:30.480 including our own data that  
NOTE Confidence: 0.83295316

01:05:30.480 --> 01:05:31.470 you brilliantly presented.  
NOTE Confidence: 0.83295316

01:05:31.470 --> 01:05:33.438 Can you reconcile all of this  
NOTE Confidence: 0.83295316

01:05:33.438 --> 01:05:35.740 for us and how we should think  
NOTE Confidence: 0.83295316

01:05:35.740 --> 01:05:37.060 about using convalescent plasma  
NOTE Confidence: 0.83295316

01:05:37.060 --> 01:05:38.050 and COVID-19 patients?  
NOTE Confidence: 0.83295316

01:05:38.050 --> 01:05:39.030 Yeah, it thank  
NOTE Confidence: 0.83295316

01:05:39.030 --> 01:05:40.346 you all for that.  
NOTE Confidence: 0.83295316

01:05:40.346 --> 01:05:42.320 I think it's been challenging 'cause,  
NOTE Confidence: 0.83295316

01:05:42.320 --> 01:05:44.665 as you mentioned that the data has  
NOTE Confidence: 0.83295316

01:05:44.665 --> 01:05:46.599 been quite mixed and you know,  
NOTE Confidence: 0.83295316

01:05:46.600 --> 01:05:48.826 I think just recently we're getting  
NOTE Confidence: 0.83295316

01:05:48.826 --> 01:05:50.310 additional information from from

NOTE Confidence: 0.83295316

01:05:50.372 --> 01:05:52.227 larger and more randomized trials.

NOTE Confidence: 0.83295316

01:05:52.230 --> 01:05:54.799 The early trials that were randomized had

NOTE Confidence: 0.83295316

01:05:54.799 --> 01:05:57.209 stopped early for a number of reasons,

NOTE Confidence: 0.83295316

01:05:57.210 --> 01:05:59.695 one being that there were patients that

NOTE Confidence: 0.83295316

01:05:59.695 --> 01:06:01.874 actually actually were SERO positive at

NOTE Confidence: 0.83295316

01:06:01.874 --> 01:06:03.974 the time they got convalescent plasma,

NOTE Confidence: 0.83295316

01:06:03.980 --> 01:06:06.974 and then there were issues with

NOTE Confidence: 0.83295316

01:06:06.974 --> 01:06:08.970 recruitment in other studies.

NOTE Confidence: 0.83295316

01:06:08.970 --> 01:06:11.018 I, I think we're going to have to

NOTE Confidence: 0.83295316

01:06:11.018 --> 01:06:12.826 really kind of look through the

NOTE Confidence: 0.83295316

01:06:12.826 --> 01:06:14.366 details of what antibody titer

NOTE Confidence: 0.83295316

01:06:14.366 --> 01:06:16.372 was an neutralizing function in

NOTE Confidence: 0.83295316

01:06:16.372 --> 01:06:18.422 the convalescent plasma with each

NOTE Confidence: 0.83295316

01:06:18.422 --> 01:06:20.405 randomized trial as well as timing

NOTE Confidence: 0.83295316

01:06:20.405 --> 01:06:22.376 and timing of receiving the plasma

NOTE Confidence: 0.83295316

01:06:22.376 --> 01:06:24.428 and the severity of the disease,  
NOTE Confidence: 0.83295316

01:06:24.430 --> 01:06:26.320 because I think there has been  
NOTE Confidence: 0.83295316

01:06:26.320 --> 01:06:28.320 signal for patients who get high  
NOTE Confidence: 0.83295316

01:06:28.320 --> 01:06:30.025 titer plasma earlier in disease,  
NOTE Confidence: 0.83295316

01:06:30.030 --> 01:06:31.998 that there there is benefit there,  
NOTE Confidence: 0.83295316

01:06:32.000 --> 01:06:32.582 you know,  
NOTE Confidence: 0.83295316

01:06:32.582 --> 01:06:34.910 and I I don't know that there the  
NOTE Confidence: 0.83295316

01:06:34.987 --> 01:06:37.225 details of the recovery trial have  
NOTE Confidence: 0.83295316

01:06:37.225 --> 01:06:39.399 been released yet in terms of.  
NOTE Confidence: 0.83295316

01:06:39.400 --> 01:06:42.478 The timing of convalescent plasma and  
NOTE Confidence: 0.83295316

01:06:42.478 --> 01:06:44.530 how heterogeneous the convalescent  
NOTE Confidence: 0.83295316

01:06:44.602 --> 01:06:46.738 donor plasma was at that time.  
NOTE Confidence: 0.8631877

01:06:48.480 --> 01:06:49.158 Great, thank you.  
NOTE Confidence: 0.796499

01:06:52.590 --> 01:06:54.226 Sabrina question about it  
NOTE Confidence: 0.796499

01:06:54.226 --> 01:06:56.680 for two zaran if I could.  
NOTE Confidence: 0.796499

01:06:56.680 --> 01:06:59.144 So you mentioned that there

NOTE Confidence: 0.796499  
01:06:59.144 --> 01:07:01.115 were some adverse events,  
NOTE Confidence: 0.796499  
01:07:01.115 --> 01:07:02.103 notably thrombosis,  
NOTE Confidence: 0.796499  
01:07:02.103 --> 01:07:04.568 presumably due to the sustained  
NOTE Confidence: 0.796499  
01:07:04.570 --> 01:07:07.196 reduction in anti thrombin levels.  
NOTE Confidence: 0.796499  
01:07:07.196 --> 01:07:09.856 Do you know if those individuals  
NOTE Confidence: 0.796499  
01:07:09.856 --> 01:07:11.206 were treated with antithrombin  
NOTE Confidence: 0.796499  
01:07:11.206 --> 01:07:12.558 concentrates as a as  
NOTE Confidence: 0.81299037  
01:07:12.560 --> 01:07:13.580 a in in  
NOTE Confidence: 0.81299037  
01:07:13.580 --> 01:07:14.591 along with anticoagulation?  
NOTE Confidence: 0.81299037  
01:07:14.591 --> 01:07:16.613 That's a great question but I  
NOTE Confidence: 0.81299037  
01:07:16.620 --> 01:07:17.968 I don't, I don't.  
NOTE Confidence: 0.81299037  
01:07:17.970 --> 01:07:20.458 I didn't find any evidence that or any  
NOTE Confidence: 0.81299037  
01:07:20.458 --> 01:07:23.380 data on whether or not they were treated,  
NOTE Confidence: 0.81299037  
01:07:23.380 --> 01:07:26.076 so I don't know the answer to that.  
NOTE Confidence: 0.81299037  
01:07:26.080 --> 01:07:28.446 I do know when dosing was paused,  
NOTE Confidence: 0.81299037

01:07:28.450 --> 01:07:30.613 you know they looked at the group  
NOTE Confidence: 0.81299037

01:07:30.613 --> 01:07:32.714 and found that patients who had  
NOTE Confidence: 0.81299037

01:07:32.714 --> 01:07:34.549 an antithrombin level that was  
NOTE Confidence: 0.81299037

01:07:34.549 --> 01:07:37.006 less than 20% and had the higher  
NOTE Confidence: 0.81299037

01:07:37.006 --> 01:07:38.826 risk highest risk of thrombosis.  
NOTE Confidence: 0.81299037

01:07:38.830 --> 01:07:40.804 And those patients that were greater than  
NOTE Confidence: 0.81299037

01:07:40.804 --> 01:07:42.510 20% actually had no thrombotic events,  
NOTE Confidence: 0.81299037

01:07:42.510 --> 01:07:44.372 and so that's why the the trials  
NOTE Confidence: 0.81299037

01:07:44.372 --> 01:07:45.910 have preceded with the redosing,  
NOTE Confidence: 0.81299037

01:07:45.910 --> 01:07:47.772 which is initially going to start at  
NOTE Confidence: 0.81299037

01:07:47.772 --> 01:07:49.589 every other month and then kind of  
NOTE Confidence: 0.81299037

01:07:49.589 --> 01:07:51.423 increased back to where they had been  
NOTE Confidence: 0.81299037

01:07:51.423 --> 01:07:53.403 previously with the goal of monitoring  
NOTE Confidence: 0.81299037

01:07:53.403 --> 01:07:54.974 and antithrombin levels closely so  
NOTE Confidence: 0.81299037

01:07:54.974 --> 01:07:56.983 that they stay kind of between 15  
NOTE Confidence: 0.81299037

01:07:56.983 --> 01:07:59.208 and 35% is what what it's report is,

NOTE Confidence: 0.81299037

01:07:59.210 --> 01:08:00.620 but I don't know about

NOTE Confidence: 0.8318267

01:08:00.620 --> 01:08:02.040 the concentrates. OK, great thank

NOTE Confidence: 0.8318267

01:08:02.040 --> 01:08:03.450 you, that's interesting, thank you.

NOTE Confidence: 0.79507476

01:08:05.350 --> 01:08:07.456 Question for George. So you know,

NOTE Confidence: 0.79507476

01:08:07.460 --> 01:08:09.916 in the abstract that you presented on

NOTE Confidence: 0.79507476

01:08:09.916 --> 01:08:12.720 using CRISPR CAS to target BCL 11 A.

NOTE Confidence: 0.79507476

01:08:12.720 --> 01:08:14.480 I was literally just Googling

NOTE Confidence: 0.79507476

01:08:14.480 --> 01:08:16.230 what else detail 11/8 does.

NOTE Confidence: 0.79507476

01:08:16.230 --> 01:08:18.340 And you know there are interesting

NOTE Confidence: 0.79507476

01:08:18.340 --> 01:08:20.091 reports about it being involved

NOTE Confidence: 0.79507476

01:08:20.091 --> 01:08:22.197 in metal pieces in B cell,

NOTE Confidence: 0.79507476

01:08:22.200 --> 01:08:23.950 lymph, Genesis and so forth.

NOTE Confidence: 0.79507476

01:08:23.950 --> 01:08:26.410 And so I'm just wondering if the

NOTE Confidence: 0.79507476

01:08:26.410 --> 01:08:27.810 investigators talked about potential,

NOTE Confidence: 0.79507476

01:08:27.810 --> 01:08:28.863 you know, humans,

NOTE Confidence: 0.79507476



01:08:28.863 --> 01:08:30.267 allergic effects or immunological  
NOTE Confidence: 0.79507476

01:08:30.267 --> 01:08:32.730 effects and and the reason being that  
NOTE Confidence: 0.79507476

01:08:32.730 --> 01:08:35.830 you know there there is another set of.  
NOTE Confidence: 0.79507476

01:08:35.830 --> 01:08:36.095 Essentially,  
NOTE Confidence: 0.79507476

01:08:36.095 --> 01:08:37.152 gene editing treatments that  
NOTE Confidence: 0.79507476

01:08:37.152 --> 01:08:38.724 we can use in these disorders,  
NOTE Confidence: 0.79507476

01:08:38.730 --> 01:08:40.055 which is stem cell transplant.  
NOTE Confidence: 0.79507476

01:08:40.055 --> 01:08:41.834 So it just makes you wonder that  
NOTE Confidence: 0.79507476

01:08:41.834 --> 01:08:43.310 if there are these unknown effects  
NOTE Confidence: 0.79507476

01:08:43.354 --> 01:08:44.538 with these newer therapies,  
NOTE Confidence: 0.79507476

01:08:44.540 --> 01:08:44.810 then  
NOTE Confidence: 0.80985254

01:08:44.810 --> 01:08:46.388 why not just go for stem  
NOTE Confidence: 0.80985254

01:08:46.390 --> 01:08:48.388 cell transplant instead?  
NOTE Confidence: 0.80985254

01:08:48.390 --> 01:08:49.620 Yeah, thank you.  
NOTE Confidence: 0.80985254

01:08:49.620 --> 01:08:51.670 Yeah that's a great question.  
NOTE Confidence: 0.80985254

01:08:51.670 --> 01:08:53.495 Of course, stem cell transplant

NOTE Confidence: 0.80985254

01:08:53.495 --> 01:08:54.955 also has adverse effects.

NOTE Confidence: 0.80985254

01:08:54.960 --> 01:08:56.994 An events just like gene editing

NOTE Confidence: 0.80985254

01:08:56.994 --> 01:08:59.718 does in the in the initial study,

NOTE Confidence: 0.80985254

01:08:59.720 --> 01:09:02.011 so they've completed follow up in

NOTE Confidence: 0.80985254

01:09:02.011 --> 01:09:04.790 at least two patients and they have

NOTE Confidence: 0.80985254

01:09:04.876 --> 01:09:07.652 another I think 6 to 9 patients in

NOTE Confidence: 0.80985254

01:09:07.652 --> 01:09:10.338 in each of the 111 and STD 121.

NOTE Confidence: 0.80985254

01:09:10.340 --> 01:09:13.730 There is nothing that I saw.

NOTE Confidence: 0.80985254

01:09:13.730 --> 01:09:14.998 Talking about specifically human,

NOTE Confidence: 0.80985254

01:09:14.998 --> 01:09:16.266 logical and immunological effects,

NOTE Confidence: 0.80985254

01:09:16.270 --> 01:09:17.510 notable things were infectious

NOTE Confidence: 0.80985254

01:09:17.510 --> 01:09:19.770 from both of the first 2 pages,

NOTE Confidence: 0.80985254

01:09:19.770 --> 01:09:21.047 but The thing is,

NOTE Confidence: 0.80985254

01:09:21.047 --> 01:09:22.990 those other patients still need at

NOTE Confidence: 0.80985254

01:09:22.990 --> 01:09:25.300 least another year of follow up before

NOTE Confidence: 0.80985254

01:09:25.368 --> 01:09:27.398 we can start talking about this right.

NOTE Confidence: 0.80985254

01:09:27.400 --> 01:09:29.630 And then beyond that long term too,

NOTE Confidence: 0.80985254

01:09:29.630 --> 01:09:31.744 'cause it's not just a year or

NOTE Confidence: 0.80985254

01:09:31.744 --> 01:09:33.760 two that people will live right.

NOTE Confidence: 0.80985254

01:09:33.760 --> 01:09:37.069 Hopefully in that good state so.

NOTE Confidence: 0.80985254

01:09:37.070 --> 01:09:38.390 Yeah, I I don't know more.

NOTE Confidence: 0.8540588

01:09:42.670 --> 01:09:44.740 So I have a question.

NOTE Confidence: 0.8540588

01:09:44.740 --> 01:09:46.803 Maybe for George about the

NOTE Confidence: 0.8540588

01:09:46.803 --> 01:09:48.454 the anticoagulant. I'm sorry.

NOTE Confidence: 0.8540588

01:09:48.454 --> 01:09:50.514 Not George Alex about the

NOTE Confidence: 0.8540588

01:09:50.514 --> 01:09:51.338 anticoagulant inhibitor.

NOTE Confidence: 0.8661554

01:09:52.290 --> 01:09:54.010 Where, where are we

NOTE Confidence: 0.8661554

01:09:54.010 --> 01:09:56.590 in 2021 in terms of first

NOTE Confidence: 0.8661554

01:09:56.590 --> 01:09:58.310 line therapy for reversal,

NOTE Confidence: 0.8661554

01:09:58.310 --> 01:10:00.425 bleeding for, let's say, induce?

NOTE Confidence: 0.8661554

01:10:00.425 --> 01:10:01.968 Buy a doac you think?

NOTE Confidence: 0.8702791

01:10:04.180 --> 01:10:08.468 Well, so we do have access to both.

NOTE Confidence: 0.7811392

01:10:11.320 --> 01:10:13.216 And extra an assistant

NOTE Confidence: 0.7811392

01:10:13.216 --> 01:10:15.586 either season map I believe.

NOTE Confidence: 0.7811392

01:10:15.590 --> 01:10:18.428 I personally have not used them,

NOTE Confidence: 0.7811392

01:10:18.430 --> 01:10:23.926 but I know several people have used them.

NOTE Confidence: 0.7811392

01:10:23.930 --> 01:10:29.400 And, um. I believe it's costly and

NOTE Confidence: 0.7811392

01:10:29.400 --> 01:10:33.080 what's interesting is that the decision,

NOTE Confidence: 0.7811392

01:10:33.080 --> 01:10:35.990 as far as I know,

NOTE Confidence: 0.7811392

01:10:35.990 --> 01:10:39.511 decision is made still on the timing

NOTE Confidence: 0.7811392

01:10:39.511 --> 01:10:43.540 of the last those event equivalent.

NOTE Confidence: 0.7811392

01:10:43.540 --> 01:10:46.548 Furthermore, the both trial

NOTE Confidence: 0.7811392

01:10:46.548 --> 01:10:50.308 trial so far both for.

NOTE Confidence: 0.7811392

01:10:50.310 --> 01:10:54.930 Typical Tran and Doac and the factor

NOTE Confidence: 0.7811392

01:10:54.930 --> 01:10:58.310 of 10 anticoagulants inhibitors.

NOTE Confidence: 0.7811392

01:10:58.310 --> 01:11:01.134 Both those trials for the rest of the

NOTE Confidence: 0.7811392

01:11:01.134 --> 01:11:03.640 reversal agents were without control arms,  
NOTE Confidence: 0.7811392

01:11:03.640 --> 01:11:05.926 so with efficacy is not really  
NOTE Confidence: 0.7811392

01:11:05.926 --> 01:11:07.069 well established still,  
NOTE Confidence: 0.7811392

01:11:07.070 --> 01:11:09.408 so I think there's there's one trial  
NOTE Confidence: 0.7811392

01:11:09.408 --> 01:11:11.984 right now is going on next I next  
NOTE Confidence: 0.7811392

01:11:11.984 --> 01:11:14.222 one is for the internal hemorrhage  
NOTE Confidence: 0.7811392

01:11:14.222 --> 01:11:16.217 reversal of anticoagulation.  
NOTE Confidence: 0.7811392

01:11:16.220 --> 01:11:18.120 People patient with intracranial hemorrhage,  
NOTE Confidence: 0.7811392

01:11:18.120 --> 01:11:20.406 which is which is randomized trial.  
NOTE Confidence: 0.7811392

01:11:20.410 --> 01:11:24.099 I think that's going to be informative.  
NOTE Confidence: 0.7811392

01:11:24.100 --> 01:11:30.382 But I I think it's data is not super.  
NOTE Confidence: 0.7811392

01:11:30.390 --> 01:11:33.252 Super strong about how to reverse  
NOTE Confidence: 0.7811392

01:11:33.252 --> 01:11:35.160 and whether to wait.  
NOTE Confidence: 0.7811392

01:11:35.160 --> 01:11:36.990 Just kind of, you know,  
NOTE Confidence: 0.7811392

01:11:36.990 --> 01:11:38.820 hours since the last administration.  
NOTE Confidence: 0.7811392

01:11:38.820 --> 01:11:40.292 So secret parent tag,

NOTE Confidence: 0.7811392

01:11:40.292 --> 01:11:42.943 as far as I understand it's a

NOTE Confidence: 0.7811392

01:11:42.943 --> 01:11:45.109 small market which is very easy

NOTE Confidence: 0.7811392

01:11:45.109 --> 01:11:46.870 to fairly easy to make,

NOTE Confidence: 0.7811392

01:11:46.870 --> 01:11:49.396 which probably will reduce the cost

NOTE Confidence: 0.7811392

01:11:49.396 --> 01:11:52.882 an it's rapid and you don't need to

NOTE Confidence: 0.7811392

01:11:52.882 --> 01:11:55.940 necessarily think about when was the last.

NOTE Confidence: 0.7811392

01:11:55.940 --> 01:11:59.012 Dose I think that I would think that

NOTE Confidence: 0.7811392

01:11:59.012 --> 01:12:02.148 that might be an advantage of using it.

NOTE Confidence: 0.7811392

01:12:02.150 --> 01:12:04.460 Um?

NOTE Confidence: 0.7811392

01:12:04.460 --> 01:12:07.022 But I think the world of antic

NOTE Confidence: 0.7811392

01:12:07.022 --> 01:12:09.238 of reversal agents is an infancy.

NOTE Confidence: 0.7811392

01:12:09.240 --> 01:12:09.608 Yeah,

NOTE Confidence: 0.7811392

01:12:09.608 --> 01:12:10.344 I agree.

NOTE Confidence: 0.7811392

01:12:10.344 --> 01:12:11.448 I think we're

NOTE Confidence: 0.8041131

01:12:11.450 --> 01:12:13.290 waiting for some head to

NOTE Confidence: 0.8041131

01:12:13.290 --> 01:12:15.130 head trials with some of  
NOTE Confidence: 0.8041131

01:12:15.130 --> 01:12:17.340 these drugs in the prothrombin complex  
NOTE Confidence: 0.8041131

01:12:17.340 --> 01:12:19.178 concentrates as well. Thank you.  
NOTE Confidence: 0.85915107

01:12:19.900 --> 01:12:21.736 Well, thank you so much everybody.  
NOTE Confidence: 0.85915107

01:12:21.740 --> 01:12:23.270 Thank you Doctor Pine, Victor,  
NOTE Confidence: 0.85915107

01:12:23.270 --> 01:12:24.538 Joshua and Doctor Browning,  
NOTE Confidence: 0.85915107

01:12:24.538 --> 01:12:26.123 and the excellent moderation by  
NOTE Confidence: 0.85915107

01:12:26.123 --> 01:12:27.548 Doctor Lee and Doctor Bonner.  
NOTE Confidence: 0.85915107

01:12:27.550 --> 01:12:29.200 We probably could go another hour  
NOTE Confidence: 0.85915107

01:12:29.200 --> 01:12:31.220 with all of these great questions.  
NOTE Confidence: 0.85915107

01:12:31.220 --> 01:12:33.412 Please remember you can reach out to all  
NOTE Confidence: 0.85915107

01:12:33.412 --> 01:12:35.722 of the speakers and the moderators by  
NOTE Confidence: 0.85915107

01:12:35.722 --> 01:12:38.060 email for any questions and there will  
NOTE Confidence: 0.85915107

01:12:38.060 --> 01:12:40.396 be a recording of this session for your  
NOTE Confidence: 0.85915107

01:12:40.400 --> 01:12:42.236 convenience will be posted next week.  
NOTE Confidence: 0.85915107

01:12:42.240 --> 01:12:43.464 Thank you so much.

NOTE Confidence: 0.85915107

01:12:43.464 --> 01:12:44.688 Please remember next week.

NOTE Confidence: 0.85915107

01:12:44.690 --> 01:12:47.306 next Friday is the last session which will

NOTE Confidence: 0.85915107

01:12:47.306 --> 01:12:50.010 be focused on cell therapy and bone marrow.

NOTE Confidence: 0.85915107

01:12:50.010 --> 01:12:51.950 A transplantation and that will

NOTE Confidence: 0.85915107

01:12:51.950 --> 01:12:53.908 conclude our post. Ash highlights.

NOTE Confidence: 0.85915107

01:12:53.908 --> 01:12:55.484 Thank you so much.